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Abstract
Aim: Internal dosimetry is recommended during radionuclide therapy to primarily avoid toxicity of
organs-at-risk (OAR). State-of-the-art internal dosimetry is simplistic and based on tabulated absorbed
dose conversion factors (S-values), while sequential quantitative imaging is the preferred method to
determine the patient-specific time-activity-curve (TAC) in OAR and lesions. The hematologically
active bone marrow is an important OAR during Lu-177-PRRT of advanced neuroendocrine tumors
(NET), and Lu-177-PSMA therapy of metastasized castration-resistant prostate cancer (mCRPC). While
for non-marrow OAR and lesions sequential quantitative SPECT imaging is advisable, classical bone
marrow dosimetry requires additional sequential whole-body planar imaging in combination with
excreta collection, and blood sampling to derive the TAC in all relevant accumulating regions. These
multiple examinations cause a large patient burden and a high clinical workload, which limits routine
bone marrow dosimetry in clinical practice. On the other hand, classical S-value dosimetry was initially
developed regarding organ dosimetry during daily radiation protection, and thus includes only a very
simplified lesion concept. The applicability of S-value bone marrow dosimetry is limited particularly
for mCRPC patients, who usually present with excessive skeletal metastases, and as skeletal radio-
pharmaceutical uptake can cause a substantial bone marrow cross-irradiation. Skeletal metastases can
further initiate bone marrow displacement processes, which cannot be handled via tabulated S-values.
Starting from these limitations, the aim of this thesis was to optimize clinical bone marrow dosimetry.
In a first step, an efficient and patient-friendly measurement scheme for routine bone marrow internal
dosimetry was defined. The overall dosimetry scheme aims to allow for SPECT-based dosimetry for
lesions and non-marrow OAR, and bone marrow dosimetry within a clinically acceptable uncertainty.
Further, a clinical Monte-Carlo-based internal dosimetry workflow was established, to in particular
provide an improved patient-specific concept regarding bone marrow dosimetry for mCRPC patients
with high skeletal lesion load.
Material & methods: In a preceding study, a TAC model for efficient single-SPECT kidney and lesion
dosimetry applicable to selected therapy cycles was investigated. This single-SPECT TAC model
was then extended to allow for bone marrow dosimetry via single whole-body planar and sequen-
tial abdominal SPECT imaging. This hybrid SPECT-planar model is based on a function decaying
mono-exponentially with the effective wash-out of the abdominal activity, scaled with a single uptake
measurement at either 24, 48, or 72 h post infusion. Further, for a sub-cohort of patients, SPECT-based
whole-body planar image calibration was compared to classical net-activity calibration to skip the need
for patient excreta counting. A clinically feasible blood sampling scheme based on five blood probes
was developed, using the identical sub-cohort of patients with available extended blood sampling at
20, 30, 40, 60, and 80 min and 24, 48, and 72 h post start of infusion.
For 14 mCRPC patients (3.7-6 GBq Lu-177-DKFZ-PSMA-617) the relevance of the kidneys, representing
an important non-marrow OAR, and of the active bone marrow was studied in dependence upon the
patient-specific skeletal lesion load. Conventional S-value-based dosimetry was used, in combination
with sequential abdominal SPECT imaging, and the optimized bone marrow measurement protocol.
xv
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Based on these preceding results, a template-based Monte Carlo bone marrow dosimetry workflow
was developed and applied to 11 mCRPC patients of varying bone lesion load. The patient-specific
information from pre-therapeutic Ga-68-PSMA-11 PET/CT whole-body imaging and therapeutic
Lu-177 quantitative TAC measurements was condensed into a patient-specific accumulation template,
including full consideration of the 3D lesion distribution. A weighting-based model was implemented
into the FLUKA Monte Carlo code to simulate the absorbed dose deposition solely within the active
bone marrow. Different models regarding active bone marrow localization were investigated, i. e.
without and with complete bone marrow displacement by PSMA-avid lesions (methods MC1 and
MC2), and with usage of exemplarily performed patient-specific active bone marrow localization via
Tc-99m-anti-granulocyte SPECT/CT. These Monte-Carlo-based results were further compared to the
respective values from classical S-value dosimetry (SMIRD), and all absorbed doses were evaluated
with regard to the course of blood element counts.
Results: Single-SPECT dosimetry for both, lesions and kidneys, was found to be feasible, particularly
if SPECT imaging is performed at 72 h post infusion. Mean deviations compared to sequential SPECT
imaging were found to be below 10 % for Lu-177-PRRT and Lu-177-PSMA therapy. Similarly, bone
marrow dosimetry based on single whole-body planar imaging at 72 h p. i. showed the smallest
differences compared to sequential imaging, i. e. on average 2 ± 2 % and 3 ± 2 % for Lu-177-PRRT
and Lu-177-PSMA therapy, respectively. The proposed hybrid SPECT-planar bone marrow protocol
includes SPECT-based whole-body planar image calibration and blood sampling at 20 and 60 min, and
at 24, 48, and 72 h post infusion. Both methods showed an average deviation of 5.7 ± 4.8 % and 5.0 ±
5.6 % compared to the reference.
Regarding Lu-177-PSMA therapy, increasing bone marrow absorbed doses were verified with in-
creasing skeletal lesion load (r=0.8, p<0.05), while a significant opposite trend was observed for the
kidney absorbed dose (r=-0.9, p<0.05). These results indicate that the active bone marrow is the
relevant OAR for high-lesion-load mCRPC patients, with initial S-value dosimetry resulting in an
average absorbed dose of 16 ± 10 mGy/GBq (range: 6-36 mGy/GBq). Patient-specific 3D Monte
Carlo bone marrow dosimetry yielded on median 17-fold to four-fold higher bone marrow absorbed
doses (median: MC1: 130 mGy/GBq; MC2: 37 mGy/GBq; SMIRD: 11 mGy/GBq). Image-based active
bone marrow localization as available for two mCRPC patients resulted in intermediate absorbed
doses between MC1 and MC2 (approximately 40 % reduction with respect to MC1). A preliminary
correlation with nadir-to-baseline ratios of blood element counts resulted in a significant correlation
with the course of platelet counts for all models, while highest correlation was obtained for MC2 (r=-0.7).
Conclusion: Optimization of quantitative measurements for bone marrow dosimetry is feasible within
uncertainties of 5-10 %, which are well acceptable regarding the overall uncertainty of state-of-the-art
bone marrow internal dosimetry. These deviations might be further well acceptable for non-risk pa-
tients, i. e. low-lesion-load mCRPC patients and NET patients. By contrast, for high-lesion-load mCRPC
patients critical bone marrow absorbed doses should be expected, and patient-specific 3D Monte-Carlo-
based bone marrow dosimetry in combination with image-based active bone marrow localization is
advisable to obtain realistic absolute values. Future studies shall aim at further identifying all relevant
hematological risk factors, which is a main step to make bone marrow dosimetry predictive for hema-
tological toxicities and to appropriately stratify risk patients.
Zusammenfassung
Zielsetzung: Die Dosimetrie ist ein elementarer Bestandteil der Radionuklidtherapie, um speziell die
Strahlenbelastung der Therapie-typischen Risikoorgane möglichst niedrig zu halten. Derzeit erfolgt
die Dosimetrie in der Radionuklidtherapie mittels einfachen und vorberechneten Dosiskonversions-
faktoren (S-Werte), wobei die Bestimmung der Patienten-spezifischen Zeit-Aktivitäts-Kurven (TAC)
in Risikoorganen und Läsionen vorzugsweise mittels sequenzieller quantitativer Bildgebung erfolgt.
Das blutbildende Knochenmark ist ein bedeutendes Risikoorgan, sowohl in der Lu-177-PRRT des
fortgeschrittenen Neuroendokrinen Tumors (NET), als auch in der Lu-177-PSMA Therapie des metas-
tasierten kastrations-resistenten Prostatakarzinoms (mCRPC). Während für eine robuste Dosimetrie
in Risikoorganen und Läsionen in der Regel die sequenzielle SPECT-Bildgebung zu empfehlen ist,
erfordert die Knochenmarksdosimetrie derzeit eine zusätzliche sequenzielle Ganzkörperbildgebung,
samt Bestimmung der ausgeschiedenen Aktivitätsmenge, sowie mehrfache Blutentnahmen, um die
TAC aller relevant anreichernder Körperregionen zu ermitteln. Diese Vielzahl an Untersuchungen
führt zu einer hohen Patientenbelastung und klinischen Auslastung, und limitiert folglich die regel-
hafte Knochenmarksdosimetrie im klinischen Alltag. Da die S-Wert-basierte Dosimetrie zudem zur
Organdosimetrie im alltäglichen Strahlenschutz entwickelt wurde, besteht nur ein sehr vereinfachtes
Konzept zur Berücksichtigung von Tumoren. Die Aussagekraft der S-Wert-basierten Dosimetrie ist
folglich besonders hinsichtlich Prostatakarzinom-Patienten limitiert, da diese oftmals eine ausgeprägte
Skelettmetastasierung zeigen, deren Aktivitätsanreicherung eine signifikante Bestrahlung des um-
liegenden aktiven Knochenmarks verursachen kann. Eine vorhandene Skelettmetastasierung kann
zudem eine Verdrängung des aktiven Knochenmarks auslösen, die jedoch nicht mittels vorberechneten
S-Werten berücksichtigt werden kann.
Ausgehend von dieser Situation lag die Zielsetzung dieser Arbeit in der Optimierung der klinischen
Knochenmarksdosimetrie. Zunächst wurde ein effizientes und patientenfreundliches Messschema en-
twickelt, um die routinehafte Knochenmarksdosimetrie im klinischen Alltag zu ermöglichen. Speziell
soll eine Knochenmarksdosimetrie mit ausreichender Genauigkeit, als auch eine SPECT-basierte
Dosimetrie von Tumoren und weiteren Risikoorganen verfügbar sein. Im zweiten Schritt wurde
eine klinisch anwendbare Monte-Carlo-basierte Knochenmarksdosimetrie entwickelt, um speziell für
Prostatakarzinom-Patienten mit ausgeprägter Skelettmetastasierung eine verbesserte Berücksichtigung
der Patienten-spezifischen Gegebenheiten zu gewährleisten.
Material & Methoden: In einer Vorstudie wurde ein TAC-Modell zur Tumor- und Nierendosimetrie
mittels eines SPECT-Zeitpunkts im Hinblick auf ausgewählte Therapiezyklen entwickelt. Dieses
Einzelzeitpunktmodell wurde im weiteren Verlauf zur Knochenmarksdosimetrie mittels einer einzel-
nen Ganzkörperbildgebung und einer sequenziellen SPECT-Bildgebung des Abdomens erweitert.
Das genannte Hybridmodell skaliert im Speziellen die als mono-exponentiell angenommene effektive
Aktivitätsabnahme im Abdomen mit der Ganzkörperanreicherung 24, 48 oder 72 h nach Injektion. Für
eine Subkohorte an Patienten wurde zudem eine SPECT-basierte Kalibration der Ganzkörperbildge-
bung mit dem bisherigen Verfahren basierend auf Messung der Aktivitätsausscheidungen verglichen.
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Zudem wurde ein klinisch anwendbares Schema zur Blutentnahme entwickelt, basierend auf der
selbigen Patientenkohorte, für die eine Vielzahl an Blutentnahmen zu den Zeitpunkten 20, 30, 40, 60
und 80 Minuten, sowie 24, 48 und 72 h nach Injektion verfügbar war.
Für 14 Prostatakarzinom-Patienten (3.7-6 GBq Lu-177-DKFZ-PSMA-617) wurde im Weiteren die
Relevanz des Knochenmarks, sowie der Nieren als bedeutendes weiteres Risikoorgan untersucht, im
Hinblick auf die Abhängigkeit der absorbierten Dosen von der Patienten-spezifischen Knochentu-
morlast. Die Dosimetrie erfolgte dabei S-Wert-basiert, sowie unter Verwendung einer sequenziellen
SPECT-Bildgebung und des optimierten Messschemas zur Knochenmarksdosimetrie. Basierend auf
den Ergebnissen dieser Vorstudie wurde ein Template- und Monte-Carlo-basiertes Verfahren zur
Knochenmarksdosimetrie entwickelt, sowie auf 11 Prostatakarzinom-Patienten angewendet. Alle
Patientengegebenheiten der prä-therapeutischen Ga-68-PSMA-11 PET/CT Diagnostik, als auch der
therapeutischen Messungen der Lu-177-Anreicherung wurden dabei zu einem Template des Patienten-
spezifischen Anreicherungsmusters kombiniert, das die 3D Verteilung der Tumorlast vollständig
berücksichtigt. Die Simulation der Dosisdeposition speziell im aktiven Knochenmark erfolgte mittels
FLUKA, sowie einem implementierten Gewichtungsmodell. Die Simulationsstudie beinhaltete ver-
schiedene Modelle zur aktiven Knochenmarksverteilung: keine als auch die komplette Verdrängung
des aktiven Knochenmarks durch PSMA-exprimierende Tumoren (Methoden MC1 und MC2), sowie
die Bild-basierte Knochenmarkslokalisation mittels Tc-99m-Anti-Granulozyten SPECT/CT. Ergebnisse
der Monte Carlo und S-Wert (SMIRD) Knochenmarksdosimetrie wurden miteinander verglichen und
hinsichtlich des Verlaufs der Blutparameter beurteilt.
Ergebnisse: Sowohl für die Lu-177-PRRT als auch für die Lu-177-PSMA Therapie erwies sich die
Nieren- und Tumordosimetrie mittels eines SPECT-Zeitpunkts als möglich, insbesondere unter Ver-
wendung eines späten Messpunktes 72 h nach Injektion. Dabei ergab sich eine mittlere Abweichung
von weniger als 10 % im Vergleich zur sequenziellen Bildgebung. Ebenfalls zeigte die Knochenmarks-
dosimetrie basierend auf einer einzelnen Ganzkörperszintigrafie 72 h nach Injektion die geringste
Abweichung zur sequenziellen Bildgebung, sowohl für die Lu-177-PRRT (2 ± 2 %), als auch für die
Lu-177-PSMA Therapie (3 ± 2 %). Das entwickelte Hybridmodell wurde mit einer SPECT-basierten
Kalibration kombiniert, als auch mit einem Blutentnahmeschema 20 und 60 Minuten, sowie 24, 48 und
72 h nach Injektion. Für beide Methoden ergab sich eine Abweichung von 5.7 ± 4.8 % und 5.0 ± 5.6 %
zur Referenz.
Im Hinblick auf die Lu-177-PSMA Therapie zeigte sich eine Zunahme der absorbierten Knochenmarks-
dosis mit steigender Tumormasse im Skelett (r=0.8, p<0.05), während die absorbierte Nierendosis einen
gegensätzlichen Trend aufwies (r=-0.9, p<0.05). Diese Ergebnisse bestätigen das aktive Knochenmark
als relevantes Risikoorgan für Prostatakarzinom-Patienten mit hoher Knochentumorlast. Die mittlere S-
Wert-basierte absorbierte Knochenmarksdosis ergab sich dabei zu 16 ± 10 mGy/GBq (6-36 mGy/GBq).
Eine weitergehende Monte-Carlo-basierte Patienten-spezifische 3D Knochenmarksdosimetrie ergab um
17-fach, sowie vierfach erhöhte absorbierte Knochenmarksdosen (Median: MC1: 130 mGy/GBq; MC2:
37 mGy/GBq; SMIRD: 11 mGy/GBq). Die Bild-basierte Lokalisation des aktiven Knochenmarks ergab
beispielhaft für zwei Patienten eine Reduktion der absorbierten Dosis um 40 % im Vergleich zu MC1,
resultierte jedoch in höhere Werte als MC2. Eine erste Korrelation der Knochenmarksdosimetrie mit
dem Verlauf der Blutparameter zeigte eine signifikante Korrelation mit der Thrombozytenabnahme für
alle Modelle, während die stärkste Korrelation für MC2 beobachtet wurde (r=-0.7).
Schlussfolgerung: Eine Optimierung der Knochenmarksdosimetrie ist im Rahmen einer Unsicherheit
von 5-10 % möglich, die besonders im Hinblick auf die generelle Unsicherheit der Knochenmarkdosime-
trie akzeptabel ist. Hierbei erlaubt das entwickelte Hybridmodell eine effiziente Knochenmarkdosime-
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trie für Prostatakarzinom-Patienten mit niedriger Knochentumorlast, sowie NET-Patienten. Im Gegen-
satz dazu sollte die Knochenmarksdosimetrie für Prostatakarzinom-Patienten mit hoher Tumorlast um
eine Patienten-spezifische 3D Monte Carlo Dosimetrie unter Verwendung einer Bild-basierten Knochen-
markslokalisation erweitert werden, um realistische Absolutwerte zu erhalten. In weiterführenden Stu-
dien sollen relevante hämatologische Risikofaktoren identifiziert werden, um die Vorhersagbarkeit der
Knochenmarksdosimetrie hinsichtlich des Therapieverlaufs zu verbessern, sowie um eine angemessene
Stratifizierung von Risikopatienten zu ermöglichen.
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1 | Introduction to radionuclide therapy
Over the past decades, radionuclide therapy (RT) evolved as a promising therapy approach for pro-
gressed or inoperable cancer disease. Beginning with radio-iodine therapy for benign or malignant
thyroid disease approximately 70 years ago [18, 93, 96], in the meanwhile more and more radiopharma-
ceuticals were investigated and introduced for nuclear medicine therapy. Glass or resin microspheres
labelled with Yttrium-90 evolved as promising option for metastatic liver disease [77, 103, 111], while
Lutetium-177-labelled compounds (Lu-177) were extensively studied for the treatment of inoperable or
metastasized neuroendocrine tumors (NET) (peptide-receptor-radionuclide-therapy (PRRT) via, e. g.,
Lu-177-[DOTA0,Tyr3]-Octreotate) [122], or metastasized castration-resistant prostate cancer (mCRPC)
(e. g. Lu-177-DKFZ-PSMA-617 or Lu77-PSMA-I&T) [9, 40, 101, 102] (Figure 1.1). In the last years,
common radiopharmaceuticals have been more and more used in combination with Actinium-225, to
benefit from the superior biological and thus therapeutical effectiveness of alpha particle emitters [25,
80]. Radium-223-dichloride therapy (Alpharadin) is a possible option regarding the treatment of skele-
tal metastases [97].
To ensure a safe and efficient therapy, the radiopharmaceutical has to be trapped within the malignant
tissue. Therefore, the radiopharmaceutical can be either manually delivered in close proximity to the
tumor cells (e. g. delivery via catheters into the tumor blood supply during Yttrium-90 therapy of liver
metastases), or transported to the tumor cells via molecular processes (e. g. bone metabolism during
Alpharadin therapy). Most of the radiopharmaceuticals make use of carrier molecules, specifically de-
signed to target binding sites which are ideally solely located on, but at least overexpressed by the tumor
cells. For example, Lu-177-PRRT is designed to target somatostatine receptors (sstr) typically expressed
by NET cells, while Lu-177-DKFZ-PSMA-617 or Lu-177-PSMA-I&T bind to the prostate-specific mem-
brane antigene (PSMA), located predominantly on mCRPC cells. Further, diagnostic Gallium-68-, Fluor-
18-, or Technetium-99m-labelled compounds targeting sstr-expression or PSMA were developed, to al-
low for pre-therapeutic disease staging and for monitoring of the therapy effect via Positron-Emission-
Tomography (PET) or Single-Photon-Emission-Computed-Tomography (SPECT) within a theranostic
concept (Figure 1.1) [1, 2, 8, 73, 74, 81].
After injection into the blood stream, carrier-based radiopharmaceuticals distribute in the patient body
over time according to the patient-specific and compound-dependent pharmacokinetic. Besides the
desired uptake in malignant tissues, a compound accumulation is commonly also observed for organs-
at-risk (OAR), which either express respective binding sites, or which are affected via excretion or other
metabolic mechanisms. This non-target uptake leads to an undesired radiation effect to healthy tissues.
Further, the active bone marrow is a standard OAR during RT due to its severe relevance for the hema-
tological system, pronounced radiation sensitivity, and as it can be exposed to radiation in multiple
ways (e. g. blood activity circulation) [70]. For Lu-177-PRRT, liver, spleen, kidneys, and the pituitary
gland show normal tissue uptake, while the kidneys and hematological active bone marrow are consid-
ered as most important OAR [65, 110]. For Lu-177-PSMA therapy, kidneys and the active bone marrow
likewise represent the relevant OAR, in combination with the PSMA-positive salivary glands, lacrimal
glands, and intestine [33, 40] (Figure 1.2). Thus, patient-specific dosimetry is highly recommended to in
1
2Figure 1.1: Response to Lu-177-DKFZ-PSMA-617 therapy shown for an exemplary mCRPC patient, as
evaluated via Ga-68-PSMA-11 PET/CT (maximum-intensity projection (MIP)).
Figure 1.2: Sequential whole-body planar imaging of a mCRPC patient at selected time points post
injection of 3.7 GBq Lu-177-DKFZ-PSMA-617 (anterior and posterior views) .
particular avoid severe OAR toxicities.
Despite its importance to guarantee safe and efficient RT, appropriate methods for internal dosimetry
(ID) are still under investigation. Although patient-specific ID has been continuously improved over re-
cent years, the uncertainty or error, respectively, of absorbed dose estimates is still high. Thus, the possi-
bility to fully exploit the therapeutic window is limited [29, 37, 117], although absorbed-dose-response-
relations could be established for several therapies [121]. ID is hardly standardized, however, involves
multiple methodological aspects, i. e. the determination of the patient-specific three-dimensional ac-
tivity distribution over time, the appropriate co-registration and segmentation of image data to identify
accumulating source regions and target structures, and the absorbed dose calculation itself [46, 47, 64,
66, 68, 115]. On the other hand, ID requires a high number of quantitative measurements to assess
the patient-specific time-activity-curve (TAC) in malignant tissues and OAR. The latter results in a se-
vere increase in clinical workload and patient burden. Thus, offering RT to a high number of patients
suffering from advanced cancer disease and a bad health condition requests a permanent trade-off be-
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tween dosimetric accuracy and clinical feasibility. The latter is in particular true regarding bone marrow
dosimetry, as the active bone marrow is probably the most critical although most challenging and most
effort-demanding OAR [29, 70, 102].
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2 | Basics of nuclear medicine imaging and internal
dosimetry
2.1 Nuclear medicine imaging devices
2.1.1 Basics of Lutetium-177 imaging for internal dosimetry
Figure 2.1: Quantitative Lu-177 SPECT/CT imaging (a) and quantified whole-body planar scintigraphy
(b) for a mCRPC patient 24 h post injection of 3.7 GBq Lu-177-DKFZ-PSMA-617.
Nuclear medicine imaging is a vitally important tool in radionuclide therapy (RT) and internal dosime-
try (ID), as the latter relies on the knowledge of the spatial and temporal intra-patient radionuclide dis-
tribution. For RT, β−-emitting or α-emitting radionuclides are employed, however, radionuclides with
co-emission of an additional diagnostic component are preferred, as the latter allows to measure the ra-
diopharmaceutical distribution in vivo with regard to ID applications [35, 86, 115]. Lu-177 (17771 Lu) is the
currently most widely used radionuclide during RT of neuroendocrine tumors (NET) and metastasized
castration-resistant prostate cancer (mCRPC), as it is characterized by a long physical half-life (6.7 days)
suitable for therapeutic applications, and a short-range therapeutic β−-component (maximum energy
498 keV; maximum range for soft tissue: 1.7 mm), accompanied by a sufficiently strong γ-emission [39,
86, 122]. Lu-177 undergoes β−-decay to Hafnium-177 (17772 Hf),
177
71 Lu→17772 Hf∗ + e− + ν¯e, (2.1)
while after 20.7 % of all disintegrations Hafnium-177 is in an excited state (17772 Hf∗) [10]. Both, the β−-
particle (e−) and the electron anti-neutrino (ν¯e), are released to maintain physical conservation laws [7].
The further de-excitation of Hafnium-177 to its ground state (17772 Hf ) results in the formation of two
main γ-emissions of 113 keV and 208 keV at an abundance of 6.2 % and 10.4 %, respectively, which can
both be employed for Gamma camera imaging [10, 86]:
177
72 Hf
∗ →17772 Hf + γ. (2.2)
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Figure 2.2: Dual-headed Siemens Symbia Intevo T16 SPECT/CT Gamma camera system.
2.1.2 Gamma camera imaging
Gamma cameras, also called Anger or scintillation cameras, employ the scintillation principle to gen-
erate two-dimensional (planar scintigraphy) or 3D (Single-Photon-Emission-Computed-Tomography
(SPECT)) views of the intra-body radionuclide distribution (Figure 2.1). Most systems are equipped
with two detector heads, which are capable to move around the patient within a defined orbit to gather
multiple two-dimensional projections through the intra-patient radionuclide distribution (Figures 2.2
and 2.3). For state-of-the-art systems, each detector head is build up of a changeable collimator, a large
scintillation crystal, and multiple photomultiplier tubes (Figure 2.4). The collimator consists of a high-Z
material (e. g. lead) and acts as a mechanical lens, which focuses the isotropically emitted γ-radiation
to the detector head. In particular, for image generation a relation between the point of γ-origin and
γ-detection has to be established. The collimator is composed of small, typically parallel-oriented, and
usually hexagonal-shaped holes, which are separated by walls or so-called septa of high-Z material.
Thus, all γ-photons that enter the holes within a pre-defined opening angle can pass the collimator (Fig-
ure 2.4), while γ-photons from undesired directions are ideally absorbed by the septa. Different collima-
tors of varying thickness, hole diameter, and consequently resolution as well as sensitivity are available,
and selected according to the clinical imaging application and γ-energy of the radionuclide of interest.
The scintillation crystal is likewise manufactured from a high-Z material, typically sodium-iodine doted
with Thallium (NaI(Tl)), to ideally enforce complete and immediate absorption of incoming γ-photons.
However, incoming γ-photons usually undergo multiple interactions and only deposit a fraction of their
energy within the scintillation material. Each energy deposition leads to an excitation of electron transi-
tions within the crystal material. During relaxation of these excited states, appropriate doting causes the
generation of photons in the visible light range, which are further guided to the photomultiplier tubes.
The latter convert the relaxation photons to an amplified electrical signal, via photoelectric interactions
in the photomultiplier cathodes plus a subsequent acceleration and multiplication of the released photo-
electrons within multiple dynodes. The resulting electrical signal can be post-processed by appropriate
subsequent electronics to form a final projection of the radionuclide distribution through the patient
body, resulting in measured γ-events per projection pixel within the energy window of interest (Figure
2.3) [5, 7, 132].
2.1.3 Image-degrading effects
The measured projection data, i. e. the measured signal intensity at a given pixel of the projection ma-
trix, is not solely linked to the intra-patient radionuclide distribution, but distorted by various physical
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Figure 2.3: Schematic representation of projection generation via Gamma camera measurement. Values
aij denote the activity distribution within the object of interest, which is projected onto the detector
head. pak describes the γ-events measured in projection pixel k and at projection angle a.
Figure 2.4: Schematic view of a Gamma camera detector.
effects originating either within the patient body or the Gamma camera device [7, 35, 115, 132]. When
passing through the patient body, γ-photons interact with the surrounding body tissues, i. e. they can
be absorbed or scattered. Both processes lead to photon flux attenuation from the original photon path:
N(x) = N0 · exp
(
−
∫ x
0
µ(E, x′)dx′
)
, N0 = N(x = 0). (2.3)
N(x = 0) and N(x) refer to the initial photon flux and the photon flux after distance x, respectively.
µ(E, x′) denotes the photon attenuation coefficient, which describes the probability for an interaction to
occur per unit path length. µ(E, x′) is different for each γ-energy E and each body tissue [95]. While
photon flux attenuation in general leads to a decrease of the measured intensity signal per defined pixel
of the projection matrix, photon scattering itself causes an additional distortion of the overall intensity
distribution [35, 86].
Motion, e. g. breathing motion or sudden patient movements during the image acquisition, is another
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Figure 2.5: SIMIND simulation study of a Lu-177 point source measured at different distances to the
detector head and for a Siemens medium-energy-low-penetration collimator. The broadening of the point
source representation with increasing distances is well noticeable, in combination with collimator scatter
(halo) and septal penetration (star pattern).
important patient-related effect that distorts the signal distribution within each projection, i. e. it leads
to a blurring of the projection data. Especially sudden, random, and thus not predictable patient move-
ments are challenging to model, and are more likely to appear for patients with a bad health condition
(e. g. pain) and for long measurement times [7, 35, 66].
Image-degrading physical effects are also caused by the collimator, which ideally solely focuses the inci-
dent γ-radiation within a pre-defined direction to the detector head. However, this focusing is in general
not perfect, and the interaction between γ-photons and collimator leads to a very complex pattern. More
precise, a point source of activity is in general not represented as a simple point on the detector [7, 28,
35]. The finite size of the collimator hole allows only for a focusing within a geometrically defined open-
ing angle (geometrical collimation; Figure 2.4), which leads to a broadened representation of the origi-
nal point source, with the extent of broadening being additionally dependent on the source-to-detector
distance (Figure 2.5). This effect is called distance-dependent geometrical collimator-detector-response
(CDR). Further, γ-photons impinging from undesired directions are not perfectly shielded by the septa.
Scattering within the collimator septa can direct undesired γ-photons to the crystal surface, and espe-
cially high-energy γ-photons can fully pass the septa (septal penetration). Collimator scattering leads
to an additional isotropic blurring of the detector response function, while septal penetration can lead
to a pronounced anisotropy of the detector response. For hexagonal-shaped holes, septal penetration
produces a well-known star pattern (Figure 2.5).
Crystal and the photomultiplier system define a specific intrinsic and finite energy and spatial resolu-
tion of the system, although for Gamma camera imaging the overall system spatial resolution is more
dominated by the collimator and radionuclide under usage [132]. The finite system spatial resolution
causes the so-called spill-over effect. In particular, spill-over is noticeable for objects with a size below
approximately three times the characteristic spatial resolution of both, system and radionuclide. The
measured intensity signal is blurred over the object boundaries (spill-out) into the surrounding struc-
tures (spill-in), leading to a loss of intensity signal within the object itself [7, 35, 132].
Further, the finite relaxation time of the crystal material leads to a loss of detection sensitivity in case of
high count rates or high activity concentrations. If the crystal is in a fully excited state, further incoming
γ-photons cannot be detected until relaxation has been reached (dead time), resulting in an intensity
loss with regard to the measured signal (dead time loss) [7, 127, 132].
2.1.4 SPECT reconstruction
As already stated, the acquisition of multiple projections around the patient body allows for 3D recon-
struction of the intra-body radionuclide distribution (SPECT). A detailed description of SPECT image
reconstruction can be found in [7, 24, 132]. The currently most common reconstruction algorithm is the
ordered-subset-expectation-maximization (OSEM) algorithm, which is in turn based on the maximum-
likelihood-expectation-maximization (MLEM) algorithm [114]. MLEM tries to iteratively find that vec-
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tor ~x of image elements xj , j = 1, ..., N with the highest likelihood to obtain the measured projection
data ~y of pixel values yi, i = 1, ...,M . Starting from an initial image estimate ~x0 (e. g. image containing
a homogeneous non-zero distribution), the image is updated step-by-step by comparing the measured
projection data ~y with the projection estimate A~xk of the current image estimate ~xk:
~xk+1 = ~xk
1
AT 1
·AT
(
~y
A~xk
)
, (2.4)
[104] or equivalently using index spelling
xk+1j = x
k
j ·
1∑
i aij
∑
i
aij
yi∑
j aijx
k
j
. (2.5)
~xk+1 denotes the updated image estimate. A and AT correspond to the forward-projection and
backward-projection operator, respectively. More precisely, A is a mathematical representation of the
measurement process, and ideally composes a realistic model of the measurement device and all phys-
ical processes during the image acquisition (see section 2.1.3). Thus, elements aij of A represent the
probability that a γ-photon emitted in image voxel j is detected by projection pixel i. AT mathemati-
cally corresponds to the reverse operation of A.
For OSEM, the update process is not performed over all projections at once, but by using a projection
subset S of them, leading to an increased reconstruction speed:
xk+1j = x
k
j ·
1∑
i∈S aij
∑
i∈S
aij
yi∑
j aijx
k
j
. (2.6)
Iterative reconstruction based on OSEM provides good image quality for nuclear medicine purposes
within an acceptable computational time. However, maximum-likelihood-based reconstruction is
known to be more and more affected by image noise and edge artefacts with increasing number of
iterations, i. e. increasing convergence [116, 126]. Thus, to obtain an acceptable image quality, usu-
ally a trade-off between convergence, noise and artefacts is necessary, and image reconstruction has to
be stopped before the maximum-likelihood of the reconstructed activity distribution is reached. Image
regularization can be employed for noise and artefact suppression, e. g. via post-reconstruction filters,
or by specially designed intra-reconstruction filters, so-called priors. These can be, e. g., designed to
restrict the deviation between voxels of a defined neighbourhood (maximum-a-posteriori (MAP) recon-
struction) [24, 36, 83].
2.1.5 Quantitative imaging
Performing image-based ID requires quantitative images of the patient-specific radionuclide distribu-
tion, e. g. in units of Becquerel (Bq). However, the number of γ-events per voxel or pixel is the direct
measure obtained via SPECT or planar imaging, while the measured distribution of γ-events is addition-
ally distorted from physical factors during the imaging process (see section 2.1.3) [35, 86, 115]. Using
iterative reconstruction algorithms (e. g. OSEM), SPECT quantification can be directly performed during
the reconstruction process itself, as the modelling of physical disturbing factors can be directly included
within the projection modelA (see equation (2.4)) [7, 35]. Most of the state-of-the-art quantitative SPECT
reconstruction algorithms used for ID include corrections for photon flux attenuation, photon scattering,
and the distance-dependent geometrical collimator-detector-response (CDR) (see sections 2.1.5.1-2.1.5.3)
[35, 86]. Methods to correct for other sources of errors (e. g. patient motion, dead time) are less in use,
respectively, not yet fully investigated or introduced for applications in ID, although available for a few
dedicated applications [38, 82, 92, 127]. After the corrected number of measured γ-events (usually units
of counts per second (cps)) is obtained, this number of events has to be converted to radioactive decays.
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Figure 2.6: Relevance of attenuation correction for an exemplary mCRPC patient (6 GBq Lu-177-DKFZ-
PSMA-617). a) and b) denote SPECT reconstruction without and with attenuation correction, respec-
tively. Without attenuation correction, a pronounced loss of kidney uptake is noticeable.
Therefore, a suitable calibration factor has to be determined (see section 2.1.5.4) [35, 86].
2.1.5.1 SPECT attenuation correction
In case of modern hybrid SPECT/CT systems, the patient-specific Computed Tomography (CT) image
can be directly used for attenuation correction [35, 99]. CT imaging exploits the specific attenuation
characteristics of different body tissues to generate an anatomical image of the patient, and therefore
directly includes the patient-specific spatial distribution of attenuation coefficients (µ) in Hounsfield
Units (HU ) per voxel j:
HUj =
µj(E)− µH2O(E)
µH2O(E)
· 1000. (2.7)
However, the patient CT is usually acquired using a photon energy (e. g. 120-130 keV) different from
the photopeak energy of the radionuclide of interest (e. g. 208 keV for Lu-177). Thus, the CT-based HU-
distribution has to be converted to a distribution of attenuation coefficients at the γ-energy of interest.
Therefore, different body-tissue-imitating inserts of known density and chemical composition can be
imaged within the CT scanner [35]. From the known density and chemical composition, the tissue-
specific attenuation coefficients at the desired photopeak energy can be calculated. Both, measured HU-
values and calculated µ-values, are then usually fitted by a bi-linear model to establish a relationship
between both parameters. In this way, conversion of an arbitrary patient CT to a patient-specific µ-
distribution can be achieved, which can further be employed for attenuation correction during SPECT
quantification (Figure 2.6).
2.1.5.2 SPECT scatter correction
Scatter correction can be performed in multiple ways, with the optimal method of choice being highly
nuclide-specific [35, 72]. For most radionuclides, scatter correction is based on the acquisition of multiple
additional scatter windows, which can then be employed to estimate the amount of scattered, though
detected γ-events within the photopeak window. For radionuclides with multiple photopeaks (e. g.
Lu-177), usually one lower and one upper adjacent scatter window per photopeak window is acquired
[86]. The amount of scattered photons per pixel i of the photopeak projection (Ci,scattered) can then be
estimated from a weighted average of the γ-signal measured within the corresponding pixel of both
scatter projections (Ci,lower, Ci,upper):
Ci,scattered =
1
2
·
(
wpeak
wlower
· Ci,lower + wpeak
wupper
· Ci,upper
)
. (2.8)
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Figure 2.7: Exemplary abdominal SPECT of a mCRPC patient (6 GBq Lu-177-DKFZ-PSMA-617) recon-
structed without (a) and with (b) Gaussian-based resolution compensation. Figure a) was post-filtered
via a Gaussian filter of full-width half-maximum of 10 mm (post-reconstruction regularization).
wpeak, wlower, and wupper refer to the respective photopeak, lower, and upper energy window width.
The respective scatter estimate si = Ci,scattered can then be considered during quantitative SPECT re-
construction [72]:
xk+1j = x
k
j ·
1∑
i∈S aij
∑
i∈S
aij
yi(∑
j aijx
k
j
)
+ si
. (2.9)
2.1.5.3 SPECT collimator-detector-response compensation
SPECT imaging requires the acquisition of multiple projections through the patient body, whereupon for
each projection angle each activity signal within the patient shows a different distance to the detector
head. As the geometrical CDR is distance-dependent (see section 2.1.3), each activity signal within the
patient is imaged with a different spatial resolution. CDR or resolution compensation aims at correcting
this effect to obtain a 3D SPECT reconstruction with comparable spatial resolution for each image point.
Therefore, a small point source of activity can be imaged in varying distance to the detector head. After-
wards, a model describing the full-width half-maximum of the measured point source representation in
dependence on the source-to-detector distance can be fitted to this data set. This CDR model can finally
be considered within the reconstruction-specific projection model A (see section 2.1.4) [28, 35]. CDR
compensation reduces spill-over effects, however, at the cost of a possible increase of edge artefacts [36]
(Figure 2.7).
Correction of the distance-dependent geometrical CDR is part of many state-of-the-art quantitative
SPECT reconstruction algorithms, in contrast to corrections for collimator scatter and septal penetra-
tion. The importance of these effects for quantification is nuclide-dependent, while a respective CDR
compensation could be realized, e. g., by modelling the distance-dependent two-dimensional CDR
point-spread-function within the projection model A [28].
2.1.5.4 SPECT calibration
Absolute quantification, i. e. calibration, of SPECT images to obtain units of activity or activity con-
centration (Bq or Bqml ) can be performed via several methods [30, 134]. The appropriate method should
be chosen according to radionuclide of interest and the accuracy of the reconstruction algorithm under
usage [35]. A common way to determine calibration factors for absolute SPECT quantification is to use
a large homogeneous phantom of known activity concentration, whereupon the phantom should be
imaged and reconstructed in the same manner as it is done for patient cases. The reconstructed and
relatively quantified counts per second can be set into relation to the known phantom activity to obtain
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Figure 2.8: NEMA body phantom containing six spheres of varying volume (0.5-26.5 ml), filled with a
Lu-177 sphere-to-background ration of 16-to-1 and 8-to-1. Reconstruction was based on a MAP algorithm
(20 subsets and 16 iterations), which included corrections for photon flux attenuation, photon scattering,
and resolution compensation.
Table 2.1: Recovery for the NEMA body phantom of Figure 2.8.
sphere volume [ml] RC 16-to-1 [%] RC 8-to-1 [%]
26.5 94 88
11.5 88 75
5.6 79 54
2.6 56 45
1.2 41 32
0.5 17 22
background 99 96
a final calibration factor (Bqcps ).
2.1.5.5 Accuracy of SPECT quantification
The accuracy of SPECT quantification is highly dependent on the reconstruction algorithm including
the considered corrections, the radionuclide and the γ-energy under usage, and the typical object size of
interest [35, 86]. Especially, the finite spatial resolution of the imaging system for the radionuclide and γ-
energy of interest limits the quantification capabilities for small objects (see section 2.1.3). Although for
iterative reconstruction algorithms quantification of small objects improves with increasing number of
iterations, full object recovery cannot be reached, considering also that convergence has to be balanced
against noise and artefacts for MLEM- or OSEM-based reconstruction (see section 2.1.4). Figure 2.8
shows a NEMA body phantom containing six spheres of varying size (0.5-26.5 ml) within a fillable
background volume, and which contains a Lu-177 solution with a sphere-to-background ratio of 16-to-
1 and 8-to-1. Via such an experimental setting, the expected recovery (RC) for a given reconstruction
algorithm and imaging setting can be investigated, while the RC is obtained by comparing the known
activity within spheres and background (Atrue) with the reconstructed activity in each compartment
(Areconstructed):
RC[%] =
Areconstructed
Atrue
· 100. (2.10)
Table 2.1 indicates a RC of less than 100 % for the largest sphere of 26.5 ml, for a MAP reconstruction
(20 iterations and 16 subsets), which included corrections for photon flux attenuation, scattering, and
resolution compensation [33]. Further, a decreasing RC for decreasing sphere sizes is noted, while for
the large background volume a RC close to 100 % is reached. Particularly, for the background volume a
RC less than 100 % is more likely attributed to an uncertainty in the dose calibrator measurement, i. e.
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Atrue.
A RC of less than 100 % for small objects especially implies a systematic underestimation of the activity
within small lesions, and thus of the absorbed radiation dose to malignant structures. Methods for
experimental or intra-reconstruction RC-correction (i. e. spill-over correction) exist, however, applying
these corrections in a correct manner is challenging, as the RC is known to be affected by various aspects,
e. g. lesion-specific foreground-to-background ratio (Figure 2.8 and Table 2.1) or the exact object shape.
Furthermore, the determined RC is highly dependent on the exact contouring method (e. g. CT volume,
isocontour) [35, 75]. Experimental RC-correction aims at determining correction factors from phantom
measurements as shown in Figure 2.8. Intra-reconstruction RC-correction, e. g., tries to estimate object
boundaries from additional image information (e. g. CT, MRI) to correct for spill-over effects [36].
However, the quality of the latter correction method is highly dependent on the quality of the employed
additional information. Using an inadequate object information can even lead to a worsening of the
results compared to a reconstruction without RC-correction. Particular care has to be taken if anatomical
images (e. g. CT, MRI) shall be used for spill-over correction in molecular imaging.
2.1.5.6 Planar image quantification and comparison to quantitative SPECT
Planar image quantification usually covers corrections for photon flux attenuation and photon scatter-
ing, and final image calibration. While planar scatter correction can be performed window-based as dur-
ing quantitative SPECT reconstruction, particularly accurate attenuation correction is more challenging,
as an appropriate whole-body transmission measurement - unlike for hybrid SPECT/CT imaging - is in
general not available a priori. The situation is further complicated as during planar scintigraphy only
two-dimensional projections, e. g. anterior and posterior (Figure 1.2), of the radionuclide distribution
are acquired, leading to an inherent overlap between main accumulating structures [115]. Planar atten-
uation correction, to obtain the corrected activity As within a region of interest, is usually performed via
the conjugate view method:
As =
√
Ia · Ip
e−µ·L
·
µs·Ls
2
sinh
(
µs·Ls
2
) . (2.11)
Ia and Ip denote the measured anterior and posterior count signal, respectively, while µ, L, µs, and
Ls refer to the effective attenuation coefficient and thickness of both, patient and region of interest [43,
115]. However, particularly the determination of pixel-wise values for µ, L, µs, and Ls is challenging
without an appropriate transmission measurement, and usually a reference attenuation coefficient (e.
g. soft tissue) is applied, in combination with reference thicknesses for L and Ls (e. g. average ab-
dominal diameter and average kidney thickness). However, as attenuation correction is one of the most
relevant factors during image quantification, such simplifying assumptions can lead to large errors. Pla-
nar transmission measurements can be performed in principal, however, these are time-consuming and
limit patient comfort and throughput [69, 76].
Planar scintigraphy is inherently associated with a signal overlap of main activity-accumulating sub-
structures, which complicates the determination of activity for individual regions of interest, i. e. single
OAR or lesions (Figure 2.9). Background subtraction can be applied to correct the activity assessment in
the region of interest for superimposed signal from the environment, although careful attention has to
be paid to appropriately select the background region of interest [45, 115]. If sub-regions of the overall
region of interest can be identified as overlap-free, these can be employed to derive an estimate of the
overall region activity otherwise [45]. The challenging correction for background signal in planar im-
ages leads to an often observed positive bias of planar-based ID compared to absorbed dose estimates
from 3D SPECT-based imaging [46].
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Figure 2.9: Sequential anterior whole-body planar scintigraphy of a mCRPC patient treated with 3.7 GBq
Lu-177-DKFZ-PSMA-617. In particular, an increasing superposition of kidney and intestine activity is
noticeable for late time points.
Due to the limited accuracy of planar image correction, final calibration has to be performed patient-
specific. For calibration of patient-images, typically a patient-specific calibration factor is obtained via
the known net activity within the patient body (e. g. administered activity minus measured excretion)
[115]. Patient-specific net-activity-based calibration can adjust for a systematic bias in the whole-body
activity, however, errors in smaller substructures cannot be generally full balanced. In combination with
an increasing interest for 3D absorbed dose modelling, planar scintigraphy is more and more replaced
by quantitative SPECT imaging for issues of ID, favoured by the fact that more and more commercial
tools for quantitative SPECT reconstruction in combination with modern hybrid SPECT/CT systems
are available. If full SPECT-based therapeutic imaging is not possible, at least combined SPECT-planar
imaging protocols are recommended [46, 69, 78].
2.1.6 Positron-Emission-Tomography
Diagnostic compounds, targeting sstr or PSMA, and labelled with Gallium-68 (short: Ga-68) or Fluor-18
(short: F-18) are widely used for pre-therapeutic disease staging or therapy response evaluation (Figure
1.1) [1, 2, 8, 73, 74, 81]. Ga-68 and F-18 decay via a short half-life of approximately 70 and 110 minutes,
respectively, via β+-decay. Within the patient body, the released positron or β+-particle nearly immedi-
ately (range of a few mm in soft tissue) annihilates with a surrounding electron, under subsequent emis-
sion of two co-incident and almost oppositely directed 511-keV annihilation photons. For 3D imaging of
the intra-patient radionuclide distribution via Positron-Emission-Tomography (PET), this annihilation
radiation can be measured in co-incidence within a ring detector, which is build up of various scintil-
lation crystals. The requirements regarding image-degrading effects, image reconstruction, and image
quantification are quite similar to Gamma camera imaging. A detailed description of PET imaging and
PET image reconstruction can be found in [7]. An important difference of PET compared to Gamma
camera imaging poses the electronic instead of mechanical collimation, which leads to a superior spatial
resolution and quantification capabilities for PET.
Chapter 2. Basics of nuclear medicine imaging and internal dosimetry 15
2.2 Internal Dosimetry
2.2.1 MIRD scheme
Dosimetry during RT is needed to ensure a sufficiently high radiation absorbed dose to malignant struc-
tures to guarantee disease remission or at least control, while ensuring an absorbed dose as low as
reasonable achievable to OAR. The physical radiation absorbed dose for a target of interest, e. g. lesion
or OAR, can be derived from the radiation-deposited energy E per target mass m [95]:
D =
E
m
. (2.12)
As a nuclide-specific amount of energy is released per radioactive decay, ID requires the knowledge of
the amount of activity at each location within the patient body and for each time point. Quantitative
imaging, preferably via SPECT, is the easiest and at the same time probably most accurate method
to asses the intra-body radionuclide distribution in OAR and lesions (see section 2.1.5.6) [17, 35, 86].
However, a permanent measurement of the patient-specific intra-body activity distribution is in general
not possible. Thus, usually the activity Ai at a defined number of time points ti with i = 1, ..., N is
measured. To describe the full time course of the intra-body activity within a region of interest (source;
e. g. lesion, OAR, or single voxel) from injection (i. e. t=0) until infinity (i. e. until the last decay), an
appropriate mathematical function model A(t) has to be fitted to the data points (Ai,ti) (Figure 2.10).
Selected fit model, and the number and frequency of sampling points should be in agreement with the
therapy-dependent pharmacokinetic [115]. However, routine clinical ID requires a trade-off between
accuracy on the one hand, and patient burden as well as clinical workload on the other. Thus, the
selected fit model and sampling of data points should be additionally adjusted according to clinical
feasibility. Most of the pharmacokinetic models in use are based on a mono-exponential function (single
pharmacokinetic phase),
A(t) = A(t = 0) · exp
(
− ln(2)
T 1
2 ,eff
· t
)
, (2.13)
or a sum of exponential terms to model multiple pharmacokinetic phases [115, 118]. For the mono-
exponential model of equation (2.13), A(t = 0) denotes the initial phase activity (e. g. at start of
injection), while T 1
2 ,eff
represents the phase-specific effective half-life, respectively, effective activity
wash-out a, being driven by both, physical decay and biological processes:
T 1
2 ,eff
=
T 1
2 ,physical
· T 1
2 ,biological
T 1
2 ,physical
+ T 1
2 ,biological
. (2.14)
Both, A(t = 0) and T 1
2 ,eff
, have to be determined from the function fit to the measured data (Ai,ti).
Although, e. g., a bi-exponential function model can come closer to the real patient pharmacokinetic
for some applications (e. g. kidneys during Lu-177-PRRT), a bi-exponential function model (four free
parameters) ideally requires at least five to six quantitative measurements, compared to at least three for
a mono-exponential model (two free parameters) [115]. Thus, the gain of accuracy has to be balanced
against clinical requirements [34].
The total number of disintegrations within a source region, i. e. the so-called time-integrated activity
A˜source, can then be obtained via integration over the full time span of irradiation [17]:
A˜source =
∫ ∞
0
Asource(t). (2.15)
According to the dosimetry scheme developed by the Medical-Internal-Radiation-Dose (MIRD) commit-
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Figure 2.10: Kidney dosimetry based on sequential quantitative SPECT imaging at 24, 48, and 72 h
p. i. for a NET patient treated with 7.4 GBq Lu-177-[DOTA0,Tyr3]-Octreotate. Respective dosimetry
was based on mass-scaled kidney S-values and a mono-exponential function model, resulting in absorbed
doses of 5.3 Gy (left kidney) and 4.4 Gy (right kidney).
tee, the mean absorbed doseD to a target region of interest can be derived via multiplication of the time-
integrated activity A˜source within a defined source region with appropriate absorbed dose conversion
factors (S-values (S)). These S-values have been tabulated for many radionuclides and source-to-target
organ combinations of interest [120]:
Dtarget←source = A˜source · Starget←source. (2.16)
Starget←source thereby describes the nuclide-specific fraction of energy, which is released in the source
region and deposited in the target region, per single radioactive decay, and per target mass m. For
short-range-dominated emitters (β−-emitter or α-emitter), the self-irradiation or self-absorbed dose (i.
e. source = target) is the dominating absorbed dose component for main accumulating tissues (e. g.
lesions, kidneys). For other targets, which show no or only a minor accumulation of the radiopharma-
ceutical (e. g. bone marrow for Lu-177-PRRT or Lu-177-PSMA), cross-irradiation (i. e. source 6= target)
from the therapy-specific main accumulating structures (e. g. via a long-range photon component) can
become important [33, 110].
Absorbed dose calculation via S-values represents the state-of-the-art method due to its simplicity. How-
ever, S-values are pre-calculated based on reference anatomies (phantoms) and standardized activity
accumulations, i. e. a homogeneous uptake in source regions. Thus, S-values enable only a highly re-
stricted consideration of the patient-specific anatomical and molecular characteristics [117, 118]. Mass-
scaling via phantom and patient target masses can be employed to adapt S-values more to the patient-
specific anatomy [29]. However, although mass-scaled S-values can be used to calculated the mean
absorbed dose for self-irradiation and for short-range radiation (i. e. β−,α), mass-scaling is particu-
larly complex and inaccurate for the description of photon-based cross-irradiation (e. g. bone marrow
dosimetry for Lu-177-based therapies) [64, 125]. Furthermore, consideration of lesions within S-value
dosimetry is challenging, as particularly advanced cancer disease is typically associated with multiple
lesions of varying shape, size, and location. Only a very simplistic approach to model the self-absorbed
dose for lesion dosimetry via S-values is available, as no pre-calculation of S-values for all kind of lesion
sizes, shapes, and positions is feasible. Thus, for lesion dosimetry, S-values for unity density spheres of
varying size are employed [119].
2.2.2 Patient-specific 3D internal dosimetry
Classical use of organ or sphere S-values, although practical in their application, allows only for a re-
stricted consideration of the 3D patient-specific anatomical and molecular characteristics, and only pro-
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Figure 2.11: Simulated energy distribution around a Lu-177 source voxel (0.1 x 0.1 x 0.1 mm3; FLUKA
Monte Carlo code).
vides mean target absorbed doses [29, 117, 118]. However, tomographic imaging (e. g. quantitative
SPECT/CT) directly enables to asses the patient-specific 3D tissue and activity distribution, and there-
fore can be employed for 3D absorbed dose modelling down to the size of a single voxel (approximately
5 mm for SPECT), which represents the smallest unit of a three dimensional image, similar to a kind of
technical spatial resolution. The physical spatial resolution of the derived 3D absorbed dose distribu-
tion is in turn driven by the physically available spatial resolution of the imaging system, radionuclide,
and reconstruction algorithm (2.1.5.5), but can be roughly estimated as 5-25 mm for SPECT(full-width
half-maximum) [35].
The Monte Carlo method represents the gold standard for absorbed dose modelling, as it is capable to
simulate all physical effects relevant for absorbed dose deposition within a defined environment in a
step-by-step matter, by sampling all relevant information from the known physical probability laws of
particle-matter-interaction [112]. Further, many common codes offer the possibility to directly import
the patient-specific medical image data (CT, SPECT, PET), leading to a full consideration of the patient-
specific 3D tissue and accumulation characteristics [19, 27, 79, 87, 89]. However, due to their high com-
plexity Monte Carlo simulations require a high computational demand, and should be performed on
computing clusters to ensure an acceptable calculation time. Further, although default non-commercial
solutions for many codes exist, the capabilities to set up a Monte-Carlo-based ID workflow is limited to
larger clinics.
The use of absorbed dose kernels constitutes an intermediate method between a full Monte Carlo simu-
lation and simplistic absorbed dose conversion factors. Absorbed dose kernels are simulated for a fixed
tissue type (e. g. soft tissue), and model the absorbed dose distribution around a point source of activity
(dose point kernel), or around a whole voxel containing a homogeneous activity distribution (voxel S-
value kernel) (Figure 2.11) [16, 84, 98]. The latter is more practical for clinical use, as the medical image
data is usually represented on a voxel grid, and as voxel S-value kernels can be consequently directly
convolved with the patient-specific activity distribution [16]. Absorbed dose kernels can fully consider
the patient-specific 3D activity information, however, as absorbed dose kernels are pre-calculated based
on a fixed tissue type their validity in highly heterogeneous anatomic regions is limited, although ap-
proaches to adjust absorbed dose kernels to the anatomical environment exist [4, 91, 108, 109]. Voxel
S-value kernels can provide a fast and sufficiently accurate method to calculate the 3D absorbed dose
distribution of short-range particles with a maximum range below the employed voxel size, while the
accuracy to describe the long-range photon absorbed dose component is limited, particularly without
any corrections for tissue heterogeneity [64].
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The currently most limiting factor of 3D image-based absorbed dose modelling is the challenging deter-
mination of the voxel-wise time-integrated activity. The latter requires a voxel-wise fit to multiple quan-
titative image acquisitions, and therefore ideally demands a perfect co-registration of all time points.
However, co-registration is complicated by imperfect patient re-positioning between individual image
acquisitions, as well as by intra-body or patient motion between or during the imaging sessions. Non-
rigid co-registration can improve voxel-wise fitting for sub-body parts (e. g. organ-based), however,
nonetheless requires careful and time-consuming monitoring. Special care has to be taken regarding
activity preservation in case of larger deformations and volume changes [6, 68].
Besides imperfect co-registration, 3D absorbed dose distributions during ID are affected by spill-over,
noise, and image artefacts (see sections 2.1.4 and 2.1.5.5). These effects are known to significantly al-
ter the absorbed dose distributions, which currently prevents a pure physiological interpretation for
evaluation of therapy response [88]. Image-errors are one of the most relevant sources of absorbed dose
uncertainties [66], although ongoing effort tries to optimize in particular quantitative SPECT reconstruc-
tion for 3D ID [26].
2.2.3 State-of-the-art bone marrow dosimetry
The bone marrow is currently the most challenging and most effort-demanding, although probably also
the most important OAR during ID. The latter is particularly true for Lu-177-PSMA therapy, as patients
suffering from advanced mCRPC typically show a pronounced cancer infiltration of bone structures, a
resulting pronounced uptake of the radiopharmaceutical within usual marrow-bearing regions (Figure
1.1 and 1.2), and a potentially already limited hematological function due to various pre-therapies [33,
102, 110].
State-of-the-art bone marrow ID is likewise based on the usage of S-values to model all relevant
absorbed-dose-delivering components, and generally requires a large effort regarding appropriate data
collection, including blood activity counting, whole-body activity measurements, and quantitative
imaging [70]. The total bone marrow absorbed dose can be described as the composition of the bone
marrow (BM) self-irradiation, as well as of the cross-irradiation via accumulation within non-marrow
bone structures, major accumulating organs, and the remainder of the body (ROB):
DBM = DBM←BM +DBM←bone +DBM←organs +DBM←ROB (2.17)
= A˜BM · SBM←BM + A˜bone · SBM←bone + A˜organs · SBM←organs + A˜ROB · SBM←ROB . (2.18)
The ROB time-integrated activity is thereby defined as the whole-body time-integrated activity (A˜WB),
minus the time-integrated activity of all defined source regions:
A˜ROB = A˜WB − A˜BM − A˜bone − A˜organs. (2.19)
The bone marrow self-absorbed dose is in turn dependent on a potential specific binding of the radio-
pharmaceutical by bone marrow or blood cells, as well as on an activity uptake within the extracellular
fluid fraction (ECF) of the bone marrow compartment:
DBM←BM = DBM←BMcells +DBM←BLOODcells +DBM←ECF (2.20)
= (A˜BMcells + A˜BLOODcells + A˜ECF ) · SBM←BM . (2.21)
As stated in section 2.2.1, the appropriate modelling of cross-irradiation is limited via usage of S-values,
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although the accuracy can be improved via mass scaling with phantom and patient organ masses [125].
Furthermore, classical S-value bone marrow ID does not include a concept for the cross-irradiation from
tumor lesions, as no tabulated S-values can be provided for each kind of patient-specific lesion dis-
tribution [110]. However, even if S-values for all kind of lesion positions, shapes, and sizes could be
tabulated, the manual or semi-automatic determination of each lesion time-integrated activity and bone
marrow cross-absorbed dose would not be feasible for high-lesion-load patients.
In addition to these restrictions, S-value bone marrow ID is further complicated as the patient-specific
bone marrow distribution is not accounted for. As S-values are pre-calculated based on reference
anatomies, S-value bone marrow dosimetry assumes a physiological bone marrow distribution [70].
However, the bone marrow is a highly variable OAR, and its exact distribution is known to be altered
by multiple patient-specific parameters, particularly the presence and extent of bone metastases [90, 94].
As the patient-specific bone marrow distribution is, so far, not assessed prior to RT, the validity of state-
of-the-art bone marrow ID is highly restricted by an undefined target localization. In particular, the
heterogeneous bone marrow micro-structure is not accessible throughout the whole skeleton via state-
of-the-art in vivo imaging. Further, even if the patient-specific whole-body bone marrow distribution
can be made available prior to RT, a complete adjustment of tabulated S-values to the patient-specific,
highly in-homogeneous, and 3D bone marrow distribution is not possible. Thus, to increase patient-
specificity during bone marrow ID advanced Monte-Carlo-based methods are required [71, 113].
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3 | Studies
3.1 Motivation and objectives of this thesis
The aim of this thesis was to extend classical bone marrow internal dosimetry (ID) for Lu-177-based
radionuclide therapy (RT) to clinical demands, which require a permanent trade-off between efficiency,
patient-comfort, and accuracy. The hematologically active and highly radio-sensitive bone marrow is
an important organ-at-risk (OAR) for Lu-177-PRRT of neuroendocrine tumor (NET) disease, and cur-
rently possibly the most critical organ during Lu-177-PSMA therapy of metastasized castration-resistant
prostate cancer (mCRPC), particularly regarding high-risk mCRPC patients with a pronounced skeletal
tumor burden. However, state-of-the art bone marrow dosimetry requires a large number of quanti-
tative measurements to gather the Lu-177 time-activity-curve (TAC) information in all relevant accu-
mulating source regions (see section 2.2.3). The so far requested large number of patient examinations
limits the application of routine bone marrow dosimetry, if multiple therapies per week shall be offered
to patients suffering from advanced cancer disease and a bad health condition. In addition, classical
ID for RT is based on absorbed dose conversion factors (S-values), which were tabulated for reference
anatomies and simplified accumulation patterns (i. e. homogeneous uptake in defined source regions).
However, S-value-based ID was originally transferred from applications of radiation protection (e. g.
diagnostic applications) to radionuclide therapy, and consequently provides only a very simplistic con-
cept to account for the presence of lesions (see section 2.2.1). By contrast, bone marrow ID for patients
with excessive skeletal metastases requires an improved consideration of the patient-specific 3D disease
and anatomical characteristics, to model the bone marrow cross-irradiation via radiopharmaceutical up-
take in skeletal metastases.
In the scope of the first publication underlying this thesis [51], an efficient and patient-friendly quan-
titative measurement scheme for clinical bone marrow ID was developed. The latter was compared to
a state-of-the-art, although clinically hardly feasible measurement protocol during S-value-based bone
marrow ID of patients suffering from NET or mCRPC. The included hybrid planar-SPECT approach is
based on a TAC model developed during the attempts to provide an efficient multi-cycle dosimetry for
kidneys and lesions for both, Lu-177-PRRT of NET and Lu-177-PSMA therapy of mCRPC. Thus, the pro-
posed overall dosimetry protocol shall meet the requirements to provide an absorbed dose assessment
for the bone marrow, non-marrow OAR, and lesions.
The second objective of this thesis was to design an approach for clinical patient-specific 3D bone mar-
row dosimetry, via usage of Monte-Carlo-based 3D absorbed dose modelling in combination with the
Lu-177 TAC information gathered via the optimized measurement scheme of the first objective. This
proposed dosimetry workflow can be further combined with image-based localization of the patient-
specific 3D distribution of the hematologically active bone marrow. During the second publication un-
derlying this thesis [58], this Monte Carlo dosimetry workflow was applied to Lu-177-PSMA therapy, as
a preliminary study based on a sub-group of mCRPC patients already indicated a positive correlation
between S-value-based bone marrow absorbed doses and the patient-specific metastatic bone load. This
preceding study therefore clarified the need to provide more accurate and patient-specific dosimetry
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methods for risk patients with pronounced skeletal metastases.
3.2 Objective 1
3.2.1 Preceding investigation of the feasibility of single-SPECT kidney and lesion dosimetry
The following preceding study was presented in [56] and [57].
Table 3.1: Imaging parameters used for Lu-177 SPECT and Lu-177 whole-body planar acquisitions.
Photopeak (width) 208 keV (15 %)
Collimator MELP (medium-energy low-penetration)
Scatter windows (width) lower: 170 keV (15 %)
upper: 240 keV (10 %)
SPECT configuration 2 heads in H-mode (180◦-orbit per head)
SPECT projections per head & time per projection 64 & 15 s
SPECT projection matrix 128 x 128 pixel (4.8 x 4.8 mm2)
Planar scan length & scan speed 200 cm and 10 cm/min
Figure 3.1: Overview of measurement schemes for lesion and kidney internal dosimetry: Full sequen-
tial quantitative SPECT (QSPECT) imaging is proposed for dosimetry during cycle 1, and applied for
reference dosimetry of cycle 2. Further, for cycle 2 a reduced single-SPECT measurement scheme is
investigated.
As it is the case for bone marrow ID, absorbed dose assessment for lesions and kidneys usually requires
multiple quantitative measurements, preferably via SPECT imaging (see section 2.1.5.6). Further, pa-
tients usually undergo several therapy cycles of Lu-177-PRRT or Lu-177-PSMA therapy. This therapy
scheme implies the question whether the same number of quantitative measurements is required for
each individual therapy cycle, or whether information gathered over multiple cycles can be appropri-
ately combined to reduce the number of measurements for selected therapy cycles with preservation of
a defined demand on accuracy. In this context, a reduced measurement scheme was investigated and
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established for lesion and kidney dosimetry for both, Lu-177-PRRT and Lu-177-PSMA therapy [56, 57].
The aim was to combine a single SPECT image acquired during the therapy cycle of interest with the
patient-specific pharmacokinetic information gathered in a previous therapy cycle, for which sequential
SPECT imaging had been performed. This approach required both, to identify the appropriate timing
of SPECT imaging within the reduced dosimetry measurement scheme and to understand the course of
the patient-specific pharmacokinetic behaviour over multiple therapy cycles.
The study employs data from the first and second therapy cycle of 12 patients, who underwent Lu-177-
PRRT (six patients with on average 7.4 GBq Lu-177-[DOTA0,Tyr3]-Octreotate) or Lu-177-PSMA therapy
(six patients with on average 3.7 or 6 GBq Lu-177-DKFZ-PSMA-617). Each patient obtained, amongst
others, three 15-minute lasting SPECT acquisitions at approximately 24, 48, and 72 h p. i., either on
a dual-headed Siemens Symbia T2 SPECT/CT or on a Siemens ECam SPECT system, with usage of a
standard Lu-177 imaging protocol (Table 3.1) [33, 86].
For cycle 1 and cycle 2, reference dosimetry was assessed for the kidneys, representing an important
OAR for both, Lu-177-PRRT and Lu-177-PSMA therapy, and three selected lesions. For each cycle,
volumes of interest (VOI) were semi-automatically drawn on the SPECT at 24 h p. i., by usage of an
isocontour 30-40 % of the kidney maximum, or a 40-%-isocontour with regard to the mean over the
lesion-specific three highest voxel values. Each VOI was manually co-registered onto the SPECT images
at 48 and 72 h. Further, reference dosimetry was based on a mono-exponential fit to the time-activity-
data, in combination with mass-scaled kidney and soft-tissue sphere S-values (see section 2.2.1) [120]:
Starget←source,patient = Starget←source,phantom · mphantom
mpatient
. (3.1)
After full dosimetry assessment for both cycles, the VOI-specific percent changes regarding absorbed
dose, uptake concentration (fitted at t=0), and effective half-life were investigated.
For cycle 2, reference dosimetry results were compared to the absorbed dose assessment via a reduced
single-SPECT dosimetry scheme. The latter combines a mono-exponential function model with the
VOI-specific effective half-life of the first therapy cycle (T 1
2 ,Cycle1
), and a SPECT-based VOI-uptake
measurement at time t∗ p. i. of cycle 2 (ACycle2(t∗)) (Figure 3.1). 24, 48, and 72 h p. i. were investigated
as possible time points for t∗. From this single-SPECT TAC model, the VOI-specific time-integrated
activity can be obtained as follows:
A˜Cycle2(t∗) = ACycle2(t∗) · exp
(
ln(2)
T 1
2 ,Cycle1
· t∗
)
·
T 1
2 ,Cycle1
ln(2)
. (3.2)
For Lu-177-PRRT, no significant change of the mean (± standard deviation) kidney absorbed dose from
cycle 1 to 2 was found (cycle 1: 0.8 ± 0.3 Gy/GBq; cycle 2: 0.8 ± 0.4 Gy/GBq), although for individual
cases changes of up to 74 % were observed. An increasing absorbed dose from cycle 1 to 2 was mostly
attributed to a respective increase in the effective half-life (Figure 3.2). Regarding all investigated kidney
VOIs, changes of 18 % and 22 % were observed regarding the fitted uptake concentration and the effec-
tive half-life, respectively. The mean lesion absorbed dose slightly decreased from 4.9 ± 4.0 Gy/GBq to
3.9 ± 1.9 Gy/GBq, due to a reduction of the individual lesion absorbed dose particularly for patients P4
and P6 (Figure 3.2). This absorbed dose decrease was mainly attributed to an uptake decrease. Concern-
ing all selected tumors, the absolute change of lesion uptake concentration and effective half-life was
found to be 31 % and 46 %, while in 50 % of the all investigated tumor VOIs the effective half-life was
the dominating factor for a change in the absorbed dose (Figure 3.2).
The analysis of Lu-177-PSMA data revealed similar results. For the mean kidney absorbed dose no
severe change was observed from cycle 1 to 2 (cycle 1: 0.6 ± 0.2 Gy/GBq; cycle 2: 0.6 ± 0.2 Gy/GBq),
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Figure 3.2: Multi-cycle dosimetry for Lu-177-PRRT: The upper row visualizes percent changes of the
absorbed dose for both, kidneys and lesions. The lower row compares the change of uptake concentration
(t=0) and effective half-life. E. g., a value grater that one indicates that the change in absorbed dose
from cycle 1 to 2 was mostly driven by a respective uptake change.
Figure 3.3: Multi-cycle dosimetry for Lu-177-PSMA therapy: The upper row visualizes percent changes
of the absorbed dose for both, kidneys and lesions. The lower row compares the change of uptake
concentration (t=0) and effective half-life. E. g., a value grater that one indicates that the change in
absorbed dose from cycle 1 to 2 was mostly driven by a respective uptake change.
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Table 3.2: Percent deviations of absorbed dose estimates achieved with the reduced dosimetry protocol
using a single SPECT at 24, 48, or 72 h p. i., compared to respective results from the reference protocol
employing sequential SPECT imaging.
VOI 24 h 48 h 72 h
Lu-177-PRRT
Kidney 14.7 ± 7.9 % 6.4 ± 3.5 % 5.8 ± 3.4 %
Tumor 21.6 ± 12.6 % 20.8 ± 12.6 % 7.4 ± 5.1 %
Lu-177-PSMA
Kidney 10.8 ± 11.3 % 5.2 ± 2.2 % 8.0 ± 4.0 %
Tumor 49.1 ± 38.4 % 16.8 ± 16.0 % 9.6 ± 9.3 %
despite an increase of individual absorbed doses for 50 % of the investigated VOIs. The latter was
mainly attributed to an increased uptake, i. e. for five out of six VOIs (Figure 3.3). Both, the change
of kidney uptake concentration and effective half-life, were calculated to be 15 %. The average tumor
absorbed dose severely decreased from 5.0 ± 5.1 Gy/GBq to 1.8 ± 1.3 Gy/GBq. This observation was
linked to a reduction of the individual lesion absorbed dose for 83 % of the investigated VOIs, with
effective half-life and lesion uptake concentration being nearly equally responsible (Figure 3.3). With
regard to all investigated lesion VOIs, the effective half-life changed on average by 38 %, while for the
uptake concentration a mean change of 62 % was observed from cycle 1 to 2.
Although the effective half-life can significantly change between successive treatment cycles, a reduced
dosimetry scheme based on the effective half-life of the previous cycle was found to be feasible within
an expected uncertainty of approximately 10 %, if imaging is based on a late time point (72 h p. i.)
(Table 3.2). This accuracy is well satisfying regarding the typical uncertainty of image-based ID [66] (see
section 2.1.5.5), if routine dosimetry particularly for non-risk patients shall be balanced against clinical
workload and patient burden. The maximum time point of 72 h p. i. is defined according to the local
institution’s dosimetry scheme, while the applicability of a single-SPECT measurement protocol based
on a later time point has to be investigated separately, if necessary.
3.2.2 Studies on an efficient data acquisition for clinical bone marrow internal dosimetry
This section provides a short description and summary of the first publication [51] underlying this thesis. Further,
relevant findings presented in [52] and [53] shall be described, to give a complete overview of efficient data
acquisition for clinical bone marrow ID.
Complementary to the investigations described in the previous section, which resulted in the single-
SPECT protocol for non-marrow OAR and lesion dosimetry for, e. g., every second cycle, an efficient
and robust acquisition and processing protocol had to be explored and established for the estimation of
the radiation absorbed dose to the active bone marrow during Lu-177-PRRT and Lu-177-PSMA therapy.
While dosimetry for lesions and non-marrow OAR can be performed solely relying on 3D quantitative
SPECT (see section 2.1.5.6), bone marrow ID additionally requires the determination of the whole-body
and blood time-activity-curves (TAC) to derive the absorbed dose contribution from the remainder-of-
the-body (ROB) and the blood (see section 2.2.3). Whole-body activity measurements can be performed
via probe measurements, however, whole-body imaging is preferable, as it provides additional infor-
mation regarding the patient-specific activity distribution for therapy evaluation. The optimum would
be to acquire a whole-body quantitative SPECT, however, whole-body SPECT acquisitions within an
acceptable patient examination time have not been fully introduced to clinical routine, yet. Thus, in
order to obtain high-quality dosimetry for lesions and non-marrow OAR, and to allow for bone marrow
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Figure 3.4: Classical (reference) dosimetry measurement protocol to allow for tumor, non-marrow OAR,
and bone marrow ID, and proposed hybrid dosimetry scheme.
dosimetry, sequential SPECT and whole-body planar acquisitions including net-activity counting are
typically combined, leading to an increase in clinical workload and patient burden (Figure 3.4) [110].
A common image-based Lu-177 dosimetry protocol, as described in Table 3.1 and Figure 3.4, requires
examination times of approximately 45 minutes three times per patient and per treatment cycle. On the
other hand, determination of the blood time-activity-curve is usually based on a bi-exponential model,
which ideally requires a high number of sampling points to accurately model each pharmacokinetic
phase. The minimum number would be five, however, using the lowest possible number of blood sam-
ples requires adequate timing of each sample.
The aim of this study was to provide a more efficient workflow for routine bone marrow dosimetry
by appropriately condensing SPECT and planar whole-body information into a hybrid SPECT-planar
protocol, which allows for both, SPECT-based dosimetry for lesions and non-marrow OAR, as well as
an estimation of the whole-body TAC (Figure 3.4) [51–53]. The proposed dosimetry scheme is based on
the single-SPECT TAC model proposed in section 3.2.1 [56, 57], and combines sequential quantitative
SPECT imaging of the abdomen with a single whole-body planar scintigraphy acquired at a suitable
time point t∗. The sequential SPECT was employed to estimate the effective whole-body wash-out by
applying a mono-exponential fit to the total abdominal SPECT activity. This SPECT-based TAC was
scaled with the whole-body uptake measurement at time point t∗ (AWB(t∗)) afterwards, resulting in an
estimate of the true whole-body TAC and its respective time-integrated activity (A˜WB,pseudo):
A˜WB,pseudo = AWB(t
∗) · exp
(
ln(2)
T 1
2 ,SPECT
· t∗
)
·
T 1
2 ,SPECT
ln(2)
. (3.3)
Similar to study 3.2.1, the appropriate timing t∗ of the single whole-body planar measurement had to be
determined. In agreement with the institution’s therapy procedures, 24, 48, and 72 h p. i. were investi-
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Figure 3.5: Analysis of the ratio of fast-to-slow blood clearance (average over eight Lu-177-PSMA cycles);
the dashed blue line denotes the proposed timing for early blood sampling (i. e. 20/60 min post infusion).
The red line denotes the drop of the fast-to-slow clearance ratio from 1 to 0.01.
gated as possible time points.
Further, a cross-calibration of whole-body planar images via the quantitative SPECT of the correspond-
ing time point was investigated (Figure 3.4), to replace the need for excreta counting. The latter had been
performed, so far, to allow for planar image calibration via the known patient-specific net-activity (see
section 2.1.5.6), however, was likewise associated with a high clinical workload. The proposed cross-
calibration is based on the fact that the total abdominal SPECT activity (ASPECT ) should be equal to the
counts per second (xplanar) contained in the equivalent body region of the corresponding planar image,
multiplied with a suitable patient-specific calibration factor (CSPECT−planar):
CSPECT−planar =
ASPECT
xplanar
. (3.4)
This SPECT-based cross-calibration of planar images was pre-investigated for eight Lu-177-PSMA ther-
apy cycles of four mCRPC patients, who received on average 3.7 GBq Lu-177-DKFZ-PSMA-617 [52].
For these patient cohort excreta counting, and full sequential Lu-177 SPECT imaging and whole-body
planar imaging was available (Table 3.1). A comparison of conventional net-activity calibration and
SPECT-based calibration at 24 h p. i. yielded an average deviation of 5.7 ± 4.8 %, and strong correlation
(Pearson'r=0.7). This difference is well acceptable, considering also multiple sources of errors during
reference net activity counting itself (e. g. appropriate excreta sampling and uncertainty of activity mea-
surement).
Results from this study demonstrated that for both, Lu-177-PRRT and Lu-177-PSMA therapy, hybrid
SPECT-planar bone marrow dosimetry as proposed in Figure 3.4 is feasible within an average deviation
of less than 5 % compared to full sequential whole-body planar imaging, if single whole-body planar
imaging is performed at approximately 72 h (Lu-177-PRRT (mean ± standard deviation): 2 ± 2 %; Lu-
177-PSMA therapy: 3 ± 2 %) [51]. These results are thus in well correspondence with the experience
gathered during single-SPECT lesion and kidney dosimetry (see section 3.2.1 [56, 57]).
To achieve full optimization of quantitative measurements regarding clinical bone marrow dosimetry,
a reduced blood sampling scheme, was likewise investigated [52]. For the respective patient cohort,
extended blood sampling was performed, i. e. 2-3 ml of venous blood were drawn from the side contra-
lateral to injection at approximately 20, 30, 40, 60, and 80 min post start of infusion, to describe the fast
blood pharmacokinetic, as well as before each image acquisition session at 24, 48, and 72 h p. i. to
model the slow pharmacokinetic phase. The blood pharmacokinetic of this patient cohort was analyzed
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in order to find the optimal sampling scheme based on five blood samples, which is the minimum to
allow for bi-exponential curve fitting. The average effective half-life of the fast and slow blood clearance
phases were identified as 11 min and 8.5 h, respectively, while the fast blood clearance was found to
contribute on average 22 % to the total time-integrated blood activity and consequently blood-to-bone-
marrow absorbed dose. Analysis of patient-specific blood clearance curves indicated, that particularly
the appropriate blood sampling during the transition from fast to slow blood clearance is critical to accu-
rately represent the overall shape of the bi-exponential curve fit. Both phases equally contributed to the
overall blood clearance around 37 min post start of infusion, while the mean ratio of fast-to-slow blood
clearance rapidly drops to one-tenth and one-hundredth until 74 min and 111 min, respectively (Figure
3.5). Consequently, the full blood sampling protocol was compared to a reduced sampling scheme rely-
ing on an early blood sampling at approximately 20 and 60 min p. i., yielding an average deviation of
5.0 ± 5.6 %. For one investigated cycle, the deviation of the five-sample protocol from extended early
blood sampling reached 30 %, however, for this patient an untypically prolonged fast blood clearance
was noticed.
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3.3.1 Preceding study on the relevance of kidneys and bone marrow for high-lesion load mCRPC
patients
The following preceding study was presented in [59, 61, 62].
A simplification of ID by using a reduced number of quantitative measurements, as proposed in the
previous studies 3.2 and 3.3, is accompanied by the limitation that some dosimetric information can
not be retrieved, resulting in a decrease of accuracy. However, the accuracy of both, single-SPECT-
based dosimetry for lesions and non-marrow OAR and hybrid SPECT-planar bone marrow dosimetry,
is tolerable without doubt during clinical dosimetry for Lu-177-based RT of non-risk patients. By con-
trast, a dosimetry as accurate as clinically achievable should be performed for, e. g., NET or mCRPC
patients suffering from a decreased kidney excretion, or for patients with an expected high bone mar-
row absorbed dose. The risk of critical bone marrow absorbed doses is especially of concern during
Lu-177-PSMA therapy of mCRPC, and is currently probably the most limiting factor to exploit the full
therapeutic window of PSMA-targeting RT [102].
Figure 3.6 exemplarily shows the whole-body planar scintigraphy of two mCRPC patients at 24 h post
Lu-177-PSMA therapy (3.7-6 GBq Lu-177-DKFZ-PSMA-617). For patient case a), a strong retention of
the radiopharmaceutical in the visceral liver metastases is visible, accompanied by an accumulation in
typical OAR, i. e. both kidneys, the PSMA-positive salivary and lacrimal glands, as well as a begin-
ning accumulation in the PSMA-positive intestine. mCRPC patient b) presents with a pronounced bone
lesion load, leading to a nearly complete absorption of the radiopharmaceutical in the skeleton, while
the accumulation in kidneys, glands, and intestine is almost negligible. Patient b) thereby represents a
common clinical case during Lu-177-PSMA therapy of mCRPC, and further illustrates a severe conflict
regarding the current therapy approach: The accumulation pattern of patient case b) indicates a low ab-
sorbed dose to the typical non-marrow OAR, which would initially allow for a more aggressive therapy
approach by usage of higher amounts of radioactivity. However, the pronounced radiopharmaceutical
retention in the skeleton might lead to a significant cross-irradiation of the highly radio-sensitive active
bone marrow, and potentially result in severe hematological toxicity.
The presented study aimed at providing a first investigation of this initially intuitive assessment [59,
61, 62]. Using the developed hybrid SPECT-planar dosimetry protocol of study 3.2.2 in combination
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Figure 3.6: Anterior (left) and posterior (right) view of two mCRPC patients 24 h p. i. of approximately
3.7 (patient a) and 6 GBq (patient b) Lu-177-DKFZ-PSMA-617.
with a conventional sequential Lu-177 SPECT-based dosimetry (see study 3.2.1), the absorbed dose to
the bone marrow and the kidneys as exemplary non-marrow OAR was evaluated for 14 mCRPC pa-
tients (3.7 or 6 GBq Lu-177-DKFZ-PSMA-617; 10 mCRPC patients with available blood sampling), and
finally correlated to the patient-specific whole-lesion or bone tumor burden, respectively. The latter
was semi-automatically segmented on the pre-therapeutic Ga-68-PSMA-11 PET/CT data, based on a
40-%-isocontour threshold of the PET image maximum, intersected with a bone VOI derived from the
diagnostic CT of the PET/CT acquisition. To derive the total bone marrow absorbed dose, ROB, blood,
and the kidneys were considered as specific source regions (see section 2.2.3) [33, 44, 51, 110].
Average (± standard deviation) kidney and bone marrow absorbed doses were 0.33 ± 0.16 Gy/GBq
(range: 0.03-0.59 Gy/GBq) and 16 ± 10 mGy/GBq (range: 6-36 mGy/GBq). Kidney absorbed doses
were proven to show a significant and strong negative correlation with the segmented bone lesion load
(Pearson’s r=-0.9, p<0.05), while the bone marrow absorbed dose significantly increased with increas-
ing metastatic bone load (Pearson’s r=0.8, p<0.05) (Figure 3.7). For patient case a) presented in Figure
3.6, kidney and bone marrow absorbed doses of 0.56 Gy/GBq and 13 mGy/GBq were found, while for
mCRPC patient b) respective values were 0.07 Gy/GBq and 36 mGy/GBq. For the patient cohort under
study, ROB and blood contributed on average 66 % and 30 % to the total bone marrow absorbed dose,
while the contribution of the kidneys was nearly negligible (mean of 4 %; Figure 3.8).
Results from this study demonstrate that for mCRPC patients with a high metastatic lesion load the
bone marrow is the main OAR, leading to a strong need of dosimetry calculations as realistic as possi-
ble. Although S-value bone marrow absorbed doses were found to be well below the typically applied
critical threshold of 2 Gy [110], the significance of classical S-value bone marrow dosimetry for Lu-177-
PSMA therapy is limited, especially due to a missing patient-specific concept to accurately consider
bone marrow cross-irradiation from skeletal lesions (section 2.2.1). In this study, the overall lesion ac-
tivity was considered as part of the ROB compartment, which is one possible simplified approach to at
least account for the prolonged lesion-associated activity retention in the patient body (Figure 3.8) [110,
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Figure 3.7: Correlation of bone marrow (a) and kidney (b) absorbed doses with the patient-specific bone
lesion volume.
Figure 3.8: Source-specific contributions to the total bone marrow absorbed dose as evaluated for 10
mCRPC patients.
124]. Despite the high correlation between S-value bone marrow absorbed doses and the segmented
bone lesion load, absolute values might be severely underestimated during classical S-value ID. Partic-
ularly, the high correlation coefficient found for S-value bone marrow dosimetry and patient-specific
bone lesion load is somewhat mis-leading, as it is mainly driven by the data of patient b). Omitting
the respective data from the patient cohort of Figure 3.7 a) leads to a less pronounced (Pearson’s r=0.6),
although still positive correlation.
3.3.2 Investigation of a clinical 3D Monte-Carlo-based bone marrow dosimetry workflow
This study summarizes the second publication underlying this thesis [58], as well as related findings presented in
[49, 50, 54, 55].
Study 3.3.1 illustrated the strong request for 3D bone marrow dosimetry for Lu-177-PSMA therapy, to
particularly account for the patient-specific 3D lesion distribution. Thus, the first Monte-Carlo-based
bone marrow ID workflow was developed, which is applicable in clinical routine for high-risk mCRPC
patients [58]. The Monte Carlo workflow was set up based on the FLUKA code, which has already been
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Figure 3.9: Simulation study to demonstrate the relevance of patient motion during voxel-wise absorbed
dose calculation for an exemplary mCRPC patient case (6 GBq Lu-177-DKFZ-PSMA-617.); BL (a)
denotes the baseline motion-free absorbed dose calculation, while Figures b-d visualize the change of the
absorbed dose distribution after different magnitudes of patient motion had been artificially introduced
into the SPECT raw data.
Table 3.3: Effect of patient motion (Figure 3.9) on absorbed dose calculation for three selected lesions;
percent deviations are calculated with respect to a motion-free SPECT acquisition.
Motion Tumor 1 Tumor 2 Tumor 3
4.8 mm -8 % 0 % 0 %
12 mm -95 % -92 % -50 %
24 mm -97 % -97 % -57 %
validated for nuclear medicine applications in previous studies [19].
The first working step was to set up a basic Monte-Carlo-based ID workflow, which accurately imports
both, the desired patient-specific molecular and anatomical information. A validation of simulated Lu-
177 organ S-values and Lu-177 S-value kernels via usage of tabulated data led to an excellent agreement
(deviation approximately 1 %) [84, 120]. Further, in a second step, the appropriate patient data for
3D bone marrow absorbed dose modelling had to be identified. As described in section 2.2.2, full 3D
absorbed dose modelling relies on voxel-wise fitting of sequential SPECT data to obtain the voxel-wise
time-integrated activity. However, voxel-wise fitting of sequential SPECT data is challenging due to
image noise and artefacts, as well as mis-alignments between individual SPECT scans due to patient
motion and uncertainties in patient re-positioning. Even small motion magnitudes can lead to severe
artefacts in calculated absorbed dose distributions [49, 50] (Figure 3.9 and Table 3.3).
In studies 3.2.2 and 3.3.1, the ROB including the lesions and the blood were identified as main source re-
gions, which contribute to the total bone marrow absorbed dose during Lu-177-PSMA therapy, followed
by the kidneys. Thus, the method of choice for patient-specific bone marrow dosimetry was to combine
compartment-based time-integrated activity determination for ROB, lesions, kidneys, and blood with
Monte-Carlo-based absorbed dose simulation to balance both, strength and limitations, of simplistic
organ-level and full 3D dosimetry [58]. A template-based dosimetry workflow was introduced, which
combines a PET/CT-based segmentation of all relevant source compartments plus the skeleton as tar-
get region with the TAC information gathered during therapeutic Lu-177-imaging and blood sampling
according to the optimized measurement scheme proposed in study 3.2.2 [51] (Figure 3.10).
Using the PET/CT data for template generation offers several advantages for issues of bone marrow
dosimetry: first, Ga-68 PET/CT offers a higher spatial resolution compared to Lu-177 SPECT/CT imag-
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Figure 3.10: Template-based dosimetry workflow for patient-specific 3D bone marrow dosimetry.
Figure 3.11: Comparison of Ga-68-PSMA-11 PET lesion accumulation (a) with image-based active bone
marrow localization via Tc-99m-anti-granulocyte SPECT/CT (b) for a mCRPC patient suffering from a
pronounced skeletal metastasis. The upper row visualizes the respective maximum-intensity projection
(MIP), while the lower row shows an exemplary transverse slice (denoted by the red dashed line in both
MIPs).
ing; second, the pre-therapeutic Ga-68-PSMA PET/CT usually covers a large part of the patient body
from the middle of the head to approximately the knees, while for most of the mCRPC patients included
in this study only Lu-177 SPECT imaging of the abdomen was available [58].
Chapter 3. Studies 33
Table 3.4: Comparison of different models regarding macroscopic active bone marrow localization: MC1
and MC2 denote results from Monte-Carlo-based absorbed dose calculation assuming either no or com-
plete active marrow displacement from skeletal lesions, respectively. For gMC3, Monte Carlo absorbed
dose calculation was combined with image-based patient-specific active bone marrow localization via
Tc-99m-anti-granulocyte SPECT/CT. SMIRD corresponds to results from classical organ S-value bone
marrow dosimetry.
Case MC1 [mGy] MC2 [mGy] gMC3 [mGy] SMIRD [mGy]
1 1123 225 718 46
2 684 202 408 40
Bone marrow ID is further generally limited by the fact that the bone marrow micro-structure is not
visible on clinical imaging modalities. The bone marrow itself consists of a mixture of hematologically
active bone marrow (red marrow), which represents the important target for applications in RT, and
in-active bone marrow (yellow marrow). This bone marrow mixture is in turn mostly located in small
marrow cavities with a typical diameter of the order of 100 µm, which are further separated by small
ridges of hard bone. Thus, an abstract weighting-based model was adapted to applications in RT, to ad-
just Monte-Carlo-based absorbed dose calculation to the small-scale nature of the bone marrow target
[54, 55, 58]. It estimates the absorbed dose to the active bone marrow from the absorbed dose deposited
within the total bone mixture, multiplied with a weighting factor w, which is dependent on the mass
fractions, as well as the energy-dependent electron and photon interaction probabilities of each bone
compartment. Thus, w represents an effective probability for an absorbed dose deposition to occur
specifically in the active bone marrow.
Besides consideration of the microscopic characteristics of the bone marrow, also the macroscopic local-
ization is of crucial importance for absorbed dose calculations. The active bone marrow compartment
is a highly dynamic OAR, which can alter its distribution throughout the whole patient body, depen-
dent on the patient age or with regard to self-protecting mechanisms [90, 94]. Skeletal metastases, as
typically encountered during Lu-177-PSMA therapy, can release a displacement of active bone marrow
from the lesion sites, while the unknown extent of such displacement processes can lead to a large range
of possible absorbed dose values. For the patient cohort underlying the presented investigation [58],
application of both scenarios, no displacement (MC1) and complete bone marrow displacement (MC2),
resulted in a median difference by a factor of three concerning respective Monte-Carlo-derived bone
marrow absorbed doses (MC1 - median: 130 mGy/GBq; MC2 - median: 37 mGy/GBq). Consequently,
a priori assuming one scenario or the other for each patient can lead to severe over- or underestima-
tions of the bone marrow absorbed dose, indicating the need for macroscopic bone marrow localization
at least for identified risk-patients. For a sub-group of two mCRPC patients image-based active bone
marrow localization via Tc-99m-anti-granulocyte antibody SPECT/CT was available prior to therapy,
which indicated the presence of ongoing displacement mechanisms (Figure 3.11). Reanalysis of bone
marrow absorbed doses for these patients resulted in values between both extreme scenarios (Figure
3.10 and Table 3.4), due to both, technical and physiological aspects. Particularly, a mis-alignment of
image-based bone marrow localization with the compartment template, and the finite spatial resolution
of involved imaging modalities can lead to an artificial overlap between lesions and active bone marrow
distribution, and thus in an artificially increased estimate of the absorbed dose. The latter goes hand in
hand with a physiologically-driven incomplete bone marrow displacement.
However, results from this investigation also demonstrate that performing S-value bone marrow
dosimetry lead to a similar, in parts even larger overall uncertainty than compared to Monte-Carlo-
derived absorbed dose estimates without knowing the exact location of the active bone marrow [58].
Median S-value bone marrow absorbed doses (SMIRD) were 11 mGy/GBq, and on median 17-fold to
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four-fold smaller compared to MC1 and MC2, respectively. Deviations between SMIRD, MC1, and MC2
were found to be driven - as expected - by the patient-specific bone lesion load, but also by lesion activity
uptake and ROB retention. Consequently, all aspects should be considered for identification of risk pa-
tients. A correlation of bone marrow absorbed doses with the decrease of blood element counts yielded
a significant correlation regarding platelet counts for all dosimetry models, while highest correlation
was obtained for MC2 (Pearson’s r=-0.7).
4 | Discussion & outlook
This thesis aimed at the optimization of clinically feasible, patient-specific estimation of the absorbed
dose to the active bone marrow for Lu-177-based radionuclide therapy (RT). Investigations were taken
out for Lu-177-PRRT of NET and with special emphasis for Lu-177-PSMA therapy of mCRPC. After
identification of a suitable quantitative measurement protocol, various strategies for absorbed dose es-
timation were investigated.
Classical and simple S-value-based internal dosimetry (ID), resulted in an average absorbed dose es-
timate of the order of 10 mGy/GBq, which at first could be considered as uncritical in relation to the
typical bone marrow absorbed dose constraint of 2 Gy [110]. However, the prediction of hematological
toxicity via S-value bone marrow ID is limited due to the inherent lack of patient-specificity of tabulated
absorbed dose conversion coefficients, and in particular due to the lack of an appropriate concept to ac-
count for the high and heterogeneous bone lesion load which is often observed for mCRPC patients. For
Lu-177-PRRT, the classical S-value method has been further refined to the characteristic uptake pattern
of NET patients, resulting in a good agreement with the course of blood element counts [124]. Still, the
situation for NET patients during Lu-177-PRRT might be less critical, as the occurrence of pronounced
bone metastases and severe hematological events is reduced compared to the situation encountered in
Lu-177-PSMA therapy. Rahbar et al. reported hematological toxicity to be the most common severe
event during Lu-177-PSMA therapy of 145 patients (average activity 5.9 GBq), with regard to all grades
as well as grade 3-4 events [102, 122].
Data regarding the correlation between bone marrow dosimetry and hematological response has not
been available for a sufficiently large patient cohort having received Lu-177-PSMA therapy, yet, al-
though independently published data on hematological response assessment indicates a disagreement
between the incidence of hematological toxicity and so far S-value-derived bone marrow absorbed doses
[9, 40, 102]. Section 3.3.2 [58] demonstrated elevated Monte-Carlo-based bone marrow absorbed dose es-
timates compared to respective results from classical S-value ID, irrespective of the exact model used for
active bone marrow localization (MC1 - median: 130 mGy/GBq; MC2 - median: 37 mGy/GBq; SMIRD
- median: 11 mGy/GBq). The preliminary analysis of the correlation between nadir-to-baseline values
of blood element counts and model-specific bone marrow absorbed doses, as performed for the small
patient cohort of this study until eight to ten weeks after the first therapy cycle, revealed significant
results (p<0.05) regarding platelet response for both, Monte Carlo and S-value calculations. However,
the highest correlation coefficient (r=-0.7) was observed for the Monte-Carlo-based calculation with as-
sumption of complete bone marrow displacement. MC1, assuming a complete neglect of bone marrow
displacement mechanisms, can be judged to lead to too drastic bone marrow absorbed dose values, as
- according to the absorbed dose constraint of 2 Gy - severe hematological events should have been
occurred for three to four (27-37 %) of investigated mCRPC patients.
Appropriate hematological response assessment in the scope of treatment of advanced cancer disease is
challenging, as the course of blood element counts is strongly dependent on multiple patient-specific pa-
rameters, e. g. pre-therapies or hematological baseline status. Further, apart from the cross-irradiation
of the active bone marrow via bone lesions, bone marrow infiltration of cancer cells alone can cause
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Figure 4.1: Comparison of PSMA PET/CT imaging (a), active bone marrow localization via Tc-99m-anti-
granulocyte SPECT/CT (b), and results from diagnostic CT imaging (hybrid PET/CT imaging) (c) for an
exemplary mCRPC patient. Yellow arrows indicate the interplay between detection of PSMA-avid lesions,
active bone marrow displacement, and CT-detectable sclerosing processes. Red arrows denote regions
without metastatic impairment, inconspicuous CT bone structure, and active bone marrow localization.
a worsening of the patient-specific hematological function. This implies that bone marrow dosimetry
is not the sole decisive aspect to predict severe hematological events [12, 15, 102, 124, 131]. Thus, a
patient stratification according to hematological risk factors, in combination with Monte-Carlo-based
bone marrow ID and active bone marrow localization is advisable for future studies in order to obtain
both, predictive absorbed-dose-response-relationships and realistic absorbed dose constraints. In par-
ticular, a current debate focuses on the question whether the common absorbed dose constraint of 2
Gy might be too optimistic for patients of progressed cancer disease, who already underwent various
pre-therapies and consequently already present with an impaired hematological function. Further, the
immediate radiation harm on blood cells due to the activity circulation in the blood pool or the uptake
in hematological-related organs (e. g. spleen) has to be separated from the medium-term radiation effect
on the active bone marrow itself.
Concerning the absolute magnitude of the bone marrow absorbed dose, bone lesion load, prolonged
whole-body activity circulation, and a high time-integrated tumor uptake were identified as risk factors
(see section 3.3.2 [58]), which can be employed to identify patients for further pre-therapeutic image-
based active bone marrow localization. For instance, a high lesion load in combination with a high lesion
SUV in the pre-therapeutic PET, but also a decreased excretion rate with regard to the pre-therapeutic
evaluation of kidney function might justify additional image-based active bone marrow localization.
Similar findings have already been reported for Lu-177-PRRT [12]. Image-based active bone marrow
localization can be performed, e. g., via Tc-99m-anti-granulocyte scintigraphy, as described in the scope
of section 3.3.2 [58] for a small sub-cohort of patients, or via magnetic resonance imaging (MRI) [3, 11,
100]. High-resolution MRI-based active bone marrow localization, in combination with PET imaging
or improved Lu-177 SPECT imaging could further reduce the artificial spatial-resolution-related over-
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lap between active bone marrow and lesion uptake. Hybrid PET/MR imaging could be of interest to
reduce co-registration errors between active bone marrow and lesion localization. However, the exact
method for image-based active bone marrow localization should be feasible for several patients per
week and easy to be integrated in the routine therapy procedure.
S-value bone marrow absorbed doses showed a strong and significant correlation with both, time-
integrated ROB retention and tumor uptake [58], while results from study 3.3.1 and 3.3.2 indicate only a
weak to moderate correlation with the patient-specific bone lesion load, depending on the exact patient
cohort and segmentation method. Thus, in the absence of severe metastases and other therapy-related
or hematological risk factors, efficient hybrid SPECT-planar S-value bone marrow ID as proposed in
section 3.2.2 [51] could be suitable to estimate bone marrow absorbed doses within defined uncertainty
limits. Ongoing studies shall aim at finding appropriate stratification thresholds of risk parameters (e.
g. SUV cut-off to identify critical lesion uptake), and, as emphasized, appropriate absorbed dose con-
straints. Nonetheless, also for Monte-Carlo-based bone marrow dosimetry the optimized measurement
scheme proposed in section 3.2.2 [51] allows to effectively gather the Lu-177 TAC information in all rel-
evant accumulating regions.
High-resolution 3D absorbed dose estimation using Monte Carlo techniques is characterized by a
strongly elevated computational demand compared to classical S-value-based bone marrow ID. How-
ever, via usage of automatized CT, PET, and SPECT segmentation algorithms in combination with
computing clusters, Monte Carlo results using the proposed template-based approach can be obtained
within one day, which is in principal acceptable regarding the time scale of treatment planning and
evaluation during nuclear medicine RT. Future studies will additionally aim to enable absorbed dose
kernels methods, which could allow for 3D bone marrow ID within several minutes [108, 109]. The
proposed weighting-based Monte Carlo workflow for 3D bone marrow ID already compromizes accu-
racy and efficiency for clinical applications, compared to existing time-consuming hybrid Monte-Carlo-
workflows, which switch the simulation between the macroscopic and microscopic representation of
both, patient anatomy and skeletal system (paired-image radiation transport (PIRT) model) [113]. How-
ever, Lee et al. demonstrated for selected skeletal sites that voxel-wise weighting-based methods (mass-
energy-absorption-coefficient (MEAC) methods) are in good agreement with PIRT results for the typical
γ-energy range of radionuclides employed in RT [85]. These results can also be transferred to typical RT
β-energies, as absorbed dose deposition by photons occurs via release of secondary electrons.
So far, the application of PIRT models was limited to phantoms or to information gathered from cadav-
ers, for which the exact structure of the skeletal micro-environment was well known. Regarding clinical
conditions, the patient-specific 3D spongiosa structure is not available for the entire skeleton due to the
limited resolution of state-of-the-art in vivo imaging modalities. Patient-specific active marrow cellu-
larities, i. e. the hematologically active volume fraction of the overall bone marrow mixture, could be
derived from biopsies, however, these imply a large patient burden, and are further only representative
regarding the bone marrow characteristics at the direct intervention location. In a first step, a clinically
feasible method employing region-wise reference mass fractions of active and inactive bone marrow, as
well as hard bone, is proposed [58]. In a second step, voxel-wise patient-specific mass fractions could be
derived from dual-energy CT imaging, as already performed during phantom experiments [48]. There-
fore, future studies should aim at understanding the typical time scale of detectable PSMA-avid lesions,
active bone marrow displacement, and CT-detectable and lesion-induced sclerosing processes (Figure
4.1).
A similar dosimetry selection scheme, as proposed for bone marrow dosimetry during Lu-177-PSMA
therapy, was established at the nuclear medicine department of the University Hospital Munich to iden-
tify patients for efficient single-SPECT kidney dosimetry for both, Lu-177-PRRT and Lu-177-PSMA ther-
apy. Single-SPECT dosimetry can be considered as suitable if no impairment of the kidney excretion is
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Table 4.1: Dosimetry results for the simulation study presented in Figure 4.2.
VOI Absorbed dose 6 min/bed [Gy] Absorbed dose 3 min/bed [Gy]
Kidneys 2.1 2.1
Liver 0.2 0.2
Spleen 0.3 0.3
Bone lesions 8.3 7.8
Figure 4.2: Simulation study to investigate the feasibility of fast whole-body Lu-177 SPECT imaging
based on the data of an exemplary mCRPC patient (6 GBq Lu-177-DKFZ-PSMA-617). For the lower
row, a whole-body Lu-177 SPECT acquisition within 15 minutes was simulated. Respective dosimetry is
provided in Table 4.1.
expected, and if precautions such as amino acid infusion for Lu-177-PRRT are undertaken [13, 15, 106,
123]. For mCRPC patients with a high initial lesion load, therapy response might initiate severe changes
of the whole-body accumulation pattern (see sections 3.2.1 and 3.3.1) [56, 57, 59, 61, 62]. Thus, for
mCRPC patients a more frequent sequential SPECT imaging is advisable (e. g. every second cycle), than
for NET patients (e. g. every fourth cycle) [133]. As for NET patients with normal kidney excretion re-
cent studies demonstrated no severe incidence of kidney toxicity, even standard single-SPECT imaging
in combination with population-based therapy-specific pharmacokinetic information could be feasible,
if respective uncertainty limits are acceptable to detect possible organ toxicities [67, 106]. Single-SPECT
dosimetry was found to yield an increased uncertainty for lesion absorbed dose estimates. However,
the current clinical procedure in Lu-177-based RT of NET and mCRPC is rather driven by the concern
to limit the absorbed dose in OAR, than directly aims at applying a prescribed lesion absorbed dose.
More precise, multiple cycles of a standardized amount of activity are applied, while the decision to
undergo the next therapy cycle is dependent on a pre-therapy assessment of clinical parameters (e. g.
blood element counts, kidney function, PET-detectable PSMA-avid or sstr-avid lesions), in combina-
tion with a OAR dosimetry of the preceding therapy cycles, if available [110, 123]. By contrast, due
to the high uncertainty of SPECT-based lesion dosimetry, and as ongoing efforts still have to identify
all relevant influencing factors on therapy response for Lu-177-based RT, the knowledge of absorbed-
dose-response-relationships and appropriate lesion absorbed dose prescriptions is still fragmentary [14,
49, 50, 88]. Although, from a dosimetric point of perspective, the uncertainty of SPECT-based kidney
absorbed doses can be judged as lower compared to that of lesion dosimetry [66], finding appropriate
kidney absorbed dose constraints for Lu-177-based RT is still a matter of interest. So far applied ab-
sorbed dose constraints are derived from markedly different treatment regimes, such as external beam
therapy. Further, risk factors associated with nephrotoxicity, and in particular the relevant underlying
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sub-cellular mechanisms have not been fully understood, yet [15, 63, 123].
Improving Lu-177 SPECT imaging is crucial to allow for appropriate response assessment, which in
turn supports the identification of clinical risk and response factors. In this context, Figure 4.2 and Table
4.1 present the initial attempts to provide fast whole-body Lu-177 SPECT imaging, which shall allow
for a high-quality response assessment for a large part of the patient body without sacrificing patient
comfort.
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Abstract
Background: The bone marrow (BM) is a main organ at risk in Lu-177-PSMA-617 therapy of prostate cancer and
Lu-177-Octreotate therapy of neuroendocrine tumours. BM dosimetry is challenging and time-consuming, as
different sequential quantitative measurements must be combined. The BM absorbed dose from the remainder of
the body (ROB) can be determined from sequential whole-body planar (WB-P) imaging, while quantitative Lu-177-
SPECT allows for more robust tumour and organ absorbed doses. The aim was to investigate a time-efficient and
patient-friendly hybrid protocol (HP) for the ROB absorbed dose to the BM. It combines three abdominal
quantitative SPECT (QSPECT) scans with a single WB-P acquisition and was compared with a reference protocol (RP)
using sequential WB-P in combination with sequential QSPECT images. We investigated five patients receiving 7.
4 GBq Lu-177-Octreotate and five patients treated with 3.7 GBq Lu-177-PSMA-617. Each patient had WB-P and
abdominal SPECT acquisitions 24 (+ CT), 48, and 72 h post-injection. Blood samples were drawn 30 min, 80 min,
24 h, 48 h, and 72 h post-injection. BM absorbed doses from the ROB were estimated from sequential WB-P images
(RP), via a mono-exponential fit and mass-scaled organ-level S values. For the HP, a mono-exponential fit on the
QSPECT data was scaled with the activity of one WB-P image acquired either 24, 48, or 72 h post-injection (HP24,
HP48, HP72). Total BM absorbed doses were determined as a sum of ROB, blood, major organ, and tumour
contributions.
Results: Compared with the RP and for Lu-177-Octreotate therapy, median differences of the total BM absorbed
doses were 13% (9–17%), 8% (4–15%), and 1% (0–5%) for the HP24, HP48, and HP72, respectively. For Lu-177-PSMA-
617 therapy, total BM absorbed doses deviated 10% (2–20%), 3% (0–6%), and 2% (0–6%).
Conclusion: For both Lu-177-Octreotate and Lu-177-PSMA-617 therapy, BM dosimetry via sequential QSPECT
imaging and a single WB-P acquisition is feasible, if this WB-P image is acquired at a late time point (48 or 72 h
post-injection). The reliability of the HP can be well accepted considering the uncertainties of quantitative Lu-177
imaging and BM dosimetry using standardised organ-level S values.
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Background
Over the recent years, radionuclide therapy using Lu-177-
Octreotate and Lu-177-PSMA-617 evolved as a promising
approach for the treatment of metastasised and inoperable
neuroendocrine tumours (NET) and metastasised,
castration-resistant prostate cancer (mCRPC), respectively
[1–3]. The red or active bone marrow (BM) represents a
main organ at risk in radionuclide therapy [4–8]. Bone
marrow toxicity is particularly of concern in Lu-177-
PSMA-617 therapy, as patients suffering from mCRPC
often present with a high burden of bone metastases. The
latter may cause pronounced activity accumulations in
close proximity to the regions which potentially bear active
marrow. At these locations, especially the γ-component of
the Lu-177 decay might lead to a significant photon
cross-irradiation of the bone marrow [9]. However, for
Lu-177-Octreotate therapy, the bone marrow is also con-
sidered as an organ at risk, as patients with progressive can-
cer disease usually already underwent several pre-therapies
such as external radiotherapy or chemotherapy [3, 4]. These
pre-therapies may have interfered with the haematological
function of the bone marrow. Thus, bone marrow dosim-
etry is highly recommended in these patients for risk reduc-
tion of marrow toxicities and, at the same time, an as high
as possible tumour absorbed dose [10].
The total bone marrow absorbed dose is composed of
different contributions originating from various activity
source regions: (1) the bone marrow self-absorbed dose
including the active bone marrow cells, the extracellular
fluid, and the blood cells; (2) activity accumulations in
the remaining skeleton composed of compact bone or
fatty tissue (yellow or inactive marrow); (3) the
cross-absorbed dose by major organs or tumours; and
(4) the cross-irradiation coming from the remainder of
the body (ROB; whole body minus specific or unspecific
accumulations in the other source regions) [11]. Each
absorbed dose component requires a dedicated measure-
ment procedure to derive its respective time-activity
curve (TAC) and the source-specific time-integrated ac-
tivity. The cumulated actvity-to-absorbed-dose conver-
sion is usually performed via pre-calculated and
standardised organ-level S values [11].
The appropriate data collection to accurately quantify the
various possible source regions is challenging and leads to
both a high clinical workload and long patient examination
times, if bone marrow dosimetry shall be routinely
performed in the clinic. For Lu-177-Octreotate or
Lu-177-PSMA-617 therapy, the bone marrow absorbed
dose from the major accumulating organs (DBM← organs),
the ROB (DBM←ROB), and the blood (DBM← blood) can be
determined from sequential quantitative SPECT images, se-
quential quantitative whole-body planar images, and mul-
tiple blood samples, respectively, in combination with the
corresponding S values [8, 9, 11–13]. However, despite the
high metastatic load which might be observed for NET and
mCRPC patients, it is challenging to explicitly consider the
bone marrow absorbed dose from activity accumulations in
the tumours (DBM← tumours) via standardised and
pre-calculated tumour-to-bone marrow S values, as the lat-
ter intrinsically cannot consider the large inter-patient vari-
ability of the shape, size, and distribution of all lesions [14].
Our institutional protocol determines the absorbed dose
contribution from the ROB via sequential whole-body pla-
nar images [11], which are acquired at three time points at
24, 48, and 72 h post-injection. In addition, we decided to
derive organ (e.g. kidneys) and tumour absorbed doses
from sequential quantitative SPECT measurements for
improved organ and tumour dosimetry [15–18]. However,
full whole-body quantitative Lu-177 SPECT is still not
commonly used in the clinic, implicating the need of con-
secutive planar and SPECT imaging at each time point to
obtain both reliable bone marrow absorbed doses from
the ROB and reliable organ or tumour absorbed doses
[19]. Particularly, the increased examination time in case
of consecutive SPECT and whole-body planar imaging
leads to an increased clinical workload and patient dis-
comfort, as patients with progressive cancer disease may
suffer from a bad health condition. Thus, the aim of this
work was to derive a time-efficient, patient-friendly, and
simplified bone marrow dosimetry protocol for clinical
routine. Therefore, we investigated the possibility to re-
duce the number of image acquisitions from three
whole-body planar and three quantitative SPECT scans
(reference protocol (RP)) to a single whole-body planar
acquisition while maintaining the institution’s usual se-
quential quantitative SPECT protocol (hybrid protocol
(HP)). Further, we investigated the effect of this image re-
duction on the bone marrow absorbed dose from the
ROB and on the total bone marrow dose (DBM← total), to
prove whether the proposed hybrid protocol provides
comparable absorbed dose estimates for both
Lu-177-Octreotate and Lu-177-PSMA-617 therapy. For
the determination of the total bone marrow absorbed
dose, the energy depositions in the bone marrow due to
activity accumulations in the ROB, blood, major organs,
and tumours were considered. Furthermore, we deter-
mined the best-suited time point for this single
whole-body planar image acquisition with respect to the
time points available in our institutional protocol. All
absorbed dose calculations are based on the organ-level S
values (e.g. whole ROB to bone marrow) [11].
Methods
Patient selection, data acquisition, and image
quantification
Patient selection
This study is based on ten patients, with five patients suffer-
ing from somatostatin receptor-positive neuroendocrine
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metastases (P1-P5) and five patients from mCRPC with ex-
pression of PSMA-avid lesions (P6-P10). Details for each
patient are provided in Tables 1 and 2. All patients received
multiple therapy cycles of approximately 3.7 GBq
Lu-177-DKFZ-PSMA-617 (Lu-177-PSMA-617) or 7.4 GBq
Lu-177-[DOTA0,Tyr3]-Octreotate (Lu-177-Octreotate). All
patients except one mCRPC patient showed soft tissue le-
sions on the pre-therapeutic Ga-68-HBED-CC-PSMA or
Ga-68-[DOTA0,Tyr3]-Octreotate PET/CT scans, while all
prostate-specific membrane antigen (PSMA) patients and
two NET patients additionally presented with bone metas-
tases (Tables 1 and 2). The local ethics committee approved
the study protocol and did not desire any written consent
for the study entry. The study is based on retrospective and
anonymised patient data.
Data acquisition
Data for dosimetry were acquired during a routine 4-day
in-patient stay following the radiopharmaceutical injec-
tion, in conjunction with standard clinical examinations.
All patients received a 15-min one-bed abdominal SPECT
scan and a 20-min whole-body planar scintigraphy at 24,
48, and 72 h post-injection (p. i.) on a dual-headed Symbia
T2 SPECT/CT (Siemens Medical Solutions, Erlangen,
Germany). Counts were detected for the photopeak win-
dow of 208 keV (width 15%) by the usage of a
medium-energy low-penetration collimator. Two add-
itional scatter windows were measured at 170 keV (width
15%) and 240 keV (width 10%). A low-dose AC-CT was
acquired at the first image acquisition session for
anatomical correlation and attenuation correction during
quantitative SPECT reconstruction. For the determination
of the absorbed dose to the bone marrow from the activity
circulating in the blood, five venous blood samples were
drawn from the site contralateral to injection at 30 and
80 min p. i. and 24, 48, and 72 h p. i. [9, 20].
SPECT image reconstruction and quantification
Quantitative SPECT images were reconstructed as de-
scribed by Delker et al. [9] via a rotation-based, penalised,
one-step-late ordered subset expectation maximisation al-
gorithm, which included corrections for scatter, attenuation,
and distance-dependent geometrical collimator blur. At-
tenuation correction was performed for each SPECT scan
via the AC-CT, which was acquired along with the SPECT
scan 24 h post-injection. To apply the attenuation correc-
tion, especially to the SPECT scans 48 and 72 h p. i., the
single AC-CT was co-registered onto an initial SPECT re-
construction without attenuation correction by using a rigid
body co-registration algorithm with six degrees of freedom
(PMOD Version 3.609, PMOD Technologies, Zurich,
Switzerland). If only one AC-CT is acquired for sequential
SPECT imaging, special care has to be taken to minimise
misregistration between SPECT images and separately ac-
quired CT scans, as such a misalignment can distort the
proper attenuation correction and, thus, activity quantifica-
tion. This is in principal also true for serial SPECT and CT
imaging, as even within a single image acquisition session
patient movements cannot be entirely avoided. Scatter cor-
rection employed the triple energy window (TEW) method.
Table 1 Characteristics of all NET patients included in this study for Lu-177-Octreotate therapy
Octreotate P1 P2 P3 P4 P5
Sex M M F F F
Age 68 66 61 47 73
Activity investigated cycle
[MBq]
7654 7425 7420 7409 7410
Diagnosis NET small intestine NET NET terminal
ileum
NET pancreas NET stomach
Metastases (PET/CT)
- Extend Medium Medium Medium Medium Medium
- Type (VIS = visceral,
LYM = lymph,
OSS = osseous)
Mainly VIS (liver),
LYM
Mainly LYM, VIS
(liver)
Mainly VIS (liver),
LYM, OSS
Mainly LYM, VIS (liver and other) Mainly VIS (liver),
OSS
Proliferation index Ki67 3–4% Ki67 5–10% Ki67 1% Ki67 10% Ki67 10%
Pre-therapies SSA-analogues Interferon alpha Hemicolectomy,
SSA-analogues,
radioembolization
Chemotherapy (stroptozotocin/5-FU,
dacarbazapin, capecitabin/Te-modal)
SSA-analogues,
bisphosphonate
therapy
Blood pre-therapy
- Leukocytes [G/l] 7.76 10.4 3.79 3.93 10.2
- Erythrocytes [T/l] 4.58 4.50 4.43 3.73 4.42
- Thrombocytes [G/l] 207 294 297 177 303
- Haematocrit 0.421 0.442 0.373 0.341 0.399
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Correction for distance-dependent collimator blur made
use of a Gaussian blur model. Corrections for partial vol-
ume effects and dead time were not applied. For conversion
of the measured counts per second and per voxel to Bec-
querel per millilitre, an appropriate calibration factor was
determined. Therefore, we used a large cylinder of approxi-
mately 20 cm diameter, which was filled with a known ac-
tivity concentration and which has been imaged and
reconstructed via the same protocol [9, 15, 20].
Planar image correction and calibration
For each patient, all acquired whole-body planar images
were corrected for scatter and attenuation on a pixel
basis via a dedicated MATLAB routine (Fig. 1) [16, 20,
21]; for the correction of scatter, the TEW method was
applied, as for the quantitative SPECT images. For the
attenuation correction, a linear projection of μ values
along the ventral axis of the patient was created from
the diagnostic CT image of the pre-therapeutic Ga-68
PET/CT scan, which covered nearly the whole patient
body from the middle of the head to approximately the
knees. Therefore, a conversion between the Hounsfield
units (HUs) in the diagnostic CT and the μ values at
208 keV was established by acquiring a CT scan of a
Gammex tissue phantom (Gammex 467; Gammex, Inc.,
Middleton, WI) with 16 tissue rods of known compos-
ition and thus known attenuation characteristics [22].
The μ values of all rods were plotted against the
measured HUs, and a bilinear fit model (range 1:
HU = (− 688;0); range 2: HU = (0;1127)) was applied to
the whole data set [15, 22]. This calibration curve allows
for the assignment of μ values to a continuous range of
HUs. The lower arms and legs as well as a part of the
head were not included in the PET/CT data, as the arms
are usually positioned above the head during the PET/
CT scan and as the PET/CT scan is usually not acquired
over the entire patient length. By contrast, the arms,
legs, and head are fully included in the whole-body pla-
nar images, and an appropriate μ value has to be defined
for each segment (Fig. 1). Thus, mean μ values derived
from three patients with PET/CT acquisitions of the
head, legs, and arms were assigned to the missing seg-
ments. Therefore, all segments—the part visible on the
PET/CT and the missing parts of the head, arms, and
legs—were delineated on the co-registered whole-body
planar images (delineation and rigid body co-registration
via PMOD Version 3.609). The resulting map of the re-
gions of interest (ROI) was saved, with each ROI seg-
ment being characterised via a defined value. This ROI
map was then loaded by a self-designed MATLAB rou-
tine, which assigned the defined μ value to each segment
according to the ROI number. Afterwards, the resulting
whole-body integral μ-map was blurred via a Gaussian
filter with a width approximating an average resolution
of the gamma camera (geometric resolution of full width
at half maximum of 11 mm at 10 cm). Pixel-wise attenu-
ation correction was finally performed in conjunction
with geometric averaging of both planar views (conju-
gate view method) [21].
Calibration of whole-body planar images was performed
via the corresponding quantitative abdominal SPECT by
using the fact that ideally the total activity ASPECT within
the quantitative SPECT should be correlated to the
number of counts per second (cps) xplanar in the planar ab-
dominal counterpart multiplied by an appropriate calibra-
tion factor:
Fig. 1 Workflow for planar image quantification shown for patient P8. Anterior and posterior views for all three energy windows (24 h p. i.;
photopeak and both scatter windows) and attenuation map based on the projected patient-specific CT from the PET/CT scan
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ASPECT ¼ xplanar∙Cplanar;SPECT: ð1Þ
Cplanar, SPECT denotes the SPECT-based calibration fac-
tor in units of Bq/cps.
Bone marrow dosimetry formalism
To derive total bone marrow absorbed doses (DBM← total),
a sum of the bone marrow self-absorbed dose from the ac-
tivity in the blood (DBM← blood) as well as the bone mar-
row cross-absorbed dose by major organs (DBM← organs),
tumours (DBM← tumours), and the ROB (DBM← ROB) was
considered according to the findings of previous studies
[5, 7–9, 13]. If not indicated otherwise, the general term
bone marrow always refers to the red or active bone mar-
row, i.e. the radiation-sensitive part of the bone marrow
mixture [23]. The dose contribution of each source com-
ponent to the bone marrow was estimated according to
the guidelines of the European Association of Nuclear
Medicine (EANM) [11]. Following the Medical Internal
Radiation Dose (MIRD) formalism underlying the EANM
guidelines, the absorbed dose to the bone marrow origin-
ating from a specified source region (DBM← source) was cal-
culated according to Eq. (2) [24]:
DBM←source ¼ SBM←source∙~Asource
¼ SBM←source∙
Z ∞
0 injectionð Þ
Asource tð Þdt:
ð2Þ
~Asource describes the time-integrated activity per source
region and SBM← source the corresponding S value or
absorbed dose conversion factor. Asource(t) corresponds to
the source-specific time-activity curve (TAC), which is based
on sequential measurements and a subsequent fit to the
source time-activity measurements. For this study, S values
are taken from the public tabulations of Monte Carlo simula-
tion results for the standardised male (Lu-177-PSMA-617
and Lu-177-Octreotate therapy) or female (Lu-177-Octreo-
tate therapy) anthropomorphic phantom as provided,
amongst other phantoms, by RADAR [25]. To adjust these
phantom-based S values to the patient-specific conditions, all
S values were scaled according to a non-linear mass scaling
approach developed by Traino et al. [26].
Absorbed dose from the blood time-integrated activity
In the absence of specific binding to the bone marrow
or blood cells, as indicated for PSMA therapy [27, 28],
the bone marrow self-absorbed dose is solely given by
the activity in the extracellular fluid of the marrow tissue
[11]. The activity in the extracellular fluid of the bone
marrow can be derived from the activity concentration
in the blood plasma (blood method), multiplied with the
red marrow extracellular fluid fraction (RMECFF = 0.19)
of the bone marrow [11, 29, 30]. The activity concentra-
tion in the plasma can in turn be determined from the
activity concentration in the blood ( ½~Ablood ) and the
patient-specific haematocrit (HCT), if there is no specific
binding to the blood cells [11]. This yields to:
DPSMABM←blood ¼ ~Ablood
 
∙RMBLR∙mBM;patient∙SBM←BM;phantom∙
mBM;phantom
mBM;patient
 a
;
ð3:1Þ
RMBLRPSMA ¼ RMECFF
1−HCT
: ð3:2Þ
where RMBLR corresponds to the red-marrow-to-blood
activity concentration ratio [11]. m denotes the bone
marrow (BM) or whole-body (WB) masses (mBM/WB,
phantom/patient) of either the phantom or of the patient
[11, 26].
For Lu-177-Octreotate therapy, it holds that:
DOCTREOBM←blood ¼ ~Ablood
 
∙RMBLR∙mBM;patient∙SBM←BM;phantom∙
mBM;phantom
mBM;patient
 a
:
ð3:3Þ
RMBLROCTREO ¼ 1 ð3:4Þ
[11, 13]. To scale the male and female S values to the
patient anatomy, an exponent of a= 1.001 and a= 0.992 was
proposed for Lu-177-PSMA-617 and Lu-177-Octreotate
therapy, respectively [26]. To derive the patient-specific
blood TAC, 1 ml of blood of each sample was pipet-
ted into a test tube and measured within a Cobra
Gamma Counter (Packard Instrument Company, Inc.,
Meriden, CT), which has been previously calibrated
via five 1-ml test samples of known activity concen-
tration. For the calculation of the time-integrated
blood activity concentration, a bi-exponential model
was fitted to the time-activity data, followed by inte-
gration from zero to infinity according to Eq. (2).
Absorbed dose from the remainder of body and major
organs
Via subtraction of the time-integrated activity in the extracel-
lular fluid and the time-integrated activity of the main
accumulating organs from the whole-body, the respective
ROB time-integrated activity ( ~AROB ) was determined. The
whole-body and organ time-integrated activities, ~AWB and
~Aorgan , were determined from a mono-exponential fit to the
three measurement points at 24, 48, and 72 h post-injection.
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All organ activities were derived from the sequential SPECT
images, while for the determination of the whole-body activ-
ity, the sequential whole-body planar images were used. The
kidneys were considered as main accumulating organs for
both Lu-177-Octreotate and Lu-177-PSMA-617 therapy, ac-
cording to the previous studies assessing dosimetric esti-
mates [5, 7–9]. The patient-specific volumes of interest
(VOIs) for the kidneys were defined based on a percent iso-
contour of the organ maximum and of the quantitative
SPECT at 24 h p. i. (PMOD Version 3.609), since images
taken at early time points offer a high signal-to-background
ratio for organ delineation. We adjusted the isocontour level
for each patient in the best way with the usage of the CT as
guidance. For all patients, an isocontour level of 30–40% was
found to be appropriate. All kidney VOIs were copied to the
following SPECT scans 48 and 72 h p. i., which were
co-registered onto the SPECT scan 24 h p. i. in advance. We
manually re-positioned, i.e. shifted or rotated, the kidney
VOIs in case of imperfect co-registration of the individual
SPECT time points. For Lu-177-Octreotate therapy, the liver
and spleen were additionally included in the bone marrow
absorbed dose from the organs [5]. For the patient-wise de-
lineation of the liver and spleen, a similar approach as for
the kidney definition was chosen using a 10 to 15% isocon-
tour for the liver and a 30 to 40% isocontour for the spleen.
The lower isocontour for liver delineation can be explained
by the fact that NET patients often exhibit liver metastases,
which lead to a heterogeneous activity accumulation with
multiple hot spots.
The bone marrow absorbed dose from the ROB is fi-
nally given by the following formula according to Hin-
dorf et al. with adjusted exponents as proposed by
Traino et al. [11, 26]:
~AROB ¼ ~AWB− ~Ablood
 
∙RMBLR∙mBM;patient−
X
all organs
~Aorgan;
ð4:1Þ
DBM←ROB ¼ ~AROB∙
 
SBM←WB;phantom∙
mWB;phantom
mWB;patient
 b
∙
mBM;phantom
mBM;patient
 c
−SBM←BM;phantom∙
mBM;phantom
mROB;patient
∙
mBM;phantom
mBM;patient
 a
−
X
all organs
SBM←organ;phantom∙
morgan;phantom
mROB;patient
∙
mBM;phantom
mBM;patient
!
:
ð4:2Þ
Eq. (4.2) considered all phantom- and patient-specific
whole-body, ROB, bone marrow, and organ masses
mWB/ROB/BM/organ, phantom/patient for S value scaling. For
male and female patients, b = 0.896 and b = 0.894 as well
as c = 0.963 and c = 0.970 were used, as proposed by
Traino et al. [26]. The bone marrow absorbed dose contri-
bution of each individual organ is given by:
DBM←organ ¼ ~Aorgan∙SBM←organ;phantom∙
morgan;phantom
morgan;patient
∙
mBM;phantom
mBM;patient
:
ð5Þ
Due to the high tumour load, as it is frequently observed
in Lu-177-PSMA-617 therapy and sometimes in Lu-177-
Octreotate therapy, we included all tumour activities in
the ROB activity and the ROB S value was applied. As all
patients investigated for Lu-177-Octreotate therapy suf-
fered from liver metastases, the tumour activities had to
be removed from the healthy liver activity for each time
point. Therefore, tumour VOIs were delineated on the
SPECT 24 h p. i. based on a 40% isocontour and trans-
ferred to the following SPECT scans, as it was the case for
the determination of the organ activities.
Hybrid imaging for determination of the ROB cross-
absorbed dose to the bone marrow
Reference dosimetry protocol
For the reference protocol (RP), the bone marrow
absorbed dose from the ROB is determined from all three
available whole-body planar scans (Fig. 2). For the total
bone marrow absorbed dose, the absorbed dose from the
three constituents, organs, blood, and ROB, was summed.
For each dose constituent, the percentage contribution
(PCconstituent) to the total bone marrow absorbed dose was
calculated:
PCconstituent ¼ DBM←constituentDBM←total ∙100%: ð6Þ
Hybrid dosimetry protocol
The proposed hybrid protocol (HP) uses a single whole-
body image and sequential single-bed quantitative
SPECT acquisitions of the abdomen to determine the
ROB TAC, instead of deriving the ROB TAC from se-
quential whole-body planar imaging.
First, the abdominal effective decay constant λSPECT
was derived via a mono-exponential fit to the total activ-
ity in the SPECT scans 24, 48, and 72 h post-therapy.
Especially, all organs and all tumours were included in
the fitting of the TAC, as it was the case for the deter-
mination of ~AWB from the reference protocol. This ef-
fective decay constant λSPECT serves as a surrogate for
the reference-protocol-based whole-body effective decay
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constant (Fig. 2). The mono-exponential SPECT-based ab-
dominal TAC was then scaled with a chosen base point. This
base point is defined via the whole-body activity AWB(t
∗) of a
single whole-body planar image acquired at an arbitrary time
point t∗∈ 24, 48, or 72 h post-therapy. The resulting pseu-
do-whole-body TAC AWB, pseudo(t) is intended to
serve as an estimate of the reference-protocol-based
whole-body TAC (Eq. (7.1)) and can be further used
to determine a pseudo-whole-body time-integrated
activity ~AWB;pseudo (Eq. (7.2)).
AWB;pseudo tð Þ ¼ AWB;pseudo tð Þ∙ exp −λSPECT∙ t−tð Þð Þ;
ð7:1Þ
~AWB;pseudo ¼
Z ∞
t¼0
AWB;pseudo t
0ð Þdt0
¼ AWB t
ð Þ∙ exp λSPECT∙tð Þ
λSPECT
¼ AWB t
ð Þ∙ exp λSPECT∙tð Þ∙T 1=2;SPECT
ln 2ð Þ :
ð7:2Þ
T1/2, SPECT denotes the SPECT-based effective half-life.
Comparison of reference and hybrid absorbed dose values
Based on the hybrid model given in Eqs. (7.1) and
(7.2), the bone marrow absorbed dose from the ROB
can be estimated by Eqs. (4.1) and (4.2). In this work,
we investigated a combination of the sequential ab-
dominal SPECT with the whole-body planar images at
24, 48, or 72 h p. i., where each whole-body planar
image was individually calibrated via the quantitative
SPECT at the corresponding time point (Fig. 2).
These different hybrid protocols were further denoted
as HP24, HP48, and HP72. The agreement of the
bone marrow absorbed doses from the ROB, as deter-
mined via the HP and the RP, was assessed. There-
fore, the percentage deviation between absorbed dose
estimates (PDdose; Eq. (8)) was calculated, and a stat-
istical test for correlation was performed (MATLAB
Pearson correlation analysis).
PDdose ¼
DHP24=HP48=HP72−DRP
DRP
 
∙100%: ð8Þ
Furthermore, the same analysis was performed re-
garding the total bone marrow absorbed dose esti-
mates composed of all available constituents: the ROB
(including tumours), the explicitly analysed organs,
and the contribution of the blood activity. While the
application of the hybrid protocol affects the bone
marrow absorbed dose from the ROB, all other con-
stituents were not altered.
Fig. 2 Illustration of the reference protocol (RP) and the proposed hybrid protocol (HP); for the hybrid protocol, the sequential whole-body planar
imaging is replaced by a single whole-body planar acquisition at an appropriate time point at 24, 48, or 72 h p. i. (HP24, HP48, HP72); QSPECT
indicates quantitative SPECT
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Comparison of hybrid and reference ROB TAC parameters
For a mono-exponential TAC, the time-integrated activ-
ity is calculated as the product of the effective half-life
T1/2 and the y-axis intercept A0 of the fit function:
~A ¼ A0
ln 2ð Þ ∙T 1=2: ð9Þ
The proposed hybrid protocol assumes that ideally,
the SPECT-based abdominal effective half-life is equal to
the whole-body effective half-life. However, in reality,
differences in both half-lives will lead to deviations in
the area under the whole-body TACs derived from the
reference protocol and hybrid protocol, and thus in the
respective whole-body and ROB time-integrated activ-
ities. Simultaneously, these deviations in the course of
the TACs may affect the y-axis intercepts of the
reference-protocol-based and hybrid-protocol-based
TACs. To address this issue, both fit function parameters, ef-
fective half-life and the y-axis intercept, were compared for
the reference protocol, HP24, HP48, and HP72. For a perfect
agreement between the reference-protocol-based and
hybrid-protocol-based ROB time-integrated activities, ~ARP
and ~AHP, the product of the ratio of reference-to-hybrid ef-
fective half-lives ðT1=2;RPT1=2;HPÞ and the ratio of reference-to-hybrid
y-axis intercepts ðA0;RPA0;HPÞ has to yield 1:
~ARP
~AHP
¼ A0;RP
A0;HP
∙
T1=2;RP
T1=2;HP
¼ 1 ð10Þ
Results
Reference dosimetry protocol
Based on the reference protocol, median total bone marrow
absorbed doses were calculated as 12.1 mGy/GBq (range
9.6–15.6 mGy/GBq) for Lu-177-Octreotate and 10.8 mGy/
GBq (range 6.7–16.8 mGy/GBq) for Lu-177-PSMA-617
therapy (Table 3). The blood absorbed dose contribution was
higher for Lu-177-Octreotate compared with Lu-177-
PSMA-617 therapy, with a larger inter-patient variability for
Lu-177-PSMA-617 therapy. The median values were found
to be 59% (range 50–63%) for Lu-177-Octreotate therapy
and 43% (range 13–63%) for Lu-177-PSMA-617, respectively
(Table 3). The median ROB contribution was 34% (range
29–41%) for Lu-177-Octreotate and 45% (range 34–80%) for
Lu-177-PSMA-617 therapy, again with a higher variance of
the patient-specific percentage contributions for Lu-177-
PSMA-617 therapy (Table 3). For Lu-177-PSMA-617 ther-
apy, the higher percentage ROB contribution to the total
bone marrow absorbed dose is on the one hand driven by
the larger tumour load for the investigated mCRPC patients,
as all tumours were included in the ROB compartment. On
the other hand, the percentage contribution of the bone
marrow absorbed dose from the blood is reduced for
Lu-177-PSMA-617 therapy compared with Lu-177-Octreo-
tate therapy due to the weighting of the blood activity with
the patient haematocrit and the RMECFF, yielding an aver-
age weighting factor of 0.3. Furthermore, for the five mCRPC
patients in this study, a lower median effective half-life for
the slow phase of the bi-exponential fit to the blood
time-activity measurements was observed, compared with
the five NET patients (Lu-177-Octreotate, 25 h;
Lu-177-PSMA-617, 14 h; Fig. 3). The major accumulating
organs contributed at maximum 9% (median: all organs 8%,
kidneys 4%, liver 2%, spleen 1%) for Lu-177-Octreotate ther-
apy and 12% (median kidneys 8%) for Lu-177-PSMA-617
therapy (Table 3).
Hybrid protocol and comparison of reference and hybrid
absorbed dose values
For Lu-177-Octreotate therapy, the median deviations of
the bone marrow absorbed dose from the ROB were
found to be 37% (range 29–42%), 23% (range 11–38%),
and 3% (range 1–13%) for the HP24, HP48, and HP72,
respectively, compared with the results obtained via the
reference protocol (Fig. 4a). A very strong and significant
(p < 0.05) correlation between the reference and hybrid
protocol was confirmed for all base points 24, 48, 72 h
p. i. with Pearson correlation coefficients of 0.98, 0.93,
and 0.98. However, a tendency of overestimation of the
bone marrow absorbed dose from the ROB, especially
for the HP24 and the HP48, is noticed (Fig. 5a–c). The
Table 3 Results from the reference protocol. Total bone
marrow absorbed doses (DBM← total) and the percentage
contribution of ROB, blood, and organs to the total bone
marrow absorbed dose. All percentage contributions were
calculated according to Eq. (6)
Patient DBM← total [mGy/GBq] ROB [%] Blood [%] Organs [%]
Octreotate
P1 12.1 29 63 8
P2 9.6 34 60 6
P3 15.6 34 59 7
P4 11.8 36 59 5
P5 12.7 41 50 9
Median 12.1 34 59 8
PSMA-617
P6 10.2 36 56 8
P7 6.7 45 43 12
P8 16.8 80 13 7
P9 14.2 34 63 3
P10 8.3 60 28 12
Median 10.8 45 43 8
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respective deviations for Lu-177-PSMA-617 were found
to be 29% (range 3–46%), 4% (range 1–17%), and 4%
(range 1–18%) (Fig. 4c) with a very strong Pearson cor-
relation of 0.98, 1.00, and 1.00, respectively (Fig. 5d–f ).
The tendency of overestimation of the bone marrow
absorbed dose from the ROB was also evident for the
HP24, but reduced for the HP48 and HP72 (Fig. 5d–f ).
The deviations between the reference and hybrid
protocol were lower for the total bone marrow absorbed
dose estimates compared with those for the ROB alone
(Fig. 4). For Lu-177-Octreotate therapy, median differ-
ences of the total bone marrow absorbed doses were
13% (range 9–17%), 8% (range 4–15%), and 1% (range
0–5%) using the HP24, HP48, and HP72, respectively,
with a very strong and significant (p < 0.05) Pearson cor-
relation of 0.98, 0.96, and 0.99 (Figs. 4b and 5a–c). As it
was the case for the bone marrow absorbed dose from
the ROB alone, especially the use of an early base point
leads to overestimated absorbed dose values (Table 4
and Fig. 5a–c). For Lu-177-PSMA-617 therapy, the me-
dian deviations were found to be 10% (range 2–20%), 3%
(range 0–6%), and 2% (range 0–6%) with a very strong
correlation of 0.99, 1.00, and 1.00, respectively (Figs. 4d
and 5d–f ). The tendency of overestimated absorbed dose
values was particularly evident for the base point 24 h p.
i. (Table 4 and Fig. 5d–f ).
To summarise, for Lu-177-Octreotate, the best agree-
ment with respect to the reference protocol was ob-
tained with the hybrid protocol based on 72 h p. i. for all
patient cases, while for Lu-177-PSMA-617 therapy for
40% of the patients, the time point of 48 h p. i. and for
40% the acquisition of 72 h p. i. was best suited. For one
mCRPC patient, both base points, 48 and 72 h p. i.,
provided the same absolute deviation from the reference
(Table 4).
Comparison of hybrid and reference TAC parameters
For both Lu-177-Octreotate and Lu-177-PSMA-617
therapy, the whole-body effective half-life was shorter
compared with the washout in the abdominal region, ex-
cept for patient P9, who presented with pronounced and
strongly accumulating bone metastasis in the right hip
(Table 5). Median whole-body and abdominal effective
half-lives were found to be 43 h (range 40–62 h) and
61 h (range 53–87 h) for Lu-177-Octreotate therapy and
31 h (range 22–65 h) and 42 h (range 31–67 h) for
Lu-177-PSMA-617 therapy. Table 5 indicates a tendency to
lower whole-body and abdominal effective half-lives for
Lu-177-PSMA-617 compared with Lu-177-Octreotate ther-
apy, except for patient P8, who showed the highest bone
tumour load with strong and persistent retention of the ra-
diopharmaceutical (Fig. 1). The deviation between the ef-
fective half-lives was similar for both therapies with 40%
(range 30–42%) for Lu-177-Octreotate therapy and 46%
(range 4–64%) for Lu-177-PSMA-617 therapy, however,
with a larger observed variability for Lu-177-PSMA-617
therapy (Table 5).
Figure 6 shows examples of fitted reference-protocol-based
whole-body and hybrid-protocol-based whole-body
TACs for both Lu-177-Octreotate (patient P4) and
Lu-177-PSMA-617 (patient P8) therapy. The use of
the SPECT-based effective half-life for the hybrid
protocol leads to an under- and overestimation of the
reference-protocol-based TAC before and after the se-
lected base point. This under- and overestimation is
varying for the HP24, HP48, and HP72 and also affects
Fig. 3 Time-activity curves (TAC) for the bone marrow self-absorbed dose as determined via the blood method and for both Lu-177-Octreotate
(a) and Lu-177-PSMA-617 therapy (b) (according to Eqs. (3.1) and (3.3)); the patient-specific TACs are shown in black, while the median is
presented in red
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the y-axis intercept of the hybrid-protocol-based
TACs in comparison to the reference protocol. Figure 7
summarises the patient-specific ratios of the
reference-to-hybrid effective half-lives in comparison to
the ratio of the corresponding y-axis intercepts. The black
line indicates all combinations of effective half-life and y-axis
intercept ratios, for which the reference-protocol-based and
hybrid-protocol-based time-integrated activities are equal.
For Lu-177-Octreotate therapy, the median ratio of the
reference-to-hybrid effective half-lives was found to
be 0.7 (range 0.7–0.8). Simultaneously, the reference-
to-hybrid y-axis intercept ratios increase for the base
points from 24 to 72 h post-therapy. For the HP72,
the combination of effective half-life and y-axis inter-
cept ratios yields to the closest agreement between
the reference-protocol-based and hybrid-protocol-
based time-integrated activities (Fig. 7a). For Lu-177-
PSMA-617 therapy, the median ratio of the reference-
to-hybrid effective half-lives was calculated as 0.7 (range
0.6–1.3). The larger variability in the reference-to-hybrid
effective half-life ratios is also evident in Fig. 7b. For
Lu-177-PSMA-617 therapy, for the time points 48 and
72 h p. i., combinations of reference-to-hybrid effective
half-life ratios and y-axis intercept ratios were found
which result close to a ratio of 1between the
reference-protocol-based and hybrid-protocol-based ROB
time-integrated activities.
Discussion
Although all bone marrow absorbed dose estimates are
well below the typically applied critical threshold of 2 Gy
[5] and no severe marrow toxicities have been observed
for all investigated patients, bone marrow dosimetry is
still a matter of interest. This is particularly true regard-
ing the maximum absorbed dose that can be applied for
patients with progressive cancer disease, who already
underwent several pre-therapies. The absorbed dose esti-
mates determined in this study are in good agreement
with the findings of previous studies for both therapies
[5, 7, 8, 31].
Fig. 4 Percentage deviation (PD) from the reference protocol for the bone marrow absorbed dose from the ROB and the total bone marrow absorbed
dose depending on the base point used for the hybrid protocol (24, 48, or 72 h p. i.). All percentage deviations were calculated according to Eq. (8)
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Table 4 Comparison of the reference and hybrid protocol for different time points of single whole-body planar image acquisition
(24 h p. i.: HP24; 48 h p. i.: HP48; 72 h p. i.: HP72); all calculated total bone marrow absorbed doses (DBM← total) are provided
Patient DBM← total RP [mGy/GBq] DBM← total HP24 [mGy/GBq] DBM← total HP48 [mGy/GBq] DBM← total HP72 [mGy/GBq]
Octreotate
P1 12.1 13.2 12.6 12.1
P2 9.6 10.8 10.3 9.6
P3 15.6 17.1 16.2 15.7
P4 11.8 13.5 12.8 12.3
P5 12.7 14.9 14.7 13.4
Median 12.1 13.5 12.8 12.3
PSMA-617
P6 10.2 11.3 9.6 10.1
P7 6.7 8.1 6.7 7.0
P8 16.8 17.1 17.1 16.8
P9 14.2 13.5 13.6 15.1
P10 8.3 10.0 8.1 8.5
Median 10.2 11.3 9.6 10.1
Fig. 5 Comparison of bone marrow absorbed doses from the ROB and total bone marrow absorbed doses as calculated via the reference
protocol and the HP24, HP48, and HP72 (24, 48, or 72 h p. i.)
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According to the current clinical standard, an uncer-
tainty of at least 10–20% has to be expected for the de-
rived activity and absorbed dose values in case of
quantitative Lu-177 SPECT imaging, and even greater
values might be expected for planar imaging [15–17, 32,
33]. Thus, the results presented in this study suggest
that the application of a hybrid SPECT planar dosimetry
approach based on late whole-body planar images allows
for bone marrow dosimetry which is sufficiently reliable
and applicable in clinical routine. In the case of
Lu-177-Octreotate therapy of patients bearing NET and
with regard to our institutional measurement protocol,
the best time point for whole-body planar imaging was
found to be approximately at 72 h p. i., with maximum
deviations of the total bone marrow absorbed dose of
5% compared to the reference protocol. In patients with
mCRPC receiving Lu-177-PSMA-617 therapy, the
whole-body planar imaging time points 48 and 72 h p. i.
provided comparable total bone marrow absorbed dose
estimates with similar maximum differences of 6% to the
reference-protocol-based full sequential whole-body pla-
nar approach. If five to ten Lu-177-PSMA-617 or
Lu-177-Octreotate therapies are offered per week, the
reduction of whole-body planar scans from three to one
results in a reduction of examination time of 3.5 to 7 h
per week. Simultaneously, the application of the pro-
posed hybrid imaging protocol does not lead to an in-
creased workload for the absorbed dose calculations.
The magnitude of deviations depends on the differ-
ences in the abdominal and whole-body washout and
the positioning of the base point used for scaling of the
mono-exponential pseudo-whole-body TAC. Analysis of
the patient-specific reference-protocol-based and
hybrid-protocol-based TAC parameters revealed that the
use of a prolonged SPECT-based effective half-life is
compensated by a lower y-axis intercept, if a later base
point is selected. The use of a base point later than 72 h
p. i. still has to be investigated; however, such a time
point was unfortunately not available in our institutional
measurement protocol. As expected, the deviations be-
tween the reference and hybrid protocol were larger for
the bone marrow absorbed dose from the ROB com-
pared with the total bone marrow absorbed dose, as the
median ROB contribution to the total absorbed dose
Fig. 6 Whole-body TACs for (a) patient P4 (Lu-177-Octreotate) and (b) patient P8 (Lu-177-PSMA-617) to visualise the impact of the time point of
whole-body planar image acquisition during hybrid-protocol-based calculation of the bone marrow absorbed dose from the ROB (24, 48, or 72 h
p. i.)
Table 5 Comparison of planar-based whole-body (T1/2, WB) and
SPECT-based abdominal effective half-lives (T1/2, SPECT) for Lu-
177-PSMA-617 and Lu-177-Octreotate therapy
Patient T1/2, WB [h] T1/2, SPECT [h]
Octreotate
P1 40 53
P2 43 61
P3 43 56
P4 52 73
P5 62 87
Median 43 61
PSMA-617
P6 22 33
P7 31 50
P8 65 67
P9 39 31
P10 29 42
Median 31 42
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was found to be only 34% for Lu-177-Octreotate therapy
and 45% for Lu-177-PSMA-617 therapy.
The appropriate whole-body planar imaging time
point may have to be determined separately for each
type of therapy. The degree of the deviations between
abdominal and whole-body effective decay constants is
driven by the disease- or therapy-specific retention in
the organs and tumours and the corresponding typical
tumour distribution. The mCRPC patients included in
this study typically showed a larger tumour load com-
pared with the NET patients, which was additionally
strongly varying over the whole patient body. For most
of the mCRPC patients (except P9) included in this
study, the main metastatatic load was located in the
torso, and consequently, the abdominal effective half-life
was larger compared with the whole-body effective
half-life. By contrast, patient P9 suffered from a strongly
accumulating metastasis in the hip, leading to a com-
paratively larger whole-body effective half-life. The larger
variability in the whole-body tumour distribution for
mCRPC patients causes the observed larger spread in
the differences between abdominal and whole-body ef-
fective half-lives. Consequently, a high tumour load out-
side the SPECT field of view might lead to an increased
uncertainty of the proposed hybrid protocol, and this ef-
fect should be further investigated. As it was the case for
most of the mCRPC patients, the investigated NET cases
mainly presented with metastases in the torso, which lead
to an increased retention of the radiopharmaceutical in
the abdomen. However, due to the lower tumour load, the
inter-patient variability in the abdominal and whole-body
effective half-lives was reduced for the NET patients
under study.
The change from one-bed abdominal SPECT imaging
to the imaging of two or more beds could principally im-
prove the proposed hybrid protocol for bone marrow
dosimetry, as an enlarged acquisition area will lead to a
more realistic estimate of the whole-body effective
half-life. Furthermore, the introduction of fast multi-bed
SPECT imaging in the clinical routine would be benefi-
cial for a robust tumour and organ dosimetry over a lar-
ger part of the patient body [15–18]. Attempts to
introduce fast whole-body SPECT imaging into the
clinic already exist [34]. However, the effect of a reduc-
tion of scan time on absorbed dose estimates for Lu-177
therapy still has to be evaluated.
The accuracy of dosimetry based on standardised
organ-level S values is limited, as such S values are in-
herently not capable to fully consider the patient-specific
full 3D functional and anatomical characteristics. The
latter fact remains true, even if a scaling of the S values
to the specific anatomical conditions is applied [6, 14,
35–37]. For Lu-177, the ROB cross-absorbed dose of the
bone marrow is mainly driven by the long-range photon
component, which is more sensitive to the anatomy than
the locally deposited beta absorbed dose. In a previous
study based on Monte Carlo simulations, deviations of
the order of up to 100% were observed, if photon
Fig. 7 Evaluation of hybrid-protocol-based TAC parameters in comparison to the reference protocol for both therapies; the ratio of the reference-
protocol-based and SPECT-based effective half-lives (T1/2,RP/T1/2,HP) and the ratio of the y-axis intercepts for the reference-protocol-based and the
hybrid-protocol-based TACs (A0,RP/A0,HP) are provided; the black curve indicates the optimal case, for which the area under both TACs (AUC)
is equal
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cross-absorbed doses were calculated based on standar-
dised S values [38]. Furthermore, S values are deter-
mined based on the assumption of homogeneous
activity accumulation. However, the activity accumula-
tion in the ROB with the inclusion of tumours is highly
heterogeneous with the degree of heterogeneity being
caused by both tumour load and distribution. With re-
gard to both aspects the limited consideration of the
patient-specific functional and anatomical characteris-
tics, the reliablity of the proposed hybrid protocol can
be well accepted in the framework of organ-level S
values. Moreover, it should also be noted that the exact
bone marrow distribution of each patient is a priori un-
known due to the heterogeneous micro-structure of the
bone marrow and its pathologically highly variable dis-
tribution, which both lead to a highly unspecified target
for bone marrow dosimetry [23]. Particularly, for
mCRPC patients with a high bone tumour load, a dis-
placement of active bone marrow from highly metasta-
sised to tumour-free skeletal sites is possible [39].
Our decision to include all tumours in the ROB repre-
sents a simplified approach for clinical routine bone mar-
row dosimetry. On the one hand, this approach is more
practical, as in case of a high bone tumour load, a manual
determination of the time-integrated activity is not feasible
for each tumour lesion in an acceptable time. On the other
hand, even if a semi-automatic or automatic tumour seg-
mentation is available, tumour-to-bone marrow S values for
both individual tumours and the total tumour distribution
are not available, as tumours are quite variable in shape,
size, and position, and the pre-calculation of all possible S
values is not possible. Thus, at this point, a more simplified
approach was chosen, which considered all tumours at
once within the ROB compartment. The approximation to
use the S value of the compartment in which the tumours
are located to estimate the bone marrow absorbed dose
from lesions has also been applied in previous studies [5].
An alternative way, proposed by Svensson et al. for bone
marrow dosimetry for Lu-177-Octreotate therapy, differen-
tiates the activity distribution in the patient body in low-
and high-activity regions (background vs. main accumulat-
ing organs and tumours) with separate S values applied to
each of both compartments [31]. The resulting bone mar-
row absorbed doses correlated with the change of blood pa-
rameters and were found to be in a similar range compared
to previously published results. Monte Carlo studies may
help in further understanding the effect of such simplifying
assumptions for bone marrow dosimetry.
Conclusions
For both Lu-177-PSMA-617 and Lu-177-Octreotate
therapy, bone marrow dosimetry can be performed via a
single whole-body planar image and a sequential SPECT
(hybrid protocol), provided that this planar image is
acquired at a later time point. Regarding the three im-
aging time points 24, 48, and 72 h, which were available
for this study, the time points of 48 or 72 h p. i. were
found to be suitable for Lu-177-PSMA-617 therapy. For
Lu-177-Octreotate therapy, a time point of 72 h p. i. was
identified as appropriate. This hybrid protocol enables
total bone marrow absorbed dose estimates with a max-
imum deviation of 5–6% compared to a dosimetry
protocol using both sequential planar and SPECT im-
aging. These deviations can be considered acceptable
with regard to the uncertainties which currently have to
be expected for Lu-177 quantitative imaging and bone
marrow dosimetry based on organ-level S values. How-
ever, the proposed hybrid protocol allows for a more
patient-friendly and time-efficient bone marrow dosim-
etry in clinical routine due to the decreased examination
times.
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3D Monte Carlo bone marrow dosimetry
for Lu-177-PSMA therapy with guidance of
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antibody SPECT/CT
Astrid Gosewisch1, Harun Ilhan1, Sebastian Tattenberg1, Andrea Mairani2, Katia Parodi3, Julia Brosch1, Lena Kaiser1,
Franz Josef Gildehaus1, Andrei Todica1, Sibylle Ziegler1, Peter Bartenstein1 and Guido Böning1*
Abstract
Background: The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-
resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on S values, which are pre-computed for reference
anatomies, simplified activity distributions, and a physiological BM distribution. However, mCRPC patients may show a
considerable bone lesion load, which leads to a heterogeneous and patient-specific activity accumulation close to BM-
bearing sites. Furthermore, the patient-specific BM distribution might be significantly altered in the presence of bone
lesions. The aim was to perform BM absorbed dose calculations through Monte Carlo (MC) simulations and to investigate
the potential value of image-based BM localization.
This study is based on 11 Lu-177-PSMA-617 therapy cycles of 10 patients (10 first cycles), who obtained a pre-therapeutic
Ga-68-PSMA-11 PET/CT; quantitative Lu-177 SPECT acquisitions of the abdomen 24 (+CT), 48, and 72 h p.i.; and a Lu-177
whole-body planar acquisition at 24 h post-therapy. Patient-specific 3D volumes of interest were segmented from the Ga-
68-PSMA-11 PET/CT, filled with activity information from the Lu-177 data, and imported into the FLUKA MC code
together with the patient CT. MC simulations of the BM absorbed dose were performed assuming a physiological BM
distribution according to the ICRP 110 reference male (MC1) or a displacement of active BM from the direct location of
bone lesions (MC2). Results were compared with those from S values (SMIRD). BM absorbed doses were correlated with
the decrease of lymphocytes, total white blood cells, hemoglobin level, and platelets. For two patients, an additional pre-
therapeutic Tc-99m-anti-granulocyte antibody SPECT/CT was performed for BM localization.
Results: Median BM absorbed doses were 130, 37, and 11mGy/GBq for MC1, MC2, and SMIRD, respectively. Significant
strong correlation with the decrease of platelet counts was found, with highest correlation for MC2 (MC1: r = − 0.63,
p = 0.04; MC2: r = − 0.71, p = 0.01; SMIRD: r = − 0.62, p = 0.04). For both investigated patients, BM localization via Tc-99m-
anti-granulocyte antibody SPECT/CT indicated a displacement of active BM from the direct location of lesions similar to
model MC2 and led to a reduction in the BM absorbed dose of 40 and 41% compared to MC1.
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Conclusion: Higher BM absorbed doses were observed for MC-based models; however, for MC2, all absorbed doses
were still below 2 Gy. MC1 resulted in critical values for some patients, but is suspected to yield strongly exaggerated
absorbed doses by neglecting bone marrow displacement. Image-based BM localization might be beneficial, and
future studies are recommended to support an improvement for the prediction of hematoxicities.
Keywords: Radioligand therapy, Dosimetry, Monte Carlo, Bone marrow, mCRPC, Lutetium, PSMA, Tc-99m-anti-
granulocyte antibody scintigraphy, Bone marrow localization
Introduction
In radioligand therapy, dosimetry is recommended for
appropriate treatment planning and aims for maximizing
the absorbed dose to malignant structures, while minim-
izing the absorbed dose to risk organs. A variety of strat-
egies for the assessment of tissue absorbed doses exist,
which can be distinguished depending on how detailed
the patient-specific information is considered or depend-
ing on whether a 3D-absorbed dose model is used or
absorbed dose factors (S values) are applied [1–5].
Monte Carlo techniques can be used to fully simulate all
interactions of radioactive decay particles within the sur-
rounding material in a step-by-step manner. Various
Monte Carlo codes such as FLUKA or GEANT4 were
extended to applications in nuclear medicine and are
capable to consider the patient-specific 3D activity and
anatomical characteristics via inclusion of the SPECT,
PET, and CT data into the simulation [6–12]. Thus, 3D-
absorbed dose distributions with resolution and accuracy
depending on the input image data can be provided.
However, the absorbed dose to risk organs or tumors
during radioligand therapy is usually calculated via
organ-level S values, which were pre-calculated based on
standardized anthropomorphic phantoms and which
estimate the mean absorbed dose to the whole target
region based on the mean time-integrated activity in a
specified source region.
The active bone marrow (BM) is a main organ at risk
during Lu-177-PSMA ligand therapy, especially as
patients with advanced mCRPC often present with a high
bone tumor burden and a potentially reduced
hematological function [13–15]. Typically, bone marrow
dosimetry is performed by applying the aforementioned S
values and accounts for the self-absorbed dose to the bone
marrow from the blood, the cross-absorbed dose from the
remainder of the body (ROB), and the cross-absorbed
dose from major organs and tumors as specific source re-
gions [15–19]. However, during bone marrow dosimetry
using organ-level S values, simplifying assumptions have
to be made to estimate the absorbed dose from the overall
tumor distribution, as no pre-calculated S values exist that
consider all lesions in their size, shape, number, and
location. Thus, Monte Carlo simulations may lead to
improved bone marrow absorbed dose estimates, as they
have the potential to fully account for the patient-specific
3D disease characteristics.
Another limitation of classical bone marrow dosimetry
is that the actual localization of the active bone marrow
is a priori unknown. Bone lesions might lead to a dis-
placement of active bone marrow from the direct site of
metastases and thus activity accumulation, which would
drastically reduce the absorbed dose to the active bone
marrow [20, 21]. However, bone marrow dosimetry
using pre-calculated organ-level S values assumes a
physiological bone marrow distribution [16]. Clinical im-
aging methods, such as magnetic resonance imaging or
Tc-99m-anti-granulocyte antibody scintigraphy, can be
used for non-invasive active bone marrow localization,
within the spatial resolution of the corresponding
imaging modality [22–25]. Thus, such techniques might
overcome the limitation of an a priori unknown target
region for bone marrow dosimetry.
In this study, we performed 3D simulations of the
bone marrow absorbed dose for mCRPC patients, as-
suming either an active bone marrow distribution, which
is not altered by the bone tumor load, or a displacement
of active bone marrow from the location of bone metas-
tasis. These results were compared to the respective
bone marrow absorbed dose estimates derived via
organ-level S values. Subsequently, all absorbed dose es-
timates were further correlated with the patient-specific
changes in hematological parameters. For a subgroup of
investigated patients, a Tc-99m-anti-granulocycte anti-
body SPECT/CT was acquired prior to therapy, which
was further analyzed to investigate Monte-Carlo-based
bone marrow dosimetry with and without knowledge of
the patient-specific active bone marrow distribution.
If not indicated otherwise, the term bone marrow
always refers to the active bone marrow, which repre-
sents the radio-sensitive part of the overall bone marrow
mixture.
Material and methods
Patients and data acquisition
This study is based on the first cycle of 10 patients, who
showed PSMA avid soft tissue and bone lesions on the
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pre-therapeutic whole-body Ga-68-PSMA-11 PET/CT.
Patients P1–P4 were treated with on average 3.7 GBq
Lu-177-PSMA-617, while for all other patients, the dos-
ing scheme was increased to 6 GBq, according to initial
dosimetry results at our institution [15, 26] (Table 1).
Patient P7 received a fifth therapy cycle at our institu-
tion with prior image-based active bone marrow
localization and was included as patient P8 (Table 1), as
this rare data allows for an exemplarily comparison of
patient-specific bone marrow dosimetry without and
with knowledge of the patient-specific bone marrow
distribution. All patients received a 15-min abdominal
Lu-177 SPECT/CT scan and a 20-min whole-body pla-
nar scintigraphy at 24 h p.i., as well as a 15-min abdom-
inal SPECT at 48 h and 72 h p.i. on a dual-headed
Symbia T2 SPECT/CT (Siemens Medical Solutions,
Erlangen, Germany). The SPECT and planar whole-body
acquisitions were based on a standard Lu-177 imaging
protocol, using a medium-energy low-penetration colli-
mator, the photopeak at 208 keV (width 15%), and two
additional scatter windows at 170 keV (width 15%) and
240 keV (width 10%) [15, 26, 27]. For dosimetry pur-
poses, five venous blood samples were drawn from each
patient 30 and at maximum 80min post-start of infu-
sion, and before each image acquisition. Blood parame-
ters were further monitored as a part of clinical routine
until the next therapy cycle [28]. Monitoring of blood
element counts was performed at the morning prior to
therapy (baseline), each morning during the following 3
days until discharge, and at 4 and 8 weeks until the next
therapy cycle.
For patients P8 and P9, an additional Tc-99m-anti-
granulocyte antibody SPECT/CT (Scintimun, GLYCO-
TOPE Biotechnology GmbH, Heidelberg, Germany) was
acquired prior to radioligand therapy for localization of
the active bone marrow. A 25-min two-bed SPECT/CT
scan of thorax and abdomen was performed at 3–4 h
after the injection of approximately 400MBq. Image
acquisition followed a standard Tc-99m protocol using a
low-energy high-resolution collimator, a photopeak win-
dow of 140 keV (width 15%), and an additional scatter
window at 115 keV (width 20%).
All patients gave written consent to undergo radioli-
gand therapy. The study protocol was approved by the
local ethics committee of the Medical Faculty of the
Ludwig-Maximilians-University Munich, which waived
Table 1 Characteristics of mCRPC patients included in this study
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11
Age 66 68 47 61 73 63 82 83 79 67 88
Activity (GBq) 3.7 3.7 3.7 3.7 6.0 6.0 6.0 6.0 6.0 6.1 6.1
Cycle 1 1 1 1 1 1 1 5 1 1 1
Metastases (VIS = visceral,
LYM = lymph, OSS = osseous)
OSS Mainly VIS
(liver), OSS,
LYM
Mainly
OSS, LYM
Mainly
OSS, LYM
Mainly
OSS,
LYM
OSS,
LYM
Mainly
OSS, LYM,
VIS
Mainly
OSS, LYM,
VIS
Mainly
OSS,
LYM
Mainly
OSS,
LYM
OSS
Initial TNM classification and
Gleason score
pT4, N1,
R1, G3,
Gleason 8
pT3b, pN1,
R0, G3,
Gleason 9
pT3a,
pN1, pR1,
Gleason 9
pT3b,
pN1, R1,
Gleason
9
pT3b,
pN1
T3a,
N1
pT4, pN1,
R1, G3,
Gleason 9
pT4, pN1,
R1, G3,
Gleason 9
n.a. pT3,
pN0, R1,
Gleason
7
n.a.
PSA (ng/ml) prior to RLT 1201 368 408 5436 2311 0.86 65.7 65.6 418 20.6 52.1
Pre-therapies (1, yes/0, no)
▪ Surgery 1 0 1 1 1 1 1 1 1 1 0
▪ Radiotherapy 1 1 0 1 1 0 1 1 0 1 0
▪ Anti-hormonal therapy
(including 2nd line anti-hormonal
therapy with bicalutamide,
enzalutamide, abiraterone acetate)
1 1 1 1 1 1 1 1 1 1 1
▪ Ra-223 1 0 1 0 0 0 0 0 0 1 0
▪ Chemotherapy
(docetaxel, cabazitaxel)
1 1 1 1 1 1 0 0 1 1 0
Blood baseline
▪ Leukocytes (G/l) 7.2 4.9 6 5.6 5.2 4.54 5.41 4.85 5.31 2.73 7.84
▪ Lymphocytes (G/l0 0.57 0.96 1.71 0.49 0.56 1.14 0.95 0.48 0.94 0.28 2.06
▪ Hemoglobin (g/dl) 14.1 12.3 12.8 9.6 10.9 13.3 10.5 8.4 10.5 8.3 12.1
▪ Thrombocytes (G/l) 195 307 323 291 235 227 450 305 223 89 281
▪ Erythrocytes (T/l) 4.79 4.31 4.36 4.08 3.86 4.11 3.96 3.25 3.55 3.2 3.64
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the necessity for written consent for study entry, as the
study is based on retrospective and irreversibly anon-
ymized patient data.
Image reconstruction and quantification
Quantitative SPECT reconstruction was performed with
an in-house maximum-a-posteriori reconstruction algo-
rithm, which considers the correction for photon attenu-
ation based on the co-registered low dose attenuation
correction CT (AC-CT) (PMOD Version 3.609 rigid-
body co-registration), correction for photon scattering
based on the triple-energy-window (TEW) or dual-
energy-window (DEW) method, and compensation of
distance-dependent detector resolution using a Gaussian
detector response model. Final quantification was real-
ized by applying a system-specific calibration factor,
which was determined from an identically imaged and
reconstructed cylinder phantom of homogeneous and
known activity concentration [15, 27, 29].
Quantitative reconstruction of Ga-68-PSMA-11 PET/
CT scans was conducted as part of clinical routine using
the TrueX algorithm with 3 iterations, 21 subsets, and a
3D post-reconstruction Gaussian filter with a full-width
half maximum of 2 mm. The voxel volume in the PET
data was 4.1 × 4.1 × 5.0 mm3.
All Lu-177 planar whole-body images were corrected
for photon attenuation and scattering pixel by pixel via
an in-house MATLAB routine. Correction of photon at-
tenuation was achieved via a patient-specific μ-map,
which was generated from the whole-body CT of the
pre-therapeutic Ga-68-PSMA-11 PET/CT acquisition,
while the correction of photon scattering employed the
TEW method. A patient-specific calibration factor was
determined utilizing a cross-calibration with the corre-
sponding quantitative SPECT at 24 h post-injection [28].
Reference bone marrow dosimetry using mass-scaled
organ-level S values
Bone marrow dosimetry utilizing phantom-based organ-
level S values was selected as reference method in this work.
It considered the blood, both kidneys, and the remainder of
body (ROB) as specific source regions [15–19, 28]. The re-
spective S values of the RADAR standardized male an-
thropomorphic phantom were used [30]. All S values were
scaled to the patient-specific anatomical conditions. The
time-integrated activities for the blood and both kidneys
were determined based on a bi-exponential and a mono-
exponential fit to the available time-activity measurements,
respectively. For determination of the blood-to-bone mar-
row absorbed dose, we employed a hematocrit-based red
marrow-to-blood activity concentration ratio (RMBLR), as
we assume no specific binding to bone marrow or blood
cells [16, 28, 31]. This assumption results in a reduced
RMBLR compared to a RMBLR of one, which is typically
employed for Lu-177 PRRT.
The derivation of the time-integrated activity of the
ROB from a single planar whole-body scan was achieved
by applying a suitable hybrid SPECT-planar model,
which has been investigated in a previous study [28].
Briefly, a mono-exponential curve was fitted to the total
SPECT activity over time, and this curve was scaled with
the whole-body activity at 24 h p.i. afterwards to
estimate the patient-specific whole-body time-activity
curve. After integration over time, kidney and blood
time-integrated activities were subtracted to obtain the
number of decays within the ROB compartment [16]. As
the patient-specific lesion distribution was highly
variable for the patients investigated in this study, no
pre-calculated S values were available, which consider all
lesions in their size, shape, number, and location. Thus,
the consideration of the metastases and their non-
negligible activity uptake within the S value method was
achieved by including the total lesion activity within the
ROB compartment.
In a previous study, the contribution from the ROB in-
cluding the lesion activities was found to be the domin-
ating component of the total bone marrow absorbed
dose [28]. However, the patient-specific lesion distribu-
tion is assumed to be only inadequately considered via
classical S value dosimetry. To investigate differences be-
tween Monte-Carlo-based and classical S value bone
marrow dosimetry, all bone marrow absorbed doses
were correlated to the total bone lesion load, the time-
integrated tumor uptake, and the time-integrated ROB
retention (MATLAB Pearson’s correlation). The total
bone lesion load was obtained from the pre-therapeutic
Ga-68-PSMA-11 PET via PMOD kmeans segmentation
(PMOD Version 3.609), while time-integrated tumor up-
take and ROB retention were derived by integrating both
the mono-exponential ROB and lesion time-activity
curves. To obtain a total-body lesion time-activity curve
from the sequential abdominal SPECT, the assumption
that the kinetics of all abdominal lesions is equivalent to
that of all lesions throughout the patient body was made.
The total-body lesion time-activity curve was then derived
from all segmented tumors within the abdominal
sequential SPECT (kmeans segmentation, PMOD
Version 3.609), scaled with the ratio of total-to-abdominal
lesion load.
Monte Carlo simulation of bone marrow absorbed dose
For each patient, the absorbed dose to the bone marrow
was simulated using the FLUKA MC code, which has been
extended and validated for applications in nuclear medi-
cine, and which is capable to include the patient-specific
3D anatomical and activity imaging data [6, 11, 12, 32].
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Anatomical and activity simulation data
The pre-therapeutic diagnostic CT from the Ga-68-
PSMA-11 PET/CT scan served as patient-specific
whole-body anatomical map during the Monte Carlo
simulations. Therefore, the CT was converted to a
voxel-wise map of density and anatomical composition
as described by Botta et al. and as required by the MC
code [6]. The patient-specific and time-dependent 3D
whole-body Lu-177 activity distribution was described
by combining the information contained in the sequen-
tial Lu-177 SPECT, the Lu-177 whole-body planar scin-
tigraphy, and the whole-body PET/CT data. First, a
patient-specific 3D whole-body volume of interest (VOI)
map was generated by segmenting the kidneys, the tu-
mors, and the ROB in the PET/CT volume. Using the
sequential Lu-177 SPECT and the single Lu-177 whole-
body planar scintigraphy, the activity in these compart-
ments was assessed for each time point 24, 48, and 72 h
post-injection. Therefore, kidney VOIs and the overall
tumor load were semi-automatically segmented (kmeans
segmentation, PMOD Version 3.609) from both the
quantitative SPECT scan 24 h p.i. and the Ga-68-PSMA-
11 PET. The segmented kidney VOIs were confirmed by
visual comparison with the AC-CT and the diagnostic
CT, respectively. Both, the 24-h-based SPECT kidney
and tumor VOIs were then manually registered to the
following imaging days 48 h and 72 h post-
administration. The time-integrated activity per voxel
was determined for both compartments, to directly as-
sign a total number of decays per voxel to each VOI of
the patient-specific activity template. Thereby, the ab-
dominal lesion time-integrated activity was multiplied
with the ratio of total-to-abdominal lesion volume to es-
timate the total lesion time-integrated activity from the
sequential abdominal SPECT, as already described. The
ROB time-integrated activity was defined via the men-
tioned hybrid SPECT-planar model [28], while the ROB
VOI itself was derived from a VOI outlining the whole
CT volume from the PET/CT data.
Absorbed dose to the bone marrow
For most of the skeletal sites, the bone marrow shows a
heterogeneous microstructure composed of small mar-
row cavities containing a composition of active bone
marrow (BM) and inactive bone marrow (iaBM), with
these cavities being separated by the spongiosa, i.e.,
small ridges of hard bone (HB). This highly heteroge-
neous microstructure is not visible on routine clinical
imaging modalities. Thus, for simulation and estimation
of the bone marrow absorbed dose, we implemented a
weighting factor-based model into the FLUKA code,
similar to the two-factor mass-energy absorption coeffi-
cient method described by Lee et al. [33]. It estimates
the absorbed dose to the active bone marrow from the
absorbed dose simulated within the total bone mixture,
multiplied via a weighting factor w, which describes an
effective interaction probability within the active bone
marrow. This weighting factor can be calculated from the
particle energy E of the dose-depositing photons or elec-
trons; the fractions of active bone marrow, inactive bone
marrow, and hard bone (fBM, fiaBM, and fHB, respectively)
present in the skeletal region of interest; the photon mass
attenuation coefficients (μρ) or the electron mass stopping
powers (Sρ) of the skeletal constituents:
DBM ¼ Dbone  w; ð1:1Þ
w ¼
μBM Eð Þ
ρBM
μbone Eð Þ
ρbone
or w ¼
SBM Eð Þ
ρBM
Sbone Eð Þ
ρbone
; ð1:2Þ
μbone Eð Þ ¼ f BM 
μBM
ρBM
þ f iaBM 
μiaBM Eð Þ
ρiaBM
þ f HB 
μHB Eð Þ
ρHB
 or
Sbone Eð Þ ¼ f BM 
SBM Eð Þ
ρBM
þ f iaBM 
SiaBM Eð Þ
ρiaBM
þ f HB 
SHB Eð Þ
ρHB
;
ð1:3Þ
f BM ¼
mBM
mbone
and in general f i
¼ mi
mbone
; i∈ BM; iaBM;HBf g; ð1:4Þ
f BM þ f iaBM þ f HB ¼ 1: ð1:5Þ
fBM, fiaBM, and fHB reference values were available for
13 active-marrow-bearing bone regions according to the
ICRP 110 reference male [34]. For each patient, these 13
bone regions were segmented onto the patient-specific
diagnostic CT from the Ga-68-PSMA-11 PET/CT, and
the aforementioned reference fractions fBM, fiaBM, and
fHB were assigned to each voxel according to its region
affiliation. To facilitate segmentation of these 13 regions
for each patient, a bone region template was employed.
Therefore, the whole skeleton of 5 patients was
segmented via a HU threshold of 200 on the diagnostic
CT from the Ga-68-PSMA-11 PET/CT, and the
remaining holes in these skeletal VOIs were manually
filled afterwards (PMOD Version 3.609). For template
generation, the segmented bone VOIs from all five pa-
tients were co-registered onto each other using PMOD
non-rigid co-registration. Finally, all 13 regions were
manually segmented on this template. For each patient,
the whole skeleton was segmented in the same manner
as for template generation, and the region-specific tem-
plate was non-rigidly co-registered onto each patient-
specific skeletal VOI, to automatically define both the
patient-specific bone region classification and the related
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active bone marrow distribution containing reference
values fBM (Fig. 1).
This pre-defined active bone marrow distribution was
used in two ways during Monte-Carlo-based bone mar-
row dosimetry. For model MC1, the active bone marrow
distribution remained unchanged, assuming a co-
localization of lesions and active bone marrow. For the
second model MC2, all previously segmented lesion-
containing voxels were removed from the active bone
marrow distribution, to simulate the effect of a complete
bone marrow displacement from the metastatic sites
onto the absorbed dose estimates.
As for SMIRD, absorbed dose estimates were corre-
lated to the bone lesion load, the time-integrated tumor
uptake, and the time-integrated ROB retention
(MATLAB Pearson’s correlation).
Simulation
During simulation, photon production, and transport
thresholds were set to 1 keV (mean range < 1mm for all
tissues [35]). The corresponding electron thresholds were
chosen as 10 keV (mean range < 0.01mm for all tissues).
109 decays were simulated for each simulation study.
Correlation with blood parameters
For the patients included in this study, all bone marrow
absorbed doses were correlated (MATLAB Pearson’s
correlation) with the change of hematological parame-
ters after the investigated therapy cycle (Table 1), i.e.,
the ratio of nadir-to-baseline values of platelet, lympho-
cyte, and leukocyte counts as well as of hemoglobin
level. Particularly, the goal was to assess for the overall
patient cohort whether patient-specific Monte-Carlo-
based bone marrow dosimetry results in improved cor-
relation with the hematological outcome compared to
classical S value dosimetry.
Comparison of bone marrow absorbed doses
Bone marrow dosimetry estimates derived from the bone
marrow models MC1, MC2, and SMIRD were compared
among each other, and respective differences were
further correlated with the bone lesion load, the time-
integrated tumor uptake, and the time-integrated ROB
retention (MATLAB Pearson’s correlation), to estimate
which influencing factors of absorbed dose modeling
define differences between the investigated models.
Bone marrow dosimetry using Tc-99m-anti-granulocyte
antibody scintigraphy
Pre-therapeutic Ga-68-PSMA-11 PET and Tc-99m-anti-
granulocyte antibody SPECT distributions were visually
compared with respect to the overlap between tumor up-
take and the accumulation in the Tc-99m-anti-granulo-
cyte antibody scintigraphy. In a second step, the Tc-99m-
anti-granulocyte antibody SPECT/CT was non-rigidly co-
registered to the Ga-68-PSMA-11 PET/CT data (PMOD
Version 3.609) and considered during the Monte Carlo
absorbed dose calculation as active bone marrow VOI
(gMC3). Respective absorbed dose estimates were com-
pared with those from model MC1 for no bone marrow
displacement from the direct location of metastasis, MC2
assuming full bone marrow displacement, and SMIRD.
Results
Reference bone marrow dosimetry using mass-scaled
organ-level S values
Median bone marrow absorbed dose estimates as derived
via S values (SMIRD) were found to be 11mGy/GBq (6–
25mGy/GBq) (Table 2). Individual bone marrow
absorbed doses showed a weak positive correlation with
the bone lesion load (r = 0.36, p = 0.27, R2 = 0.13). A strong
positive correlation with the time-integrated ROB reten-
tion (r = 0.87, p < 0.01, R2 = 0.74) and with the time-
integrated tumor uptake (r = 0.88, p < 0.01, R2 = 0.75) was
found.
Analysis of blood parameters revealed a weak negative
correlation of bone marrow absorbed dose estimates
with the change of hemoglobin level (r = − 0.19, p = 0.60,
R2 = 0.04). A moderate negative correlation was found
for the change of lymphocyte counts (r = − 0.49, p = 0.15,
R2=0.24) and total white blood cells (r = − 0.45, p = 0.20,
R2=0.20), while the change of platelet counts showed a
strong negative correlation (r = − 0.62, p = 0.04, R2 =
0.38) (Fig. 2).
Fig. 1 Exemplary workflow for definition of skeletal compositions. a Exemplary patient CT. b Semi-automatic segmentation of patient-specific
bone VOI. c Automatic definition of bone regions from non-rigidly co-registered template
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Table 2 Bone marrow absorbed dose estimates as derived either using S values (SMIRD), Monte Carlo simulations under the
assumption of a physiological active bone marrow distribution (MC1), or Monte Carlo simulations assuming no active bone marrow
at the direct location of the bone lesions (MC2)
Patient (administered
activity in GBq)
SMIRD
(mGy)
MC1
(mGy)
MC2
(mGy)
Bone lesion
load (ml)
Time-integrated tumor
uptake (GBq × s/ml)
Time-integrated ROB
retention (GBq × s/ml)
P1 (3.7) 30 493 81 402 141 3
P2 (3.7) 41 109 109 33 87 4
P3 (3.7) 52 274 137 448 59 5
P4 (3.7) 63 3192 281 1123 609 4
P5 (6.0) 120 2139 515 1124 523 17
P6 (6.0) 36 22 22 50 91 6
P7 (6.0) 150 5595 635 727 1130 26
P8 (6.0) 46 1123 225 1298 159 10
P9 (6.0) 40 684 202 836 128 9
P10 (6.1) 66 782 347 1383 84 17
P11 (6.1) 36 403 206 467 64 9
Additionally, bone lesion load, time-integrated tumor uptake, and ROB retention are provided for each patient
Fig. 2 Results for the correlation analysis between the investigated models for bone marrow absorbed dose calculation and the change of blood
element counts (from left to right: MC1, MC2, and SMIRD). Coefficients of the correlation model (a × x + b) were indicated, in combination with
the 95% confidence bounds (brackets)
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Monte Carlo simulation of bone marrow absorbed dose
Under the assumption of an unaltered and physiological
active bone marrow distribution (MC1), median
absorbed dose estimates were found to be 130 mGy/GBq
(4–933 mGy/GBq) (Table 2). Further, for model MC1, a
weak positive correlation with the bone lesion volume
(r = 0.38, p = 0.24, R2 = 0.15), while a strong up to very
strong positive correlation with the time-integrated ROB
retention (r = 0.71, p = 0.01, R2 = 0.50) and time-
integrated tumor uptake (r = 0.98, p < 0.01, R2 = 0.97)
was observed. Analysis of blood parameters revealed a
weak negative correlation with the change of lymphocyte
counts (r = − 0.23, p = 0.52, R2 = 0.05), total white blood
cells (r = − 0.18, p = 0.61, R2 = 0.03), and hemoglobin
level (r = − 0.39, p = 0.26, R2 = 0.15). A strong negative
correlation for the change of platelet counts (r = − 0.63,
p = 0.04, R2 = 0.38) was found (Fig. 2).
For model MC2, which assumes a full displacement of
active bone marrow from the direct location of each le-
sion, median bone marrow absorbed dose estimates were
37mGy/GBq (4–106 mGy/GBq) (Table 2). For MC2, a
moderate positive correlation with the bone lesion volume
was found (r = 0.58, p = 0.06, R2 = 0.33), while a strong up
to very strong positive correlation with the time-integrated
tumor uptake and ROB retention was observed (r = 0.82,
p < 0.01, R2 = 0.68 and r = 0.92, p < 0.01, R2 = 0.84). Con-
cerning the blood parameters, a weak negative correlation
was found for the change of hemoglobin level (r = − 0.20,
p = 0.59, R2 = 0.04) and total white blood cells (r = − 0.27,
p = 0.44, R2 = 0.08), while lymphocyte counts (r = − 0.52,
p = 0.13, R2 = 0.27) showed a moderate negative correlation.
Analysis of the change of platelet counts showed a strong
negative correlation (r = − 0.71, p = 0.01, R2 = 0.50) (Fig. 2).
Exemplary simulation results are provided in Fig. 3 for
patients 3, 4, 8, and 9. Patients 4 and 8 present with a
comparable bone lesion load; however, a clearly higher
bone marrow absorbed dose was observed for patient 4
and particularly MC1, due to a fourfold higher time-
integrated tumor uptake (Table 2).
Comparison of bone marrow absorbed doses
The median ratio between models MC1 and SMIRD was
a factor of 17 (1–50) (Table 3). The highest differences
were observed for patients 4, 7, and 8, who showed a
combination of a comparatively high bone lesion vol-
ume, a high time-integrated tumor uptake, and a high
ratio of time-integrated tumor uptake to ROB retention
(Table 3). The lowest differences were found for patients
2, 3, and 6. Patients 2 and 6 showed the lowest bone
lesion volume (< 50ml), while for patient 3 both a
comparatively low tumor uptake and ROB retention
were observed (Table 3). In general, the differences
between MC1 and SMIRD were mainly driven by the
time-integrated tumor uptake and the bone lesion
volume, respectively (r = 0.77, p < 0.01, R2 = 0.59, and r =
0.60, p = 0.05, R2 = 0.36).
Fig. 3 Exemplary Monte Carlo simulation results for patients 3, 4, 8, and 9. Upper row: MIP from pre-therapeutic Ga-68- PSMA-11 PET/CT; lower
row: MIP for simulated absorbed dose within the bone marrow
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The comparison between model MC2 and SMIRD re-
vealed a median ratio of 4 (1–6) (Table 3). The lowest
difference was obtained again for patient 6, while all
other patients showed a similar deviation by a factor of 3
to 6, whereupon the differences between MC2 and
SMIRD mainly show a strong positive correlation with
the bone lesion volume (r = 0.63, p = 0.04, R2 = 0.40).
The median ratio of MC1 to MC2 was found to be 3 (1–
11), with the highest differences being found for patients 4
and 7, which both show the highest time-integrated tumor
uptake (Table 3). In addition, a strong positive correlation
between the ratios MC1 to MC2 with the time-integrated
tumor uptake was found (r = 0.78, p < 0.01,R2 = 0.61).
Bone marrow dosimetry using Tc-99m-anti-granulocyte
antibody scintigraphy
For patients 8 and 9, bone marrow absorbed dose esti-
mates were re-analyzed using the Tc-99m-anti-granulo-
cyte-based active bone marrow VOI (gMC3). For patient
8, MC1 and MC2 revealed a bone marrow absorbed
dose of 1223 and 225 mGy, respectively, compared to 46
mGy for SMIRD. For the Tc-99m-anti-granulocyte-
based VOI, an absorbed dose of 718 mGy was found, i.e.,
a reduction of approximately 41% compared to MC1.
The ratio of model gMC3 compared to MC2 and
SMIRD was found to be 3 and 17, respectively (Table 4).
For patient 9, absorbed dose estimates for MC1, MC2,
and SMIRD were found to be 684, 202, and 40mGy, re-
spectively. Applying the Tc-99m-anti-granulocyte-based
VOI yielded a bone marrow absorbed dose of 408 mGy.
Thus, compared to MC1, the bone marrow absorbed
dose decreased by 40%, while gMC3 produced two- and
tenfold higher absorbed dose estimates compared to
MC2 and SMIRD (Table 4).
Furthermore, visual interpretation of Ga-68-PSMA-11
PET and Tc-99m-anti-granulocyte antibody scintigraphy
indicates a low overlap between accumulation patterns
and a displacement of active bone marrow from meta-
static lesions for both investigated patients (Figs. 4 and 5).
Discussion
The bone marrow is potentially the most critical organ
and most limiting factor of the therapeutic window
during Lu-177-PSMA therapy of mCRPC patients, as
those patients are usually heavily pre-treated and often
present with a considerable bone lesion load [14]. In a
study of Rahbar et al. with 145 patients and an average
administered activity of 5.9 GBq per cycle, hematoxicity
showed the highest incidence for all grades as well as for
grade 3–4 events [36]. Thus, bone marrow dosimetry is
highly recommended in those patients. However, for
bone marrow dosimetry to become predictive for hema-
toxicity, all relevant patient-specific parameters must be
considered. These include the patient-specific activity
accumulation over time, the anatomical characteristics,
an appropriate localization of the bone marrow target
region, and, not least, pre-therapies and the patient-
specific disease and hematological baseline status.
This study focuses on three relevant issues: First, we
developed an approach for Monte-Carlo-based absorbed
dose calculations, which can fully consider the patient-
specific 3D activity and anatomical characteristics in
contrast to the classical S value dosimetry. Second, we
compared the effect of different models for active bone
marrow localization during Monte-Carlo-based bone
marrow dosimetry. The latter aspect is especially linked
to the question whether patient-specific active bone
marrow localization, e.g., via Tc-99m-anti-granulocyte
scintigraphy, might be beneficial to avoid bone marrow
toxicity. Third, we investigated whether for the patient
cohort under study, Monte-Carlo-based absorbed dose
calculation shows an improved correlation with the
change of hematological parameters, and whether fully
patient-specific bone marrow dosimetry can potentially
provide an improved prediction for hematoxicities.
Table 3 Ratio of bone marrow absorbed dose estimates based
on Monte Carlo simulations and S values
Patient MC1/SMIRD MC2/SMIRD MC1/MC2
P1 17 3 6
P2 3 3 1
P3 5 3 2
P4 50 4 11
P5 18 4 4
P6 1 1 1
P7 37 4 9
P8 27 5 5
P9 17 5 3
P10 12 5 2
P11 11 6 2
Median 17 4 3
Table 4 Comparison of bone marrow absorbed dose estimates based on Monte Carlo simulations for patients 8 and 9
Patient MC1 (mGy) MC2 (mGy) gMC3 (mGy) SMIRD (mGy)
P8 1123 225 718 46
P9 684 202 408 40
gMC3 uses the patient-specific Tc-99m-anti-granulocyte-based active bone marrow VOI. MC1 assumes a physiological active bone marrow distribution, while MC2
assumes a physiological distribution, however with displacement of active bone marrow from the direct site of metastases
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Although the number of patients investigated in this
study is low, our preliminary results already indicate a large
range between bone marrow absorbed dose estimates for
Monte Carlo and S value calculations. The model-specific
correlation of bone marrow absorbed dose estimates with
segmented bone lesion volume, time-integrated tumor up-
take, and ROB retention, as performed during this study,
supports that multiple patient-specific factors should be
taken into consideration to reduce the uncertainty of bone
marrow dosimetry. SMIRD-based bone marrow dosimetry
mainly accounts for the time-integrated ROB and lesion
uptake characteristics; however, respective absorbed doses
revealed only a weak correlation with the patient-specific
and highly heterogeneous 3D bone lesion distribution. For
MC2-based absorbed dose estimates, a strong and signifi-
cant correlation with tumor uptake, ROB retention, and
bone lesion volume was found, while bone marrow
absorbed dose calculations during model MC1 are clearly
dominated by the time-integrated tumor uptake. Results
from correlation analysis support that also for 3D-based
absorbed dose calculation, the total bone lesion volume is
not the only influencing factor of the bone marrow
absorbed dose, and risk patients should be stratified accord-
ing to multiple parameters.
Fig. 4 Results from Tc-99m-anti-granulocyte antibody SPECT/CT (b) in comparison to the Ga-68-PSMA-11 PET/CT (a) for patient 8
Fig. 5 Results from Tc-99m-anti-granulocyte antibody SPECT/CT (b) in comparison to the Ga-68- PSMA-11 PET/CT (a) for patient 9
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With respect to the absolute values, patient-specific
Monte-Carlo-based calculations resulted in higher bone
marrow absorbed doses than the classical S value ap-
proach. For both models, MC2 and SMIRD, bone mar-
row absorbed dose estimates were well below the
typically applied threshold of 2 Gy [19]. Although for
MC2 the absorbed dose estimates were on median four-
fold higher than those achieved with the reference model
SMIRD, the deduction that multiple therapy cycles are
applicable for these patients without the risk of severe
marrow toxicities seems reasonable, at least with regard
to the current dose limit. However, the assumption of
full displacement of active bone marrow, as included in
model MC2, might not be a priori justified in each pa-
tient and might lead to an underestimation of the bone
marrow absorbed dose. For model MC1, assuming a
physiological and unaltered active bone marrow distribu-
tion, median absorbed doses of 130 mGy/GBq were
found with on median 17-fold and 3-fold higher
absorbed dose estimates compared to SMIRD and MC2,
respectively. According to dosimetry using model MC1,
patients 4, 5, 7, and 8 would have received a bone mar-
row absorbed dose close to or in some cases even
strongly exceeding the 2 Gy limit, with the consequent
risk for severe marrow toxicities in these patients.
However, none of the patients presented severe marrow
damage, even after multiple therapy cycles. This obser-
vation questions the general applicability and signifi-
cance of models like MC1, which do not account for
bone marrow displacement by tumor lesions, especially
in the presence of a heavy skeletal tumor burden.
Visual analysis of Tc-99m-anti-granulocyte antibody
SPECT scans supports this thesis, as it indicates a
displacement of active bone marrow from the direct lo-
cation of bone lesions for both exemplarily investigated
patients. In these patients, the re-analysis of bone
marrow absorbed dose estimates using the individual
Tc-99m-anti-granulocyte-based active bone marrow
VOIs resulted in a clear absorbed dose reduction of
approximately 40% compared to MC1, although the
absorbed dose values were still higher than those from
MC2. However, both the Ga-68-PSMA-11 PET and the
Tc-99m-anti-granulocyte antibody SPECT have a finite
resolution, which intrinsically results in a certain artifi-
cial overlap of both activity distributions and thus in an
increased absorbed dose estimate compared to MC2.
Furthermore, co-registration between both modalities is
in general not perfect, particularly for challenging
regions such as the ribs or the sternum, which might
additionally cause a local overlap between tumor and
bone marrow accumulation. Both finite spatial reso-
lution and imperfect co-registration interfere with a po-
tential incomplete active bone marrow displacement.
Despite the additional complexity introduced by the
finite resolution of the involved imaging systems and by
the imperfect co-registration, the utilization of the add-
itional image data from the Tc-99m-anti-granulocyte
antibody scintigraphy may improve individualized bone
marrow dosimetry by providing a realistic upper limit
for the bone marrow absorbed dose. For patient 8, the
usage of a Tc-99m-anti-granulocyte-based VOI resulted
in a reduction of a total bone marrow absorbed dose
from 1.1 Gy (MC1) to an expected maximum dose of
0.7 Gy. It may be hypothesized that the typically applied
upper limit for the bone marrow absorbed dose of 2 Gy
is too high for patients with advanced cancer disease, ex-
tensive skeletal tumor burden, and potentially decreased
hematological function due to various pre-therapies.
Despite the relatively small additional bone marrow
absorbed dose (approx. 10 mSv for 400MBq), Tc-99m-
anti-granulocyte antibody scintigraphy might be justified
in such patients. Studies based on a larger patient cohort
are needed to identify, whether image-based active bone
marrow localization in combination with Monte-Carlo-
based absorbed dose calculation really improves the
correlation between bone marrow dosimetry and hema-
toxicities, and may therefore be suitable to guide therapy
planning in future workflows. Still, the comparison be-
tween models MC1 and MC2 demonstrates that the a
priori unknown patient-specific active bone marrow
distribution results in a large uncertainty of the bone
marrow absorbed doses, even if Monte Carlo techniques
are applied for absorbed dose modeling. Further, future
studies should be performed to find an appropriate
threshold for the bone marrow absorbed dose for Lu-
177-PSMA therapy [14].
The resolution of non-invasive active bone marrow
localization could be further improved by MRI bone
marrow localization, which would also be beneficial if
even small additional contributions to the bone marrow
absorbed dose must be avoided [24, 25]. However, in
clinical daily routine, the localization of active bone mar-
row in a large part of the patient body should be feasible
with acceptable measurement and processing time, and
it should be available for several patients per week.
Further, a reduction of processing complexity and effort
accompanied by a potential enhancement of the accur-
acy of the derived information is desirable. This could be
achieved, for instance, by employing a standardized
method for patient positioning over multiple scans at
the same or at different imaging modalities via patient-
adaptable storage matrasses, which facilitates image co-
registration [37].
To derive a patient-specific activity template from the
Ga-68-PSMA-11 PET instead from the Lu-177-SPECT
reduces issues of spatial resolution during absorbed dose
calculation. Further, for the patients considered in this
study, only SPECT acquisitions of the abdomen were
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available, while for bone marrow dosimetry, the lesion
distribution in the overall body is important. Using the
Ga-68-PSMA-11 PET to model the 3D activity accumu-
lation during therapy is an approximation and only ap-
plicable if the delay between PET acquisition and
therapy is small (on average 2.5 weeks in this study) and
if there is no change in the overall lesion load. To switch
to a fully Lu-177-based activity template, further investi-
gations are desired to improve the spatial resolution of
the Lu-177 imaging and to enable a fast whole-body Lu-
177-SPECT acquisition. Filling a fixed patient-specific
activity VOI template with the respective segmented
VOI activities from sequential Lu-177 imaging reduces
co-registration errors, which could otherwise lead to an
artificially increased bone marrow absorbed dose.
The analysis of blood parameters revealed a significant
(p < 0.05) and strong negative correlation only for the
change of platelet counts, irrespective of the exact bone
marrow model used. The highest correlation was ob-
tained with model MC2, which includes the assumption
of full displacement of active bone marrow from the dir-
ect site of the bone lesions. To exploit the potential and
impact of bone marrow dosimetry for therapy planning,
a more comprehensive investigation of the correlation of
the change of blood element counts with bone marrow
absorbed dose estimates is desired. For this purpose,
blood analysis should consider a higher number of pa-
tients and a prolonged time period. Both the baseline
hematological status and its course after therapy are
known to be affected by various parameters, such as pre-
therapies or total lesion volume [17, 38–40]. Thus, a pa-
tient stratification as for example proposed by Walrand
et al. is mandatory, if the correlation between bone mar-
row absorbed doses and hematological response to ther-
apy shall be analyzed [40]. So far, the correlation of bone
marrow absorbed doses and blood parameters for differ-
ent Lu-177-based radioligand therapies was assessed using
S value-based methods. Svensson et al. observed moderate
and significant correlations for the decrease of
hemoglobin level, total white blood cells, and platelet
counts for Lu-177 PRRT and for 46 investigated patients
[17]. By contrast, Forrer et al. found no correlation be-
tween the decrease of platelet counts and bone marrow
absorbed dose estimates for Lu-177 PRRT based on 15
patients and monitoring of hematological function until 6
weeks after treatment [18].
In clinical routine, the application of Monte Carlo
simulations for dose calculations may be too time-
consuming, especially if the simulation has to consider a
large part of the patient body and small voxels (e.g.,
0.05–0.001 ccm). However, Monte Carlo simulations can
be made feasible with computing clusters. In this way,
results with a high statistical validity could be obtained
in 1 day, which is acceptable with respect to the time
gap between successive cycles of radioligand therapy. An
intermediate method for fast 3D dosimetry within mi-
nutes, which compromises the consideration of Monte
Carlo techniques and computational effectiveness, is the
application of Monte-Carlo-based dose kernels [41, 42].
Further investigations of this approach may be advisable
to prospectively facilitate improved clinical dosimetry for
monitoring and planning of radioligand therapies.
In this work, we introduced a weighting-based model
to represent the different compartments of active and in-
active bone marrow and hard bone. This model repre-
sents a reasonable simplification for the application to
clinical routine imaging data, which have a spatial reso-
lution above the characteristic size of the bone marrow
microstructure. Hybrid Monte-Carlo-based models that
alternate between macroscopic models of the overall pa-
tient anatomy and detailed microscopic models of the
skeletal system are time-consuming but might further
improve bone marrow absorbed dose estimates, at least
for the understanding of important mechanisms to
assess risk factors for marrow toxicities [34, 43].
Conclusion
Monte-Carlo-based bone marrow absorbed doses were
found to be significantly increased compared to those
derived from classical S value dosimetry. Particularly, a
large spread between Monte-Carlo-based and S value
bone marrow absorbed doses was observed, which im-
plies a large uncertainty, especially for S value dosimetry
due to the lack of an appropriate consideration of the
patient-specific highly heterogeneous 3D lesion distribu-
tion. However, even for Monte-Carlo-based bone mar-
row dosimetry, the a priori unknown patient-specific
active bone marrow distribution produces a large uncer-
tainty of bone marrow absorbed doses. Assuming a co-
localization between active bone marrow and all lesions
(MC1) is hypothesized to lead to too exaggerated
absorbed dose values (> 2 Gy per cycle for 27% of inves-
tigated cycles), as these values were not in concordance
with the observation of severe hematological toxicities.
Simultaneously, the a priori assumption of a full
displacement of active bone marrow for each patient
(MC2) might underestimate the patient-specific
absorbed dose. Patient-specific image-based active mar-
row localization, as performed for a small subgroup of
patients, yielded to intermediate bone marrow absorbed
doses compared to MC1 and MC2, although issues of
co-registration and finite image resolution might inter-
fere with incomplete active bone marrow displacement.
Future studies based on a larger patient cohort are rec-
ommended, to particularly determine whether patient-
specific active bone marrow localization in combination
with Monte-Carlo-based absorbed dose modeling can
improve the prediction of hematoxicities and thus
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enables to exploit the full therapeutic window of Lu-
177-PSMA therapy. Preliminary results showed a signifi-
cant and strong correlation between platelet decrease
and bone marrow absorbed doses, irrespective of the
exact dosimetry model; however, highest correlation was
observed for MC2.
Abbreviations
AC-CT: Low dose attenuation correction CT; BM: Bone marrow;
CT: Computed tomography; ICRP: Internal Commission on Radiological
Protection; MC: Monte Carlo; mCRPC: Metastasized castration-resistant
prostate cancer; MIRD: Medical Internal Radiation Dose (Committee);
PET: Positron emission tomography; PRRT: Peptide receptor radionuclide
therapy; PSMA: Prostate-specific membrane antigen; RADAR: Radiation Dose
Assessment Resource; ROB: Remainder of the body; SPECT: Single-photon
emission computed tomography; VOI: Volume of interest
Acknowledgements
Not applicable.
Authors’ contributions
AG, HI, AT, PB, SZ, and GB contributed to the concept and design of the
study. AG, HI, ST, JB, and LK carried out all the data analysis. AM and KP
provided the FLUKA MC code. FJG was responsible for the
radiopharmaceutical production. All authors contributed to the draft of the
manuscript. All authors read and approved the manuscript.
Funding
This work was partly funded by the German Research Foundation (DFG)
within the Research Training 381 Group GRK 2274.
Availability of data and materials
Please contact the corresponding author for data request.
Ethics approval and consent to participate
This study is based on retrospective and anonymized data, which was
acquired for routine clinical dosimetry (Ethics Committee of LMU Munich).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Nuclear Medicine, University Hospital, LMU Munich,
Marchioninistrasse 15, 81377 Munich, Germany. 2Heidelberg Ion Beam
Therapy Center, University Hospital Heidelberg, Heidelberg, Germany.
3Department of Medical Physics, Ludwig-Maximilians-Universität München,
Garching b. München, Germany.
Received: 14 May 2019 Accepted: 30 July 2019
References
1. Stabin M, Flux G. Internal dosimetry as a tool for radiation protection of the
patient in nuclear medicine. Biomedical Imaging and Intervention Journal.
2007;3(2):e28.
2. Ljungberg M, Sjögreen-Gleisner K. The accuracy of absorbed dose estimates
in tumours determined by quantitative SPECT: a Monte Carlo study. Acta
oncologica. 2011;50(6):981–9.
3. Grimes J, Celler A. Comparison of internal dose estimates obtained using
organ-level, voxel S value, and Monte Carlo techniques. Medical physics.
2014;41(9):092501.
4. Cremonesi M, et al. Dosimetry in peptide radionuclide receptor therapy: a
review. Journal of nuclear medicine. 2006;47(9):1467–75.
5. Bolch WE, et al. MIRD pamphlet no. 21: a generalized schema for
radiopharmaceutical dosimetry—standardization of nomenclature. Journal
of Nuclear Medicine. 2009;50(3):477–84.
6. Botta F, et al. Use of the FLUKA Monte Carlo code for 3D patient-specific
dosimetry on PET-CT and SPECT-CT images. Physics in Medicine & Biology.
2013;58(22):8099.
7. Kost SD, et al. VIDA: a voxel-based dosimetry method for targeted
radionuclide therapy using Geant4. Cancer Biotherapy and
Radiopharmaceuticals. 2015;30(1):16–26.
8. Ljungberg M, et al. 3D absorbed dose calculations based on SPECT:
evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer
Biotherapy and Radiopharmaceuticals. 2003;18(1):99–107.
9. Ljungberg M, et al. A 3-dimensional absorbed dose calculation method based
on quantitative SPECT for radionuclide therapy: evaluation for 131I using
Monte Carlo simulation. Journal of Nuclear Medicine. 2002;43(8):1101–9.
10. Chiavassa S, et al. OEDIPE: a personalized dosimetric tool associating voxel-
based models with MCNPX. Cancer biotherapy & radiopharmaceuticals.
2005;20(3):325–32.
11. Fasso, A., et al, FLUKA: a multi-particle transport code. 2005, CERN-2005-10.
12. Böhlen T, et al. The FLUKA code: developments and challenges for high
energy and medical applications. Nuclear data sheets. 2014;120:211–4.
13. Baum RP, et al. Lutetium-177 PSMA radioligand therapy of metastatic
castration-resistant prostate cancer: safety and efficacy. Journal of Nuclear
Medicine. 2016. jnumed. 115.168443.
14. Kabasakal L, et al. Lu-177-PSMA-617 prostate-specific membrane antigen
inhibitor therapy in patients with castration-resistant prostate cancer:
stability, bio-distribution and dosimetry. Molecular imaging and radionuclide
therapy. 2017;26(2):62.
15. Delker A, et al. Dosimetry for 177 Lu-DKFZ-PSMA-617: a new
radiopharmaceutical for the treatment of metastatic prostate cancer.
European journal of nuclear medicine and molecular imaging. 2016;43(1):
42–51.
16. Hindorf C, et al. EANM Dosimetry Committee guidelines for bone marrow
and whole-body dosimetry. European journal of nuclear medicine and
molecular imaging. 2010;37(6):1238–50.
17. Svensson J, et al. A novel planar image-based method for bone marrow
dosimetry in 177 Lu-DOTATATE treatment correlates with haematological
toxicity. EJNMMI physics. 2016;3(1):21.
18. Forrer F, et al. Bone marrow dosimetry in peptide receptor radionuclide
therapy with [177 Lu-DOTA 0, Tyr 3] octreotate. European journal of nuclear
medicine and molecular imaging. 2009;36(7):1138.
19. Sandström M, et al. Individualized dosimetry of kidney and bone marrow in
patients undergoing 177Lu-DOTA-octreotate treatment. Journal of Nuclear
Medicine. 2013;54(1):33–41.
20. Logothetis CJ, Lin S-H. Osteoblasts in prostate cancer metastasis to bone.
Nature Reviews Cancer. 2005;5(1):21.
21. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate
cancer bone metastasis. Journal of cellular biochemistry. 2007;101(4):873–86.
22. Agool A, et al. Radionuclide imaging of bone marrow disorders. European
journal of nuclear medicine and molecular imaging. 2011;38(1):166–78.
23. Berg BCV, et al. Magnetic resonance imaging of the normal bone marrow.
Skeletal radiology. 1998;27(9):471–83.
24. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the
bone marrow in hematologic malignancies. Blood. 1997;90(6):2127–47.
25. Pichardo JC, Milner RJ, Bolch WE. MRI measurement of bone marrow cellularity
for radiation dosimetry. Journal of Nuclear Medicine. 2011;52(9):1482–9.
26. Fendler WP, et al. Preliminary experience with dosimetry, response and
patient reported outcome after 177Lu-PSMA-617 therapy for metastatic
castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581.
27. Ljungberg M, et al. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for
quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical
therapy. Journal of nuclear medicine. 2016;57(1):151–62.
28. Gosewisch A, et al. Patient-specific image-based bone marrow dosimetry in
Lu-177-[DOTA 0, Tyr 3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy:
investigation of a new hybrid image approach. EJNMMI research. 2018;8(1):76.
29. Dewaraja YK, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-
specific 3-dimensional dosimetry in internal radionuclide therapy. Journal of
Nuclear Medicine. 2012;53(8):1310–25.
30. Stabin MG, et al. RADAR reference adult, pediatric, and pregnant female
phantom series for internal and external dosimetry. Journal of Nuclear
Medicine. 2012;53(11):1807–13.
31. Herrmann K, et al. Biodistribution and radiation dosimetry for a probe
targeting prostate-specific membrane antigen for imaging and therapy.
Journal of Nuclear Medicine. 2015;56(6):855–61.
Gosewisch et al. EJNMMI Research            (2019) 9:76 Page 13 of 14
32. Parodi K, et al. Clinical CT-based calculations of dose and positron emitter
distributions in proton therapy using the FLUKA Monte Carlo code. Physics
in Medicine & Biology. 2007;52(12):3369.
33. Lee C, et al. An assessment of bone marrow and bone endosteum
dosimetry methods for photon sources. Physics in Medicine & Biology.
2006;51(21):5391.
34. Hough M, et al. An image-based skeletal dosimetry model for the ICRP
reference adult male—internal electron sources. Physics in Medicine &
Biology. 2011;56(8):2309.
35. https://www.nist.gov/pml/stopping-power-range-tables-electrons-protons-
and-helium-ions.
36. Rahbar K, et al. German multicenter study investigating 177Lu-PSMA-617
radioligand therapy in advanced prostate cancer patients. Journal of
Nuclear Medicine. 2017;58(1):85–90.
37. Förster GJ, et al. SPET/CT image co-registration in the abdomen with a
simple and cost-effective tool. European journal of nuclear medicine and
molecular imaging. 2003;30(1):32–9.
38. Bodei L, et al. Long-term tolerability of PRRT in 807 patients with
neuroendocrine tumours: the value and limitations of clinical factors. European
journal of nuclear medicine and molecular imaging. 2015;42(1):5–19.
39. Bergsma H, et al. Subacute haematotoxicity after PRRT with 177 Lu-DOTA-
octreotate: prognostic factors, incidence and course. European journal of
nuclear medicine and molecular imaging. 2016;43(3):453–63.
40. Walrand S, et al. Experimental facts supporting a red marrow uptake due to
radiometal transchelation in 90 Y-DOTATOC therapy and relationship to the
decrease of platelet counts. European journal of nuclear medicine and
molecular imaging. 2011;38(7):1270–80.
41. Sanchez-Garcia M, et al. Implementation and validation of collapsed cone
superposition for radiopharmaceutical dosimetry of photon emitters. Physics
in Medicine & Biology. 2015;60(20):7861.
42. Sanchez-Garcia M, et al. A new approach for dose calculation in targeted
radionuclide therapy (TRT) based on collapsed cone superposition:
validation with 90Y. Physics in Medicine & Biology. 2014;59(17):4769.
43. Shah AP, et al. A paired-image radiation transport model for skeletal
dosimetry. Journal of Nuclear Medicine. 2005;46(2):344–53.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Gosewisch et al. EJNMMI Research            (2019) 9:76 Page 14 of 14
Danksagung
Zuallererst mc¨hte ich mich bei meinem Doktorvater Priv. Doz. Dr. Guido Böning bedanken, für seine
fortwährende Förderung und sein entgegengebrachtes Vertrauen. Guido hat mich stets dabei unterstüzt
eigene Forschungsansätze zu verfolgen, und stand mir mit seiner Erfahrung bei Fragen und Anliegen
aller Art immer zur Seite. In vielen anregenden Diskussionen - mit oder ohne Weißwurst-Verpflegung
- haben wir zusammen Lösungen gesucht, um die Dosimetrie ein Stück weiter voran zu bringen. Die
Zeit der Promotion hat mich sehr geprägt und wird mir stets in sehr positiver Erinnerung bleiben.
Bei Prof. Dr. Bartenstein bedanke ich mich für die Möglichkeit in der Klinik und Poliklinik für Nuk-
learmedizin zu promovieren und die Ausbildung als Medizinphysikexpertin zu absolvieren, sowie für
die Möglichkeit an vielzähligen nationalen und internationalen Konferenzen teilzunehmen. Ebenfalls
bedanken möchte ich mich für seine eingebrachte umfassende Erfahrung bei der Knochenmarksbildge-
bung.
Ein großer Dank gilt meinen Kollegen, die mich bei meinen Studien und beim Entwurf der Publika-
tionen unterstüzt haben. Im speziellen möchte ich mich bei Prof. Dr. Katia Parodi und Priv. Doz.
Dr. Andrea Mairani für die Bereitstellung des FLUKA Codes bedanken, bei Priv. Doz. Dr. Harun
Ilhan und Priv. Doz. Dr. Andrei Todica für die Unterstützung bei medizinischen Fragen, bei Prof.
Dr. Sibylle Ziegler für ihre eingebrachte Erfahrung bei der Erstellung der Publikationen, sowie bei
Dr. Lena Kaiser für Ihre Mithilfe bei der Auswahl der passenden Segmentierungsmöglichkeiten für
die Dosimetrie. Des Weiteren möchte ich im Besonderen Sebastian Tattenberg danken, der in seiner
Zeit als Bachelorstudent mit unermüdlichem Eifer zu den Vorarbeiten dieser Arbeit beigetragen hat.
Ein weiteres großes Dankeschön geht auch an Henrike von Zimmermann und Mirjam Veen, die dabei
mitwirkten die SPECT-Bildgebung für die Dosimetrie zu verbessern.
Des Weiteren möchte ich von ganzem Herzen allen Kollegen und Kolleginnen der Klinik und Poliklinik
für Nuklearmedizin danken, die mich immer unterstüzt haben, mit denen ich viele schöne und
bereichernde Momente erlebt habe, die aber auch immer ein offenes Ohr oder aufmunterndes Wort
parat hatten, wenn die Dinge mal nicht so ganz wie geplant liefen. Im speziellen möchte ich besonders
Georg ′′ Joe” Stark, Dr. Franz Josef ′′Uffi” Gildehaus und Dr. Christian Zach erwähnen, die mir jederzeit
mit Rat und Tat bei allen Problemen zur Seite standen, und mit denen ich auch abseits der Arbeit eine
sehr lustige Zeit hatte. Ich hoffe sehr, dass noch viele gemeinsame Momente folgen werden! Ebenso
möchte ich Dr. Markus Strigl erwähnen, der ebenfalls jederzeit bei Fragen und Problemen ein offenes
Ohr hatte.
Ein ganz besonderer Dank geht auch an Dr. Magdalena ′′Xuxu” Lindner, die inzwischen ein unverzicht-
barer Bestandteil meines Lebens geworden ist, und das nicht nur beim sportlichen Ausgleich im ′′Gym”
oder beim Karneval feiern. ′′Xuxu” hat während meiner Promotion keinerlei Aufwand gescheut, um
mir beiseite zu stehen und mich zu unterstützen, sowie um während meiner Schreibphasen für ausrei-
91
92
chend Ruhe im Büro zu sorgen. Gleiches gilt für Dr. Luise ′′Groot” Fiedler, mit der im Laufe unserer
gemeinsamen Zeit als Doktorandinnen eine tiefe Freundschaft und Verbundenheit entstanden ist, die
sich manchmal auch - zu Ungunsten von ′′Xuxu” - in vehementen Bekundungen im gemeinsamen
WhatsApp-Chat äußert. Max ′′Groschi” Grosch ist mittlerweile ebenfalls ein fester Bestandteil unserer
Truppe geworden, und auch mit Marcel Simmet, Julia Brosch und Larissa Ermoschkin hoffe ich noch
auf viele gemeinsame, lustige und schöne Erlebnisse.
Mein größter Dank gilt meiner Familie und ganz besonders Andreas, der in mir nicht nur die Begeis-
terung für die Dosimetrie und die Nuklearmedizin geweckt und mich in meinem ganzen Tun als Wis-
senschaftlerin geprägt hat, sondern in dem ich über die Zeit auch meinen Seelenverwandten gefunden
habe.
